

Desk by telephone or via SEND in the STNMAIL file.

=> s l4 and (ovarian or ovary or liver or hepat? or breast cancer or sarcoma or colon cancer or prostate cancer or endometrial cancer)

COMMAND INTERRUPTED

1 FILES SEARCHED...

If this message appears repeatedly, please notify the Help Desk.

Enter "HELP STN" for information on contacting the nearest STN Help Desk by telephone or via SEND in the STNMAIL file.

=> d his

(FILE 'HOME' ENTERED AT 17:29:31 ON 20 DEC 2006)

FILE 'REGISTRY' ENTERED AT 17:29:52 ON 20 DEC 2006

L1 STRUCTURE UPLOADED

L2 99066 S SSS L1 FULL

FILE 'CAPLUS, USPATFULL' ENTERED AT 17:30:30 ON 20 DEC 2006

L3 48931 S L2

L4 27791 S OV202 OR HTC OR CAO V OR MDA-MB OR HUVEC OR A431 OR HT 1080

L5 42 S L3 AND L4

L6 42 DUP REM L5 (0 DUPLICATES REMOVED)

L7 20020 S L4 AND (CANCER OR TUMOR OR TUMOUR OR CANCER? OR NEOPLAS? OR C

L8 14867 S L7 AND (OVARIAN OR OVARY OR LIVER OR HEPAT? OR BREAST CANCER

L9 307 S L8 AND (EDG OR LPA)

L10 302 DUP REM L9 (5 DUPLICATES REMOVED)

L11 302 FOCUS L10 1-

L12 175 S L11 AND PD <=2003

L13 175 FOCUS L12 1-

=> s l3 and (edg and lpa)

L14 4 L3 AND (EDG AND LPA)

=> s l3 and (cancer or tumour or tumor or sarcom? or neoplas? or cancer?)

L15 883 L3 AND (CANCER OR TUMOUR OR TUMOR OR SARCOM? OR NEOPLAS? OR CANCER?)

=> s l15 and (ovary or ovarian or liver or hepat or breast or prostate or colon or cervical or endometrial)

L16 344 L15 AND (OVARY OR OVARIAN OR LIVER OR HEPAT OR BREAST OR PROSTAT E OR COLON OR CERVICAL OR ENDOMETRIAL)

=> dup rem l14

PROCESSING COMPLETED FOR L14

L17 4 DUP REM L14 (0 DUPLICATES REMOVED)

=> d ibib abs 1-4

L17 ANSWER 1 OF 4 USPATFULL on STN

ACCESSION NUMBER: 2005:131819 USPATFULL

TITLE: Methods of treating conditions associated with an EDG-4 receptor

INVENTOR(S): Solow-Cordero, David, San Francisco, CA, UNITED STATES
Shankar, Geetha, Menlo Park, CA, UNITED STATES
Spencer, Juliet, San Mateo, CA, UNITED STATES
Gluchowski, Charles, Danville, CA, UNITED STATES

NUMBER KIND DATE

PATENT INFORMATION: US 2005113283 A1 20050526

APPLICATION INFO.: US 2003-390429 A1 20030314 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2003-347182, filed on 21 Jan 2003, ABANDONED

Day : Wednesday

Date: 12/20/2006

Time: 15:20:34

 **PALM INTRANET**

Inventor Information for 10/760063

Inventor Name	City	State/Country
SHANKAR, GEETHA	PALO ALTO	CALIFORNIA
SOLOW-CORDERO, DAVID	SAN FRANCISCO	CALIFORNIA
SPENCER, JULIET V.	SAN MATEO	CALIFORNIA
GLUCHOWSKI, CHARLES	DANVILLE	CALIFORNIA

[Appln Info](#)[Contents](#)[Petition Info](#)[Atty/Agent Info](#)[Continuity/Reexam](#)[Foreign I](#)Search Another: Application# or Patent# PCT / / or PG PUBS # Attorney Docket # Bar Code #

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1616BSK

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	AUG 09	INSPEC enhanced with 1898-1968 archive
NEWS	4	AUG 28	ADISCTI Reloaded and Enhanced
NEWS	5	AUG 30	CA(SM)/CAplus(SM) Austrian patent law changes
NEWS	6	SEP 11	CA/CAplus enhanced with more pre-1907 records
NEWS	7	SEP 21	CA/CAplus fields enhanced with simultaneous left and right truncation
NEWS	8	SEP 25	CA(SM)/CAplus(SM) display of CA Lexicon enhanced
NEWS	9	SEP 25	CAS REGISTRY(SM) no longer includes Concord 3D coordinates
NEWS	10	SEP 25	CAS REGISTRY(SM) updated with amino acid codes for pyrrolysine
NEWS	11	SEP 28	CEABA-VTB classification code fields reloaded with new classification scheme
NEWS	12	OCT 19	LOGOFF HOLD duration extended to 120 minutes
NEWS	13	OCT 19	E-mail format enhanced
NEWS	14	OCT 23	Option to turn off MARPAT highlighting enhancements available
NEWS	15	OCT 23	CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS	16	OCT 23	The Derwent World Patents Index suite of databases on STN has been enhanced and reloaded
NEWS	17	OCT 30	CHEMLIST enhanced with new search and display field
NEWS	18	NOV 03	JAPIO enhanced with IPC 8 features and functionality
NEWS	19	NOV 10	CA/CAplus F-Term thesaurus enhanced
NEWS	20	NOV 10	STN Express with Discover! free maintenance release Version 8.01c now available
NEWS	21	NOV 20	CAS Registry Number crossover limit increased to 300,000 in additional databases
NEWS	22	NOV 20	CA/CAplus to MARPAT accession number crossover limit increased to 50,000
NEWS	23	DEC 01	CAS REGISTRY updated with new ambiguity codes
NEWS	24	DEC 11	CAS REGISTRY chemical nomenclature enhanced
NEWS	25	DEC 14	WPIDS/WPINDEX/WPIX manual codes updated
NEWS	26	DEC 14	GBFULL and FRFULL enhanced with IPC 8 features and functionality
NEWS	27	DEC 18	CA/CAplus pre-1967 chemical substance index entries enhanced with preparation role
NEWS	28	DEC 18	CA/CAplus patent kind codes updated
NEWS	29	DEC 18	MARPAT to CA/CAplus accession number crossover limit increased to 50,000
NEWS	30	DEC 18	MEDLINE updated in preparation for 2007 reload
NEWS EXPRESS			NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS LOGIN			Welcome Banner and News Items
NEWS IPC8			For general information regarding STN implementation of IPC 8

NEWS X25 X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 15:34:31 ON 20 DEC 2006

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

1.26

1.26

FILE 'REGISTRY' ENTERED AT 15:38:20 ON 20 DEC 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 19 DEC 2006 HIGHEST RN 916029-54-4

DICTIONARY FILE UPDATES: 19 DEC 2006 HIGHEST RN 916029-54-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\edg-2.str

L1 STRUCTURE UPLOADED

=> s sss l1 full

FULL SEARCH INITIATED 15:38:42 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 224 TO ITERATE

100.0% PROCESSED 224 ITERATIONS

2 ANSWERS

SEARCH TIME: 00.00.01

L2 2 SEA SSS FUL L1


=> d 1-2

L2 ANSWER 1 OF 2 REGISTRY COPYRIGHT 2006 ACS on STN

RN 339245-00-0 REGISTRY


ED Entered STN: 03 Jun 2001

CN Benzaldehyde, 3,4-dihydroxy-, [4-[(3,4-dimethylphenyl)amino]-6-[(4-nitrophenyl)amino]-1,3,5-triazin-2-yl]hydrazone (9CI) (CA INDEX NAME)
 MF C24 H22 N8 O4
 SR Chemical Library
 Supplier: Zelinsky Institute of Organic Chemistry
 LC STN Files: CHEMCATS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 ANSWER 2 OF 2 REGISTRY COPYRIGHT 2006 ACS on STN
 RN 330630-42-7 REGISTRY
 ED Entered STN: 10 Apr 2001
 CN Benzaldehyde, 3,4-dihydroxy-, [4-[(4-nitrophenyl)amino]-6-(phenylamino)-1,3,5-triazin-2-yl]hydrazone (9CI) (CA INDEX NAME)
 MF C22 H18 N8 O4
 SR Chemical Library
 Supplier: Zelinsky Institute of Organic Chemistry
 LC STN Files: CA, CAPLUS, CHEMCATS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1907 TO DATE)
 3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file caplus uspatful
 COST IN U.S. DOLLARS
 FULL ESTIMATED COST

SINCE FILE ENTRY	TOTAL SESSION
170.74	172.00

FILE 'CAPLUS' ENTERED AT 15:39:12 ON 20 DEC 2006
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 15:39:12 ON 20 DEC 2006

=> s 12

L3 5 L2

=> dup rem l3

PROCESSING COMPLETED FOR L3

L4 3 DUP REM L3 (2 DUPLICATES REMOVED)

=> d ibib abs 1-3

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 1

ACCESSION NUMBER: 2005:409218 CAPLUS

DOCUMENT NUMBER: 142:441857

TITLE: Methods of treating conditions associated with an
edg-2 receptorINVENTOR(S): Solow-Cordero, David; Shankar, Geetha; Spencer,
Juliet; Gluchowski, Charles

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 43 pp., Cont.-in-part of U.S.
Ser. No. 347,420, abandoned.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005101518	A1	20050512	US 2003-390427	20030314
PRIORITY APPLN. INFO.:			US 2002-350448P	P 20020118
			US 2003-347420	B2 20030117

OTHER SOURCE(S): MARPAT 142:441857

GI



I

AB In one aspect, the present invention provides a method for modulating an Edg-2 receptor mediated biol. activity in a cell. A cell expressing the Edg-2 receptor is contacted with an modulator with formula I (where X = O, S; R20 = alkyl aryl, etc., R21 = alkyl, substituted alkyl, etc., R23 = H, alkyl, substituted alkyl; R24 = aryl, etc.) of the Edg-2 receptor, which modulates the Edg-2 receptor mediated biol. activity. In another aspect, the present invention provides a method for modulating Edg-2 receptor mediated biol. activity in a subject. A therapeutically effective amount of an modulator of the Edg-2 receptor is administered to the subject.

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 2

ACCESSION NUMBER: 2004:703122 CAPLUS

DOCUMENT NUMBER: 141:200233

TITLE: Methods of treating conditions associated with an
Edg-2 receptorINVENTOR(S): Shankar, Geetha; Solow-Cordero, David; Spencer, Juliet
V.; Gluchowski, Charles

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 21 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004167132	A1	20040826	US 2004-760063	20040116
PRIORITY APPLN. INFO.:			US 2003-440337P	P 20030116

OTHER SOURCE(S): MARPAT 141:200233

AB The invention provides a method for modulating an Edg-2 receptor-mediated biol. activity in a cell. A cell expressing the Edg-2 receptor is contacted with an modulator of the Edg-2 receptor, which modulates the Edg-2 receptor mediated biol. activity. In another aspect, the invention provides a method for modulating Edg-2 receptor mediated biol. activity in a subject. A therapeutically effective amount of an modulator of the Edg-2 receptor is administered to the subject.

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:591307 CAPLUS
 DOCUMENT NUMBER: 139:143997
 TITLE: Methods using Edg receptor modulators for the treatment of Edg receptor-associated conditions
 INVENTOR(S): Shankar, Geetha; Solow-Cordero, David; Spencer, Juliet V.; Gluchowski, Charles
 PATENT ASSIGNEE(S): Ceretek LLC, USA
 SOURCE: PCT Int. Appl., 293 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003062392	A2	20030731	WO 2003-US1881	20030121
WO 2003062392	A3	20050120		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2473740	A1	20030731	CA 2003-2473740	20030121
AU 2003214873	A1	20030902	AU 2003-214873	20030121
EP 1513522	A2	20050316	EP 2003-710713	20030121
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005519915	T	20050707	JP 2003-562260	20030121
US 2005261298	A1	20051124	US 2003-390428	20030314
PRIORITY APPLN. INFO.:			US 2002-350445P	P 20020118
			US 2002-350446P	P 20020118
			US 2002-350447P	P 20020118
			US 2002-350448P	P 20020118
			WO 2003-US1881	W 20030121
			US 2003-352579	B2 20030127

OTHER SOURCE(S): MARPAT 139:143997

AB The invention provides a method of modulating an Edg-2, Edg-3, Ed-4 or

Edg7 receptor-mediated biol. activity in a cell. A cell expressing the Edg-2, Edg-3, Edg-4 or Edg 7 receptor is contacted with a modulator of the Edg-2, Edg-3, Ed-4 or Edg 7 receptor sufficient to modulate receptor mediated biol. activity. In another aspect, the present invention provides a method for modulating an Edg-2, Edg-3, Ed-4 or Edg-7 receptor mediated biol. in a subject. A therapeutically effective amount of a modulator of the Edg-2, Edg-3, Ed-4 or Edg7 receptor is administered to the subject. Preparation of compds., e.g.

4,4,4-trifluoro-3-oxo-N-(5-phenyl-2H-pyrazol-3-yl)butyramide, is described.

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

22.41

194.41

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-2.25

-2.25

FILE 'REGISTRY' ENTERED AT 15:48:49 ON 20 DEC 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 19 DEC 2006 HIGHEST RN 916029-54-4

DICTIONARY FILE UPDATES: 19 DEC 2006 HIGHEST RN 916029-54-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\edg-2-1.str

L5 STRUCTURE UPLOADED

=> s sss full l5

FULL SEARCH INITIATED 15:49:05 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 4 TO ITERATE

100.0% PROCESSED 4 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

L6 0 SEA SSS FUL L5

=>

Uploading C:\Program Files\Stnexp\Queries\edg-2-2.str

L7 STRUCTURE UPLOADED

=> s sss l7 full
FULL SEARCH INITIATED 15:50:26 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 2769 TO ITERATE

100.0% PROCESSED 2769 ITERATIONS 896 ANSWERS
SEARCH TIME: 00.00.01

L8 896 SEA SSS FUL L7

=> file caplus uspatful
COST IN U.S. DOLLARS
FULL ESTIMATED COST

	SINCE FILE ENTRY	TOTAL SESSION
	334.32	528.73

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)
CA SUBSCRIBER PRICE

	SINCE FILE ENTRY	TOTAL SESSION
	0.00	-2.25

FILE 'CAPLUS' ENTERED AT 15:50:40 ON 20 DEC 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 15:50:40 ON 20 DEC 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

=> s l8
L9 30 L8

=> focus
PROCESSING COMPLETED FOR L9
L10 30 FOCUS L9 1-

=> dup rem l10
PROCESSING COMPLETED FOR L10
L11 26 DUP REM L10 (4 DUPLICATES REMOVED)

=> d ibib abs 1-26

L11 ANSWER 1 OF 26 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2006:291604 CAPLUS
DOCUMENT NUMBER: 144:480885
TITLE: In Silico Discovery of β -Secretase Inhibitors
AUTHOR(S): Huang, Danzhi; Luethi, Urs; Kolb, Peter; Cecchini, Marco; Barberis, Alcide; Caflisch, Amedeo
CORPORATE SOURCE: Department of Biochemistry, University of Zuerich, Zurich, CH-8057, Switz.
SOURCE: Journal of the American Chemical Society (2006), 128(16), 5436-5443
CODEN: JACSAT; ISSN: 0002-7863
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Alzheimer's disease, the most common amyloid-associated disorder, accounts for the majority of the dementia diagnosed after the age of 60. The cleavage of the β -amyloid precursor protein is initiated by β -secretase (BACE-1), a membrane-bound aspartic protease, which has emerged as an important but difficult protein target. Here, an in silico screening approach consisting of fragment-based docking, ligand conformational search by a genetic algorithm, and evaluation of free energy of binding was used to identify low-mol.-weight inhibitors of BACE-1. More than 300,000 small mols. were docked and about 15,000 prioritized according to a linear interaction energy model with evaluation of

solvation by continuum electrostatics. Eighty-eight compds. were tested in vitro, and 10 of them showed an IC50 value lower than 100 µM in a BACE-1 enzymic assay. Interestingly, the 10 active compds. shared a triazine scaffold. Moreover, four of them were active in an assay with mammalian cells (EC50 < 20 µM), indicating that they are cell-permeable. Therefore, these triazine derivs. are very promising lead candidates for BACE-1 inhibition. The discoveries of this series and two other series of nonpeptidic BACE-1 inhibitors demonstrate the usefulness of our in silico high-throughput screening approach.

REFERENCE COUNT: 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 2 OF 26 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2006:132164 CAPLUS

DOCUMENT NUMBER: 144:404124

TITLE: Automated microscopy screening for compounds that partially revert cholesterol accumulation in Niemann-Pick C cells

AUTHOR(S): Pipalia, Nina H.; Huang, Amy; Ralph, Harold; Rujoi, Madalina; Maxfield, Frederick R.

CORPORATE SOURCE: Department of Biochemistry, Weill Medical College of Cornell University, New York, NY, 10021, USA

SOURCE: Journal of Lipid Research (2006), 47(2), 284-301
CODEN: JLPRAW; ISSN: 0022-2275

PUBLISHER: American Society for Biochemistry and Molecular Biology, Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Niemann-Pick disease type C (NPC) is an autosomal recessive genetic disorder manifested by abnormal accumulation of unesterified cholesterol and other lipids. We screened combinatorially synthesized chemical libraries to identify compds. that would partially revert cholesterol accumulation. Cultured CHO cells with NPC phenotypes (CT60 and CT43) were used for screening along with normal CHO cells as a control. We developed an automated microscopy assay based on imaging of filipin fluorescence for estimating cholesterol accumulation in lysosomal storage organelles. Our primary screen of 14,956 compds. identified 14 hit compds. that caused significant reduction in cellular cholesterol accumulation at 10 µM. We then screened a secondary library of 3,962 compds. selected based on chemical similarity to the initial hits and identified 7 compds. that demonstrated greater efficacy and lower toxicity than the original hits. These compds. are effective at concns. of 123 nM to 3 µM in reducing the cholesterol accumulation in cells with a NPC1 phenotype.

REFERENCE COUNT: 66 THERE ARE 66 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 3 OF 26 CAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 1

ACCESSION NUMBER: 2005:453800 CAPLUS

DOCUMENT NUMBER: 143:7706

TITLE: Pyrazole and other heterocyclics preparation for treating conditions associated with an Edg-4 receptor
INVENTOR(S): Solow-Cordero, David; Shankar, Geetha; Spencer, Juliet; Gluchowski, Charles

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 67 pp., Cont.-in-part of U.S. Ser. No. 347,182, abandoned.
CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

US 2005113283
PRIORITY APPLN. INFO.:

A1 20050526

US 2003-390429	20030314
US 2002-350445P	P 20020118
US 2003-438996P	P 20030110
US 2003-440328P	P 20030116
US 2003-440329P	P 20030116
US 2003-440331P	P 20030116
US 2003-440332P	P 20030116
US 2003-440334P	P 20030116
US 2003-440335P	P 20030116
US 2003-440345P	P 20030116
US 2003-440346P	P 20030116
US 2003-440347P	P 20030116
US 2003-347182	B2 20030121

OTHER SOURCE(S): MARPAT 143:7706
GI




AB The present invention provides a method of modulating an Edg-4 receptor mediated biol. activity in a cell. A cell expressing the Edg-4 receptor is contacted with a modulator of an Edg-4 receptor sufficient to modulate the Edg-4 receptor mediated biol. activity. In another aspect, the present invention provides a method for modulating an Edg-4 receptor mediated biol. activity in a subject. E.g., I was prepared from Et 4,4,4-trifluoroacetoacetate and 5-phenyl-1H-pyrazol-3-ylamine. I and other derivs. were tested for inhibition of the Edg-4 receptor and other pharmacol. tests such as proliferation, IL-8 and VEGF assays.

L11 ANSWER 4 OF 26 CAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 2

ACCESSION NUMBER: 2005:409218 CAPLUS .
DOCUMENT NUMBER: 142:441857
TITLE: Methods of treating conditions associated with an
edg-2 receptor
INVENTOR(S): Solow-Cordero, David; Shankar, Geetha; Spencer,
Juliet; Gluchowski, Charles
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 43 pp., Cont.-in-part of U.S.
Ser. No. 347,420, abandoned.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	---	-----	-----
US 2005101518	A1	20050512	US 2003-390427	20030314
PRIORITY APPLN. INFO.:			US 2002-350448P	P 20020118
			US 2003-347420	B2 20030117
OTHER SOURCE(S):	MARPAT 142:441857			
GI				



AB In one aspect, the present invention provides a method for modulating an Edg-2 receptor mediated biol. activity in a cell. A cell expressing the Edg-2 receptor is contacted with an modulator with formula I (where X = O, S; R20 = alkyl aryl, etc., R21 = alkyl, substituted alkyl, etc., R23 = H, alkyl, substituted alkyl; R24 = aryl, etc.) of the Edg-2 receptor, which modulates the Edg-2 receptor mediated biol. activity. In another aspect, the present invention provides a method for modulating Edg-2 receptor mediated biol. activity in a subject. A therapeutically effective amount of an modulator of the Edg-2 receptor is administered to the subject.

L11 ANSWER 5 OF 26 CAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 3

ACCESSION NUMBER: 2004:703122 CAPLUS
 DOCUMENT NUMBER: 141:200233
 TITLE: Methods of treating conditions associated with an Edg-2 receptor
 INVENTOR(S): Shankar, Geetha; Solow-Cordero, David; Spencer, Juliet V.; Gluchowski, Charles
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 21 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004167132	A1	20040826	US 2004-760063	20040116
PRIORITY APPLN. INFO.:			US 2003-440337P	P 20030116
OTHER SOURCE(S): MARPAT 141:200233				


AB The invention provides a method for modulating an Edg-2 receptor-mediated biol. activity in a cell. A cell expressing the Edg-2 receptor is contacted with an modulator of the Edg-2 receptor, which modulates the Edg-2 receptor mediated biol. activity. In another aspect, the invention provides a method for modulating Edg-2 receptor mediated biol. activity in a subject. A therapeutically effective amount of an modulator of the Edg-2 receptor is administered to the subject.

L11 ANSWER 6 OF 26 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:1076613 CAPLUS
 DOCUMENT NUMBER: 142:32992
 TITLE: Triazine derivatives for promoting collagen accumulation and inhibiting collagen decrease
 INVENTOR(S): Takahashi, Junya; Azuma, Kiyoshi
 PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd., Japan; Sumitomo Pharmaceutical Co., Ltd.
 SOURCE: Jpn. Kokai Tokkyo Koho, 15 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

JP 2004352684	A	20041216	JP 2003-154442	20030530
PRIORITY APPLN. INFO.:			JP 2003-154442	20030530
OTHER SOURCE(S):	MARPAT 142:32992			
GI				



AB Triazine derivs. (I; X = halogen, low alkyl and alkoxy, nitro, trifluoromethyl; Y, Z = low alkyl; m, n = 0-2) are claimed for promoting collagen accumulation and inhibiting collagen decrease by increasing type I collagen gene transcription and decreasing MMP-1 gene transcription for diagnosis and treatment of low collagen-associated diseases.

L11 ANSWER 7 OF 26 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:580592 CAPLUS

DOCUMENT NUMBER: 141:123659

TITLE: Preparation of substituted 1,3,5-triazine derivatives as anti-Alzheimer's agents

INVENTOR(S): Willems, Henriette

PATENT ASSIGNEE(S): De Novo Pharmaceuticals Ltd, UK

SOURCE: Brit. UK Pat. Appl., 10 pp.

CODEN: BAXXDU


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 2397301	A	20040721	GB 2003-805	20030114
PRIORITY APPLN. INFO.:			GB 2003-805	20030114
OTHER SOURCE(S):	MARPAT 141:123659			
GI				



AB Title compds. I [wherein R1 = aryl; R2, R3 = independently H, alkyl, (hetero)aryl, alkylheteroaryl, or R2R3 = heterocycloalkyl; R4 = aryl; R = independently H or alkyl; and pharmaceutically acceptable salts thereof] were prepared (no data). I and their pharmaceutical compns. are useful for the treatment or prevention of Alzheimer's disease (no data).

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 8 OF 26 USPATFULL on STN

ACCESSION NUMBER: 2004:175230 USPATFULL
TITLE: Ink jet printing composition comprising a dye
containing hydrazine or hydrazide
INVENTOR(S): Wight, Paul, Manchester, UNITED KINGDOM
Patel, Prakash, Manchester, UNITED KINGDOM

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004134382	A1	20040715
	US 7141106	B2	20061128
APPLICATION INFO.:	US 2003-469309	A1	20030829 (10)
	WO 2002-GB810		20020227

	NUMBER	DATE
PRIORITY INFORMATION:	GB 2001-5321	20010303
	GB 2001-5324	20010303
	GB 2001-5325	20010303
	GB 2001-5328	20010303
	GB 2001-6007	20010312
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MORGAN LEWIS & BOCKIUS LLP, 1111 PENNSYLVANIA AVENUE NW, WASHINGTON, DC, 20004	
NUMBER OF CLAIMS:	16	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1842	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
AB	A composition comprising:	

(a) a liquid medium; and

(b) a compound comprising one or more chromophoric groups and one or more hydrazine or hydrazide groups;

wherein the liquid medium comprises water and an organic solvent, an organic solvent free from water, or a low melting point solid.

The composition is useful for ink jet printing.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 9 OF 26 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:591307 CAPLUS
DOCUMENT NUMBER: 139:143997
TITLE: Methods using Edg receptor modulators for the
treatment of Edg receptor-associated conditions
INVENTOR(S): Shankar, Geetha; Solow-Cordero, David; Spencer, Juliet
V.; Gluchowski, Charles
PATENT ASSIGNEE(S): Ceretek LLC, USA
SOURCE: PCT Int. Appl., 293 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003062392	A2	20030731	WO 2003-US1881	20030121

WO 2003062392 A3 20050120

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2473740 A1 20030731 CA 2003-2473740 20030121

AU 2003214873 A1 20030902 AU 2003-214873 20030121

EP 1513522 A2 20050316 EP 2003-710713 20030121

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

JP 2005519915 T 20050707 JP 2003-562260 20030121

US 2005261298 A1 20051124 US 2003-390428 20030314

PRIORITY APPLN. INFO.:

US 2002-350445P P 20020118

US 2002-350446P P 20020118

US 2002-350447P P 20020118

US 2002-350448P P 20020118

WO 2003-US1881 W 20030121

US 2003-352579 B2 20030127

OTHER SOURCE(S): MARPAT 139:143997

AB The invention provides a method of modulating an Edg-2, Edg-3, Ed-4 or Edg7 receptor-mediated biol. activity in a cell. A cell expressing the Edg-2, Edg-3, Edg-4 or Edg 7 receptor is contacted with a modulator of the Edg-2, Edg-3, Ed-4 or Edg 7 receptor sufficient to modulate receptor mediated biol. activity. In another aspect, the present invention provides a method for modulating an Edg-2, Edg-3, Ed-4 or Edg-7 receptor mediated biol. in a subject. A therapeutically effective amount of a modulator of the Edg-2, Edg-3, Ed-4 or Edg7 receptor is administered to the subject. Preparation of compds., e.g.

4,4,4-trifluoro-3-oxo-N-(5-phenyl-2H-pyrazol-3-yl)butyramide, is described.

L11 ANSWER 10 OF 26 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:311343 CAPLUS

DOCUMENT NUMBER: 142:48466

TITLE: Local structure is critical for superoxide dismutase activity in copper complexes: Relationship between EPR parameters, structure, and activity in some sterically hindered copper(II) bis(hydrazono-triazine) complexes

AUTHOR(S): Goodman, B. A.; Palivan, C. G.; Palivan, H.; Tomas, S.

CORPORATE SOURCE: Scottish Crop Research Institute, Dundee, UK

SOURCE: Applied Magnetic Resonance (2003), 25(1), 13-28

CODEN: APMREI; ISSN: 0937-9347

PUBLISHER: Springer-Verlag Wien

DOCUMENT TYPE: Journal

LANGUAGE: English


AB ESR (EPR) spectrometry and mol. mechanics force field calcns. have been performed on some sterically hindered copper(II) complexes with hydrazono-triazine ligands, in order to gain further insight into the relationship between their bonding, structures and biol. activity. As was the case with Cu(II) bis(hydrazono-triazine) complexes studied previously, the most stable configuration for all of the complexes involves coordination of two nitrogen and two oxygen atoms (2N2O) in a distorted tetragonal arrangement. With the present complexes, however, the superoxide radical scavenging activities were very low, a result which may be explained by their inability to form a (nearly) square planar structure, which facilitates the copper redox cycling during superoxide dismutation.

REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 11 OF 26 CAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 4
 ACCESSION NUMBER: 2002:6713 CAPLUS
 DOCUMENT NUMBER: 136:85833
 TITLE: Preparation of N-(diaminotriazinyl)arylaldehyde
 hydrazones and analogs as antiviral agents
 INVENTOR(S): Arenas, Jaime E.; Cload, Sharon T.; Fleming, Elizabeth
 S.; Xiang, Yi Bin
 PATENT ASSIGNEE(S): Scriptgen Pharmaceuticals, Inc., USA
 SOURCE: U.S., 114 pp.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6335339	B1	20020101	US 1999-229703	19990113
PRIORITY APPLN. INFO.:			US 1998-113656P	P 19980113
OTHER SOURCE(S):	MARPAT 136:85833			
GI				



AB Title compds. [e.g., I; R1-R8 = H, (un)substituted alk(en)yl, - (hetero)aryl, etc.; R1R2, R3R4, R7R8 = atoms to complete a ring] were prepared Preparation of select I (e.g., R1 = CH2Ph, R2 = R4 = R7 = H, R3 = CMe3,

R8 = C6H4F-2) was described. Data for biol. activity of I were given.

REFERENCE COUNT: 55 THERE ARE 55 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 12 OF 26 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2002:696050 CAPLUS
 DOCUMENT NUMBER: 137:234000
 TITLE: Ink jet printing composition comprising dyes
 containing hydrazine or hydrazide groups
 INVENTOR(S): Patel, Prakash
 PATENT ASSIGNEE(S): Avecia Limited, UK; Wight, Paul
 SOURCE: PCT Int. Appl., 69 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002070609	A1	20020912	WO 2002-GB810	20020227
WO 2002070609	A8	20040408		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				

GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
 PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
 UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB,
 GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA,
 GN, GQ, GW, ML, MR, NE, SN, TD, TG

GB 2389588	A	20031217	GB 2003-19749	20020227
GB 2389588	B	20050323		
US 2004134382	A1	20040715	US 2003-469309	20030829
US 7141106	B2	20061128		

PRIORITY APPLN. INFO.:

GB 2001-5321	A	20010303
GB 2001-5324	A	20010303
GB 2001-5325	A	20010303
GB 2001-5328	A	20010303
GB 2001-6007	A	20010312
US 2001-304161P	P	20010321
US 2001-304162P	P	20010321
US 2001-304176P	P	20010321
US 2001-813300	A	20010321
US 2001-505353P	P	20010321
WO 2002-GB810	W	20020227

AB An ink jet composition comprises (a) a liquid medium and (b) a dye comprising one or more chromophoric groups and one or more hydrazine or hydrazide groups, wherein the liquid medium comprises water and an organic solvent, an organic solvent free from water, or a low m.p. solid. The ink colors are stable and the inks have good storage stability and application properties. In an example, C.I. Acid Red 34 is treated (1:1 mol) with cyanuric chloride and the remaining 2 Cl atoms in the product are condensed with 1-amino-2,3-propanediol and then H₂NNHCONH₂ to give a magenta dye.

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 13 OF 26 USPATFULL on STN

ACCESSION NUMBER: 2002:224430 USPATFULL
 TITLE: FVIIa/TF activity inhibiting compounds
 INVENTOR(S): Jakobsen, Palle, Vaerl.o slashed.se, DENMARK
 Persson, Egon, Åkarp, SWEDEN
 PATENT ASSIGNEE(S): Novo Nordisk A/S, Bagsvaerd, DENMARK (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6444434	B1	20020903
APPLICATION INFO.:	US 2001-844828		20010427 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-616010, filed on 13 Jul 2000, now patented, Pat. No. US 6238878		
	Continuation of Ser. No. WO 2000-DK316, filed on 13 Jun 2000		

	NUMBER	DATE
PRIORITY INFORMATION:	DK 1999-840	19990614
	DK 1999-910	19990625
	DK 1999-1241	19990903
	US 1999-139714P	19990617 (60)
	US 1999-141416P	19990629 (60)
	US 1999-152863P	19990908 (60)

DOCUMENT TYPE: Utility
 FILE SEGMENT: GRANTED
 PRIMARY EXAMINER: Leary, Louise N.
 LEGAL REPRESENTATIVE: Green, Esq., Reza

NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 768

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to compounds inhibiting the activation of FX to FXa by TF/FVIIa. The compounds are anticoagulants. The invention also relates to a method of identifying a drug candidate.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 14 OF 26 USPATFULL on STN

ACCESSION NUMBER: 2001:78905 USPATFULL
TITLE: FVIIa/TF activity inhibiting compounds
INVENTOR(S): Jakobsen, Palle, V.ae butted.rl.o slashed.se, Denmark
Persson, Egon, Åkarp, Sweden
PATENT ASSIGNEE(S): Novo Norkisk AIS, Bagsvaerd, Denmark (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6238878	B1	20010529
APPLICATION INFO.:	US 2000-616010		20000713 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. WO 2000-DK316, filed on 13 Jun 2000		

	NUMBER	DATE
PRIORITY INFORMATION:	DK 1999-840	19990614
	DK 1999-910	19990625
	DK 1999-1241	19990903
	US 1999-139714P	19990617 (60)
	US 1999-141416P	19990629 (60)
	US 1999-152863P	19990908 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Leary, Louise N.
LEGAL REPRESENTATIVE: Zelson, Esq., Steve T., Green, Esq., Reza
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1
LINE COUNT: 831

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to compounds inhibiting the activation of FX to FXa by TF/FVIIa. The compounds are anticoagulants. The invention also relates to a method of identifying a drug candidate.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 15 OF 26 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2000:900841 CAPLUS
DOCUMENT NUMBER: 134:37031
TITLE: FVIIA/TF activity inhibiting compounds
INVENTOR(S): Jakobsen, Palle; Persson, Egon
PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.
SOURCE: PCT Int. Appl., 25 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000077246	A2	20001221	WO 2000-DK316	20000613

WO 2000077246 A3 20010222

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR,
CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,
ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,
LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD,
SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU,
ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1192270 A2 20020403 EP 2000-934951 20000613

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO

JP 2003530819 T 20031021 JP 2001-503687 20000613

US 6238878 B1 20010529 US 2000-616010 20000713

US 6444434 B1 20020903 US 2001-844828 20010427

PRIORITY APPLN. INFO.:

DK 1999-840 A 19990614

US 1999-139714P P 19990617

DK 1999-910 A 19990625

US 1999-141416P P 19990629

DK 1999-1241 A 19990903

US 1999-152863P P 19990908

WO 2000-DK316 W 20000613

US 2000-616010 A1 20000713

AB The invention relates to compds. inhibiting the activation of FX to FXa by
TF/FVIIa. The compds. are anticoagulants. The invention also relates to
a method of identifying a drug candidate.

L11 ANSWER 16 OF 26 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2000:200595 CAPLUS

DOCUMENT NUMBER: 132:356267

TITLE: Tailor-made derivatizing agents for carbonyl compounds
using liquid chromatography

AUTHOR(S): Kempster, C.; Potter, W.; Binding, N.; Klaning, H.;
Witting, U.; Karst, U.

CORPORATE SOURCE: Wilhelm-Klemm-Str. 8, Abteilung Analytische Chemie,
Westfalische Wilhelms-Universitat Munster,
Anorganisch-Chemisches Institut, Munster, D-48149,
Germany

SOURCE: Analytica Chimica Acta (2000), 410(1-2), 47-64

CODEN: ACACAM; ISSN: 0003-2670

PUBLISHER: Elsevier Science B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A new approach for the synthesis and application of tailor-made
derivatizing agents for liquid chromatog. is presented. The s-triazine ring
serves as the backbone for these substances. Synthesis was performed in
three steps based on substitution reactions of cyanuric chloride. A
chromophore or fluorophore, a reactive group and a 3rd moiety intended to
modify the polarity of the derivatizing agent are coupled to cyanuric
chloride. The three groups may be selected freely from mols. which carry
functional groups which might be linked to cyanuric chloride. As an
example, the synthesis and application of a resp. reagent for the
determination of

aldehydes and ketones using HPLC with fluorescence detection is carried
out. Baseline separation of the derivs. and low limits of detection ($1.5 + 10^{-9}$ mol/L for formaldehyde, $2.0 + 10^{-9}$ mol/L for
acetaldehyde and $3.0 + 10^{-9}$ mol/L for p-tolualdehyde) were obtained
with the new versatile reagent.

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 17 OF 26 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1999:464283 CAPLUS

DOCUMENT NUMBER: 131:111412
 TITLE: Triazine antiviral compounds
 INVENTOR(S): Arenas, Jaime E.; Cload, Sharon T.; Fleming, Elizabeth S.; Xiang, Yi Bin
 PATENT ASSIGNEE(S): Scriptgen Pharmaceuticals, Inc., USA
 SOURCE: PCT Int. Appl., 194 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9936410	A1	19990722	WO 1999-US945	19990113
W: CA, GD, HR, ID, IN, JP				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2318362	A1	19990722	CA 1999-2318362	19990113
EP 1053230	A1	20001122	EP 1999-902309	19990113
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002509140	T	20020326	JP 2000-540126	19990113
PRIORITY APPLN. INFO.:			US 1998-6430	A 19980113
			WO 1999-US945	W 19990113

OTHER SOURCE(S): MARPAT 131:111412

AB Pharmaceutical formulations comprising 1,3,5-triazine derivs. are provided. The compds. and formulations of the invention exhibit a range of activities, including antiviral and antibiotic activities, and the formulations may be used, alone or in combination, as a method of treating a patient in need of antiviral and/or antibiotic therapy. The triazine derivs. bind to and inhibit functional nucleic acids, and hence, have broad applicability in the treatment of conditions associated with DNA and RNA viruses.

REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 18 OF 26 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1999:653431 CAPLUS

DOCUMENT NUMBER: 132:116597

TITLE: Superoxide scavenger copper(II) complexes having bis(hydrazino-triazine) ligands: an EPR and MM+ study
 AUTHOR(S): Palivan, C. G.; Darmon, C. E.; Thomas, St.

CORPORATE SOURCE: Faculty of Physics, Department of Atomic and Nuclear Physics, University of Bucharest, Bucharest-Magurele, Rom.

SOURCE: Bulletin of Magnetic Resonance (1999), 19(1/4), 29-33
 CODEN: BUMRDT; ISSN: 0163-559X

PUBLISHER: International Society of Magnetic Resonance

DOCUMENT TYPE: Journal

LANGUAGE: English

AB EPR spectrometry and mol. mechanics force-field calcns. were used to characterize the coordination around the metal ions in four superoxide scavenger Cu(II) complexes having bis(salicylhydrazino-triazine) ligands. The distorted N2O2 square planar arrangement around Cu as well as the presence of N4O2 coordination is proposed as an explanation for the difference between their superoxide dismutase (SOD) activity and those described in a previous study.

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 19 OF 26 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1991:134825 CAPLUS

DOCUMENT NUMBER: 114:134825

TITLE: Complexation property for alkali metal salts of
hydrazone-type bis-crown ethers

AUTHOR(S): Lu, Guoyuan; Wang, Defeng; Shi, Xiaolin; Hu, Hongwen

CORPORATE SOURCE: Dep. Chem., Nanjing Univ., Nanjing, Peop. Rep. China


SOURCE: Wuji Huaxue Xuebao (1989), 5(4), 72-8

CODEN: WHUXEO; ISSN: 1001-4861

DOCUMENT TYPE: Journal

LANGUAGE: Chinese

GI



AB I (E = N, E' = CH, R = H, n = 2; E = E' = N, R = NHPh, Pr, n = 2; E = CNO₂, E' = CH, R = H, n = 2, 3) were prepared by the reactions of the bishydrazines with 4'-formylbenzo-15-crown-5 and -benzo-18-crown-6 and characterized by elemental anal., IR, ¹H NMR, and mass spectroscopy. The stoichiometry of the complexes formed by I with alkali metal cation was determined by electrocond. titration of the ligand with alkali metal tetraphenylborate solns. I containing benzo-15-crown-5 units formed 2:1 I:metal sandwich type complexes with K⁺, Rb⁺ and Cs⁺. I containing benzo-18-crown-6 units only formed 2:1 complexes with Cs⁺. Extns. were carried out from aqueous alkali metal picrates solution with I solution in CHCl₃ and extraction equilibrium consts. were evaluated. Their extractability and cation-selectivity are more effectively than the corresponding monocyclic crown ethers.

L11 ANSWER 20 OF 26 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1986:85250 CAPLUS

DOCUMENT NUMBER: 104:85250

TITLE: Studies on 1,3,5-triazines as antibacterial agents

AUTHOR(S): Patel, J. M.; Dave, M. P.; Thaker, K. A.

CORPORATE SOURCE: Dep. Chem., Bhavnagar Univ., Bhavnagar, 364 002, India


SOURCE: Journal of the Institution of Chemists (India) (1985), 57(3), 111-12

CODEN: JOICA7; ISSN: 0020-3254

DOCUMENT TYPE: Journal


LANGUAGE: English

GI



AB Twenty-six title compds. (I; R1 = Ph; 2-Cl = C6H4, 2-MeOC6H4, 4-EtCO2C6H4, α -naphthalenyl, etc. and R2 = H or Cl) were prepared, in several steps starting from the substitution reaction of p-anisidine [104-94-9] with cyanuric chloride [108-77-0], and tested for inhibitory activity against Staphylococcus aureus and Escherichia coli in vitro.

L11 ANSWER 21 OF 26 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1985:6429 CAPLUS
 DOCUMENT NUMBER: 102:6429
 TITLE: Synthesis of substituted 1,3,5-triazines as tuberculostatic agents
 AUTHOR(S): Dave, M. P.; Patel, J. M.; Langalia, N. A.; Thaker, K. A.
 CORPORATE SOURCE: Dep. Chem., Bhavnagar Univ., Bhavnagar, 364 002, India
 SOURCE: Journal of the Indian Chemical Society (1984), 61(3), 237-8
 CODEN: JICSAH; ISSN: 0019-4522
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 102:6429
 GI



AB A series of 2,4-bis(arylamino)-6-(pyridine-4-carboxyhydrazido/substituted benzhydrazido)-1,3,5-triazines has been synthesized and tested against Mycobacterium tuberculosis strain H27Rv. Some of them, e.g. I (R = o-, p-ClC6H4), have shown significant tuberculostatic activity.

L11 ANSWER 22 OF 26 USPATFULL on STN
 ACCESSION NUMBER: 77:35798 USPATFULL
 TITLE: Triazine derivatives as stabilizers for organic materials
 INVENTOR(S): Hofer, Kurt, Munchenstein, Switzerland
 Tscheulin, Guenther, Riehen, Switzerland
 PATENT ASSIGNEE(S): Sandoz Ltd., Basel, Switzerland (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4033957		19770705
APPLICATION INFO.:	US 1974-529024		19741203 (5)

	NUMBER	DATE
PRIORITY INFORMATION:	CH 1973-17269	19731210
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Rush, Raymond V.	
ASSISTANT EXAMINER:	Tovar, Jose	
LEGAL REPRESENTATIVE:	Sharkin, Gerald D., Vila, Richard E., Borovian, Joseph J.	
NUMBER OF CLAIMS:	10	
EXEMPLARY CLAIM:	1	
LINE COUNT:	379	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Triazine derivatives of formula ##STR1## in which R.sub.1 is a tertiary alkyl radical,

R.sub.2 is hydrogen or a substituent, e.g. alkyl,

n is 0 or an integer,

R.sub.3 is --NH-- or --O--CH.sub.3 --.sub.m

Wherein m is an integer,

X is --O--, --S-- or --NR.sub.6 --,

wherein R.sub.6 is hydrogen or a substituent, e.g. alkyl or phenyl,

R.sub.4 is one of the radicals signified by R.sub.6, or, when X is --NH--, a radical of formula ##STR2## R.sub.1, R.sub.2, n and R.sub.3 being as indicated above, OR R.sub.4, R.sub.6 and the common nitrogen atom, and optionally a further hetero atom, form a saturated 5- or 6-membered heterocyclic ring,

And R.sub.5 is one of the radicals signified by --X--R.sub.4, or a substituent, e.g. alkyl,

Are useful for stabilizing organic materials, e.g. polypropylene, against the degradative effects of oxygen, heat and/or light.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 23 OF 26 USPATFULL on STN

ACCESSION NUMBER: 76:27633 USPATFULL

TITLE: Aromatic heterocyclic hydrazide derivatives

INVENTOR(S): Hofer, Kurt, Munchenstein, Switzerland

Tscheulin, Guenther, Rieben, Switzerland

PATENT ASSIGNEE(S): Sandoz Ltd., Basel, Switzerland (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 3957765		19760518
APPLICATION INFO.:	US 1974-456630		19740401 (5)

	NUMBER	DATE
PRIORITY INFORMATION:	CH 1973-4917	19730405
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Curtis, Allen B.	
LEGAL REPRESENTATIVE:	Sharkin, Gerald D., Vila, Richard E., Borovian, Joseph J.	
NUMBER OF CLAIMS:	10	
EXEMPLARY CLAIM:	1	
LINE COUNT:	321	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention concerns novel aromatic heterocyclic hydrazide derivatives of the formula: ##SPC1##

Wherein A is a radical ##SPC2##

Wherein R.sub.1 is tertiary alkyl and R.sub.2 and R.sub.3 are hydrogen or substituents, e.g. alkyl, R.sub.4 is a group -X-R.sub.14.sub.1 wherein X is a bridging function, e.g. O, and R.sub.14 is a substituent, e.g. alkyl, a heterocyclic group

--N Z

wherein Z, with the nitrogen atom, forms a heterocyclic ring or a radical -NH-A, wherein A is as defined above, R.sub.5 has inter alia one of the significances of R.sub.4 and Y is -N= or -CH=, which are useful antioxidants, e.g. for stabilizing plastics material.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 24 OF 26 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1975:565032 CAPLUS
DOCUMENT NUMBER: 83:165032
TITLE: Compounds for stabilizing organic materials
INVENTOR(S): Hofer, Kurt; Tscheulin, Guenther
PATENT ASSIGNEE(S): Sandoz-Patent-G.m.b.H., Fed. Rep. Ger.
SOURCE: Ger. Offen., 28 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2456735	A1	19750612	DE 1974-2456735	19741130
CH 582231	A5	19761130	CH 1973-17269	19731210
SE 7415066	A	19750611	SE 1974-15066	19741202
US 4033957	A	19770705	US 1974-529024	19741203
FR 2253745	A1	19750704	FR 1974-39796	19741205
FR 2253745	B1	19780623		
NL 7415919	A	19750612	NL 1974-15919	19741206
BE 823135	A1	19750609	BE 1974-151319	19741209
JP 50088081	A	19750715	JP 1974-140597	19741209
ES 432714	A1	19770216	ES 1974-432714	19741209
GB 1492770	A	19771123	GB 1974-53222	19741209
AT 7409793	A	19781015	AT 1974-9793	19741209
ES 451576	A1	19780101	ES 1976-451576	19760916
PRIORITY APPLN. INFO.:			CH 1973-17269	A 19731210
			ES 1974-432714	A3 19741209

GI For diagram(s), see printed CA Issue.

AB The compds. I (7) with R and R1 = morpholino, piperidino, anilino, 2-methylanilino, and/or C8H17S and Z = NHCOCH2CH2, NHCO, or (CH2)3O2C were prepared for use as stabilizers for compds. such as polypropylene (II) [9003-07-0]. Thus, a mixture of 2-hydrazino-4,6-dimorpholino-s-triazine [13017-47-5] 4, Et3N 2, and dioxane 40 parts was treated with a solution of 4.4 parts 3-(3,5-di-tert-butyl-4-hydroxyphenyl)propionyl chloride [3062-64-4] and heated to 70° during 2 hr to prepare I (R = R1 = morpholino, Z = NHCOCH2CH2) [56631-83-5], which was mixed (0.4%) with II as an antioxidant.

L11 ANSWER 25 OF 26 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1975:99248 CAPLUS
DOCUMENT NUMBER: 82:99248
TITLE: [(Hydroxybenzylidene)hydrazino]triazines as antioxidants
INVENTOR(S): Hofer, Kurt; Tscheulin, Guenther
PATENT ASSIGNEE(S): Sandoz Ltd.
SOURCE: Ger. Offen., 26 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2416020	A1	19741024	DE 1974-2416020	19740402
CH 567484	A5	19751015	CH 1973-4917	19730405
US 3957765	A	19760518	US 1974-456630	19740401
GB 1468225	A	19770323	GB 1974-14649	19740402
BE 813260	A1	19741003	BE 1974-142818	19740403
JP 49127987	A	19741207	JP 1974-37751	19740403
ES 424900	A1	19761016	ES 1974-424900	19740403
FR 2224465	A1	19741031	FR 1974-12083	19740405
IT 1015903	B	19770520	IT 1974-50190	19740405
PRIORITY APPLN. INFO.:			CH 1973-4917	A 19730405

GI For diagram(s), see printed CA Issue.

AB Seven triazines I (R,R1 = e.g. arylamino or morpholino) were prepared and used in 0.4% addition as antioxidants for polypropylene [9003-07-0]. Thus, refluxing 2,4-dimorpholino-6-hydrazino-s-triazine [13017-47-5] and 4,3,5-HO(Me3C)2C6H2CHO [1620-98-0] in C6H6 for 12 hr gave 6-[(3,5-di-tert-butyl-4-hydroxybenzylidene)hydrazino]-2,4-dimorpholino-s-triazine [54589-58-1].

L11 ANSWER 26 OF 26 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1972:114288 CAPLUS

DOCUMENT NUMBER: 76:114288

TITLE: Stabilizers for polyolefins

INVENTOR(S): Mueller, Helmut; Rosenberger, Siegfried; Schwarzenbach, Kurt

PATENT ASSIGNEE(S): Ciba-Geigy A.-G.

SOURCE: Ger. Offen., 68 pp.

CODEN: GWXXBX

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2129996	A	19711223	DE 1971-2129996	19710616
CH 534706	A	19730430	CH 1970-9182	19700617
CH 542257	A	19731115	CH 1970-14666	19701002
US 3850918	A	19741126	US 1971-150757	19710607
GB 1335602	A	19731031	GB 1971-27846	19710614
NL 7108285	A	19711221	NL 1971-8285	19710616
FR 2099116	A5	19720310	FR 1971-21873	19710616
AT 304877	B	19730125	AT 1971-5204	19710616
ES 392294	A1	19740616	ES 1971-392294	19710616
SU 381224	A3	19730515	SU 1971-1676386	19710617
US 4007183	A	19770208	US 1974-471408	19740520
PRIORITY APPLN. INFO.:			CH 1970-9182	A 19700617
			CH 1970-14666	A 19701002
			SE 1970-9182	A 19700617
			SE 1970-14666	A 19701002
			US 1971-150757	A3 19710607

AB Salicyloylhydrazino-s-triazines (I) [e.g., R = NPr2, OPr, NMe28 morpholino, NHMe, NHPr, NHC8H17, Pr, Ph, NHPh, NHNHCO6H4OH-2, N(CH2CH2tBu)2, dicyclohexylamino, NHC18H37, N(C18H37)2], are prepared Thus 2-(dipropylamino)-4,6-hydrazino-s-triazine [prepared from N2H4.HCl and 2-(dipropylamino)-4,6-dichloro-s-triazine] reacts with salicyloyl chloride in AcNMe2 at room temperature with cooling to give 2-(dipropylamino)-4,6-bis(salicyloylhydrazino)-s-triazine (II) [34415-01-5]. I are excellent in polyolefins, (e.g., polypropylene [9003-07-0]) at 0.1-0.8 wt% as antioxidants, metal deactivators, and as color stabilizers, and in synergistic combinations with other stabilizers.

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1616BSK

PASSWORD:

* * * * * RECONNECTED TO STN INTERNATIONAL * * * * *
SESSION RESUMED IN FILE 'CAPLUS, USPATFULL' AT 16:33:15 ON 20 DEC 2006
FILE 'CAPLUS' ENTERED AT 16:33:15 ON 20 DEC 2006
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)
FILE 'USPATFULL' ENTERED AT 16:33:15 ON 20 DEC 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)
COST IN U.S. DOLLARS

	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	153.37	682.10

	SINCE FILE	TOTAL
	ENTRY	SESSION
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)		
CA SUBSCRIBER PRICE	-15.75	-18.00

=> file reg
COST IN U.S. DOLLARS

	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	153.37	682.10

	SINCE FILE	TOTAL
	ENTRY	SESSION
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)		
CA SUBSCRIBER PRICE	-15.75	-18.00

FILE 'REGISTRY' ENTERED AT 16:33:25 ON 20 DEC 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 19 DEC 2006 HIGHEST RN 916029-54-4
DICTIONARY FILE UPDATES: 19 DEC 2006 HIGHEST RN 916029-54-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\edg-2-3.str

L12 STRUCTURE UPLOADED

=> s sss full l12
FULL SEARCH INITIATED 16:33:43 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 28156 TO ITERATE

100.0% PROCESSED 28156 ITERATIONS 4053 ANSWERS
SEARCH TIME: 00.00.01

L13 4053 SEA SSS FUL L12

=> file caplus uspatful
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
166.94	849.04

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
0.00	-18.00

CA SUBSCRIBER PRICE

FILE 'CAPLUS' ENTERED AT 16:33:51 ON 20 DEC 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 16:33:51 ON 20 DEC 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

=> s l13

L14 1909 L13

=> s l14 and (cancer or tumour or tumor or carcinoma or neoplas? or chemo? or cancer?)

L15 42 L14 AND (CANCER OR TUMOUR OR TUMOR OR CARCINOMA OR NEOPLAS? OR CHEMO? OR CANCER?)

=> dup rem l15

PROCESSING COMPLETED FOR L15

L16 41 DUP REM L15 (1 DUPLICATE REMOVED)

=> focus

PROCESSING COMPLETED FOR L16

L17 41 FOCUS L16 1-

=> d ibib abs 1-41 hitstr

L17 ANSWER 1 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:754380 CAPLUS

DOCUMENT NUMBER: 137:263071

TITLE: Preparation of trisubstituted 2,4,6-triamino[1,3,5]triazines as anti-telomerase agents

INVENTOR(S): Mailliet, Patrick; Laoui, Abdelazize; Riou, Jean-Francois; Doerflinger, Gilles; Mergny, Jean-Louis; Hamy, Francois; Caulfield, Thomas

PATENT ASSIGNEE(S): Aventis Pharma S.A., Fr.

SOURCE: PCT Int. Appl., 208 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002076975	A1	20021003	WO 2002-FR1005	20020322
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
 PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
 UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
 CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG



FR 2822468 A1 20020927 FR 2001-3916 20010323
 CA 2442012 A1 20021003 CA 2002-2442012 20020322
 EP 1373252 A1 20040102 EP 2002-720068 20020322

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

JP 2004524349 T 20040812 JP 2002-576233 20020322
 US 2003087931 A1 20030508 US 2002-103883 20020325
 US 6887873 B2 20050503
 US 2005070571 A1 20050331 US 2004-993637 20041119

PRIORITY APPLN. INFO.: FR 2001-3916 A 20010323
 FR 2001-10370 A 20010802
 US 2001-332009P P 20011123
 WO 2002-FR1005 W 20020322
 US 2002-103883 A3 20020325

OTHER SOURCE(S): MARPAT 137:263071
 GI



AB Title compds. I [A = XR1R2; X = N, O, S, alkyl radical; R1-2 = H, alkyl, heterocyclyl, etc.; R3-3' = H, alkyl, isoquinolinyl, quinolinyl, etc.; Ar1-2 = (un)substituted Ph, etc., and derivs. thereof] were prepared For instance, 2,4-bis[(4-(dimethylamino)-2-methylquinolin-6-yl)amino]-6-chloro[1,3,5]triazine (prior art) was reacted with N,N-dimethyl-1,3-propanediamine in DMF with K2CO3 for 15 h at 100° to afford II. Examples include evaluation of all compds. of the invention for telomerase activity. I are anti-cancer agents.

IT 462649-12-3P, 2-[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-
[[4-dimethylamino-2-methylquinolin-6-yl]amino]-6-[[3-
(dimethylamino)propyl]amino]triazine 462649-16-7P,
2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[2-chlorophenyl]amino]-6-[[2-
(dimethylamino)ethyl]amino]triazine 462649-17-8P,
2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[2-chlorophenyl]amino]-6-[[3-
(dimethylamino)propyl]amino]triazine 462649-20-3P,
2-[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-
methylquinolin-6-yl]amino]-6-[[3-(dimethylamino)propyl]amino]triazine
462649-23-6P, 2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-
2-methylquinolin-6-yl]amino]-6-[[3-(dimethylamino)propyl]amino]triazine
462649-36-1P, 2-[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-
[[4-dimethylamino-2-methylquinolin-6-yl]amino]-6-[[2-
methoxyethyl]amino]triazine 462649-37-2P, 2-[[4-Dimethylamino-2-
methylquinolin-6-yl]amino]-4-[[4-dimethylamino-2-methylquinolin-6-
yl]amino]-6-[[phenethyl]amino]triazine 462649-38-3P,
2-[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-[[4-dimethylamino-2-
methylquinolin-6-yl]amino]-6-[[pyridin-4-yl]methyl]amino]triazine
462649-39-4P, 2-[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-
[[4-dimethylamino-2-methylquinolin-6-yl]amino]-6-[[N-(3-methylphenyl)-N-
ethylamino]methyl]amino]triazine 462649-41-8P,
2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-
yl]amino]-6-[[2-(dimethylamino)ethyl]amino]triazine 462649-42-9P
, 2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-
yl]amino]-6-((benzyl)amino)triazine 462649-44-1P,
2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-
yl]amino]-6-((2-(acetylaminomethyl)amino)triazine 462649-45-2P,
2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-
yl]amino]-6-((2-(diethylamino)ethyl)amino)triazine 462649-46-3P,
2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-
yl]amino]-6-[[2-[N-(2-(dimethylamino)ethyl)-N-
(benzyl)amino]ethyl]amino]triazine 462649-47-4P,
2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-
yl]amino]-6-((2-((methoxycarbonyl)amino)ethyl)amino)triazine
462649-48-5P, 2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-
2-methylquinolin-6-yl]amino]-6-[[2-(diisopropylamino)ethyl]amino]triazine
462649-54-3P, 2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-
2-methylquinolin-6-yl]amino]-6-[[[1-ethylpyrrolidin-2-
yl]methyl]amino]triazine 462649-55-4P, 2-[[4-Amino-2-
methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-[[2-
(pyrrolidinyl)ethyl]amino]triazine 462649-56-5P,
2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-
yl]amino]-6-[[[pyridin-4-yl]methyl]amino]triazine 462649-57-6P,
2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-
yl]amino]-6-[[[1-methylpiperidin-4-yl]methyl]amino]triazine
462649-58-7P, 2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-
2-methylquinolin-6-yl]amino]-6-[[[pyridin-2-yl]methyl]amino]triazine
462649-60-1P, 2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-
2-methylquinolin-6-yl]amino]-6-[[3-methoxybenzyl]amino]triazine
462649-61-2P 462649-72-5P, 2-[[4-Amino-2-methylquinolin-
6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-[[[pyridin-3-
yl]methyl]amino]triazine 462649-73-6P, 2-[[4-Amino-2-
methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-[[4-
chlorobenzyl]amino]triazine 462649-80-5P, 2-[[4-Amino-2-
methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-[[[4-
benzylpiperazinyl]methyl]amino]triazine 462649-86-1P,
2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-
yl]amino]-6-[[2-[morpholinyl]ethyl]amino]triazine 462649-87-2P,
2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-
yl]amino]-6-[[[isoquinolin-5-yl]methyl]amino]triazine 462649-89-4P
, 2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-
yl]amino]-6-[[4-methoxybenzyl]amino]triazine 462649-90-7P,
2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-
yl]amino]-6-[[2-methoxyethyl]amino]triazine 462649-91-8P,


2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-[[[4-dimethylaminophenyl]methyl]amino]triazine
 462649-96-3P, 2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-[[2-(piperidinyl)ethyl]amino]triazine
 462649-97-4P, 2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-[[2-(isopropylamino)ethyl]amino]triazine
 462650-53-9P, 2-[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-[[4-dimethylamino-2-methylquinolin-6-yl]amino]-6-[[[4-benzylpiperazinyl]methyl]amino]triazine 462650-55-1P
 462650-62-0P, 2-[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-[[4-dimethylamino-2-methylquinolin-6-yl]amino]-6-[[2-(acetylamino)ethyl]amino]triazine 462650-68-6P,
 2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-[[2-methoxy-2-methylethyl]amino]triazine 462650-69-7P
 , 2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-[[2-hydroxymethyl-2-ethylethyl]amino]triazine
 462650-70-0P, 2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-[[2-hydroxyethyl]amino]triazine
 462650-77-7P, 2-[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-[[4-dimethylamino-2-methylquinolin-6-yl]amino]-6-[[2-methoxy-2-methylethyl]amino]triazine 462650-78-8P, 2-[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-[[4-dimethylamino-2-methylquinolin-6-yl]amino]-6-[[2-hydroxymethyl-2-ethylethyl]amino]triazine
 462650-79-9P, 2-[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-[[4-dimethylamino-2-methylquinolin-6-yl]amino]-6-[[2-hydroxyethyl]amino]triazine 462650-82-4P, 2-[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-[[4-dimethylamino-2-methylquinolin-6-yl]amino]-6-[[1,3-dihydroxypropan-2-yl]amino]triazine 462650-83-5P
 462650-84-6P 462650-85-7P, 2-[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-[[4-dimethylamino-2-methylquinolin-6-yl]amino]-6-[[1,2-dihydroxyethyl]amino]triazine 462650-88-0P,
 2-[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-[[4-dimethylamino-2-methylquinolin-6-yl]amino]-6-[[2-morpholinoethyl]amino]triazine
 462650-89-1P, 2-[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-[[4-dimethylamino-2-methylquinolin-6-yl]amino]-6-[[2-piperidinylethyl]amino]triazine 462651-00-9P,
 2-[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-[[4-dimethylamino-2-methylquinolin-6-yl]amino]-6-[[4-methoxybenzyl]amino]triazine
 462651-01-0P, 2-[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-[[4-dimethylamino-2-methylquinolin-6-yl]amino]-6-[[2-(isopropylamino)ethyl]amino]triazine 462651-05-4P,
 2-[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-[[4-dimethylamino-2-methylquinolin-6-yl]amino]-6-[[[4-isopropylpiperazinyl]carbonyl]methyl]amino]triazine 462651-06-5P, 2-[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-[[4-dimethylamino-2-methylquinolin-6-yl]amino]-6-[[3-[2-methylpiperidinyl]propyl]amino]triazine 462651-08-7P,
 2-[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-[[4-dimethylamino-2-methylquinolin-6-yl]amino]-6-[[5-(piperidinyl)pentyl]amino]triazine
 462651-10-1P, 2-[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-[[4-dimethylamino-2-methylquinolin-6-yl]amino]-6-[[2-(imidazolyl)ethyl]amino]triazine 462652-84-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of trisubstituted 2,4,6-triamino[1,3,5]triazines as anti-telomerase agents)


RN 462649-12-3 CAPLUS

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis[4-(dimethylamino)-2-methyl-6-quinolinyl]-N''-[3-(dimethylamino)propyl]- (9CI) (CA INDEX NAME)




RN 462649-16-7 CAPLUS

CN 1,3,5-Triazine-2,4,6-triamine, N-(4-amino-2-methyl-6-quinolinyl)-N'-(2-chlorophenyl)-N''-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 462649-17-8 CAPLUS

CN 1,3,5-Triazine-2,4,6-triamine, N-(4-amino-2-methyl-6-quinolinyl)-N'-(2-chlorophenyl)-N''-[3-(dimethylamino)propyl]- (9CI) (CA INDEX NAME)




RN 462649-20-3 CAPLUS

CN 1,3,5-Triazine-2,4,6-triamine, N-(4-amino-2-methyl-6-quinolinyl)-N'-(4-(dimethylamino)-2-methyl-6-quinolinyl)-N''-[3-(dimethylamino)propyl]- (9CI) (CA INDEX NAME)




RN 462649-23-6 CAPLUS

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinolinyl)-N''-[3-(dimethylamino)propyl]- (9CI) (CA INDEX NAME)




RN 462649-36-1 CAPLUS

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis[4-(dimethylamino)-2-methyl-6-quinolinyl]-N''-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 462649-37-2 CAPLUS

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis[4-(dimethylamino)-2-methyl-6-quinolinyl]-N''-(2-phenylethyl)- (9CI) (CA INDEX NAME)




RN 462649-38-3 CAPLUS

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis[4-(dimethylamino)-2-methyl-6-quinolinyl]-N''-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 462649-39-4 CAPLUS

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis[4-(dimethylamino)-2-methyl-6-quinolinyl]-N''-[[ethyl(3-methylphenyl)amino]methyl]- (9CI) (CA INDEX NAME)




RN 462649-41-8 CAPLUS

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinolinyl)-N''-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 462649-42-9 CAPLUS

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinolinyl)-N''-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 462649-44-1 CAPLUS

CN Acetamide, N-[2-[[4,6-bis[(4-amino-2-methyl-6-quinolinyl)amino]-1,3,5-triazin-2-yl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 462649-45-2 CAPLUS

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinolinyl)-N''-[2-(diethylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 462649-46-3 CAPLUS

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinolinyl)-N''-[2-[[2-(dimethylamino)ethyl](phenylmethyl)amino]ethyl]- (9CI) (CA INDEX NAME)




RN 462649-47-4 CAPLUS

CN Carbamic acid, [2-[[4,6-bis[(4-amino-2-methyl-6-quinolinyl)amino]-1,3,5-triazin-2-yl]amino]ethyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 462649-48-5 CAPLUS

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinolinyl)-N''-[2-[bis(1-methylethyl)amino]ethyl]- (9CI) (CA INDEX NAME)




RN 462649-54-3 CAPLUS

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinolinyl)-N''-[1-ethyl-2-pyrrolidinyl)methyl]- (9CI) (CA INDEX NAME)




RN 462649-55-4 CAPLUS

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinolinyl)-N''-[2-(1-pyrrolidiny)ethyl]- (9CI) (CA INDEX NAME)




RN 462649-56-5 CAPLUS

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinolinyl)-N''-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 462649-57-6 CAPLUS

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinolinyl)-N''-[(1-methyl-4-piperidinyl)methyl]- (9CI) (CA INDEX NAME)




RN 462649-58-7 CAPLUS

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinolinyl)-N''-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 462649-60-1 CAPLUS

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinolinyl)-N''-[(3-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 462649-61-2 CAPLUS

CN Ethanaminium, 2-[[[4,6-bis[(4-amino-2-methyl-6-quinolinyl)amino]-1,3,5-triazin-2-yl]amino]-N,N,N-trimethyl-, chloride (9CI) (CA INDEX NAME)




● Cl⁻


RN 462649-72-5 CAPLUS
 CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinolinyl)-N''-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 462649-73-6 CAPLUS
 CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinolinyl)-N''-[(4-chlorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 462649-80-5 CAPLUS
 CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinolinyl)-N''-[4-(phenylmethyl)-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)




RN 462649-86-1 CAPLUS

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinolinyl)-N''-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 462649-87-2 CAPLUS

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinolinyl)-N''-(5-isoquinolinylmethyl)- (9CI) (CA INDEX NAME)




RN 462649-89-4 CAPLUS

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinolinyl)-N''-[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 462649-90-7 CAPLUS

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinolinyl)-N''-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 462649-91-8 CAPLUS

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinolinyl)-N''-[[4-(dimethylamino)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 462649-96-3 CAPLUS

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinolinyl)-N''-[2-(1-piperidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 462649-97-4 CAPLUS

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinolinyl)-N''-[2-[(1-methylethyl)amino]ethyl]- (9CI) (CA INDEX NAME)




RN 462650-53-9 CAPLUS

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis[4-(dimethylamino)-2-methyl-6-quinolinyl]-N''-[4-(phenylmethyl)-1-piperazinylmethyl]- (9CI) (CA INDEX NAME)



RN 462650-55-1 CAPLUS


CN Ethanaminium, 2-[[4,6-bis[[4-(dimethylamino)-2-methyl-6-quinolinyl]amino]-1,3,5-triazin-2-yl]amino]-N,N,N-trimethyl-, chloride (9CI) (CA INDEX NAME)



● Cl^-


RN 462650-62-0 CAPLUS

CN Acetamide, N-[2-[[[4,6-bis[[4-(dimethylamino)-2-methyl-6-quinolinyl]amino]-1,3,5-triazin-2-yl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 462650-68-6 CAPLUS

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinolinyl)-N''-(2-methoxypropyl)- (9CI) (CA INDEX NAME)




RN 462650-69-7 CAPLUS

CN 1-Butanol, 2-[[[4,6-bis[[4-amino-2-methyl-6-quinolinyl]amino]-1,3,5-triazin-2-yl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 462650-70-0 CAPLUS

CN Ethanol, 2-[[4,6-bis[[4-amino-2-methyl-6-quinolinyl]amino]-1,3,5-triazin-2-yl]amino]- (9CI) (CA INDEX NAME)




RN 462650-77-7 CAPLUS

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis[4-(dimethylamino)-2-methyl-6-quinolinyl]-N''-(2-methoxypropyl)- (9CI) (CA INDEX NAME)




RN 462650-78-8 CAPLUS

CN 1-Butanol, 2-[[[4,6-bis[[4-(dimethylamino)-2-methyl-6-quinolinyl]amino]-1,3,5-triazin-2-yl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 462650-79-9 CAPLUS

CN Ethanol, 2-[[4,6-bis[[4-(dimethylamino)-2-methyl-6-quinolinyl]amino]-1,3,5-triazin-2-yl]amino]- (9CI) (CA INDEX NAME)




RN 462650-82-4 CAPLUS

CN 1,3-Propanediol, 2-[[[4,6-bis[[4-(dimethylamino)-2-methyl-6-quinolinyl]amino]-1,3,5-triazin-2-yl]amino]- (9CI) (CA INDEX NAME)



RN 462650-83-5 CAPLUS


CN 1,3-Propanediol, 2-[[[4,6-bis[(4-amino-2-methyl-6-quinolinyl)amino]-1,3,5-triazin-2-yl]amino]- (9CI) (CA INDEX NAME)



RN 462650-84-6 CAPLUS


CN 1,2-Ethanediol, 1-[[[4,6-bis[(4-amino-2-methyl-6-quinolinyl)amino]-1,3,5-triazin-2-yl]amino]phenylmethyl]-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 462650-85-7 CAPLUS

CN 1,2-Ethanediol, 1-[[[4,6-bis[[4-(dimethylamino)-2-methyl-6-quinolinyl]amino]-1,3,5-triazin-2-yl]amino]- (9CI) (CA INDEX NAME)




RN 462650-88-0 CAPLUS

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis[4-(dimethylamino)-2-methyl-6-quinolinyl]-N''-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 462650-89-1 CAPLUS

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis[4-(dimethylamino)-2-methyl-6-quinolinyl]-N''-[2-(1-piperidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 462651-00-9 CAPLUS

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis[4-(dimethylamino)-2-methyl-6-quinolinyl]-N''-[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 462651-01-0 CAPLUS

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis[4-(dimethylamino)-2-methyl-6-quinolinyl]-N''-[2-[(1-methylethyl)amino]ethyl]- (9CI) (CA INDEX NAME)




RN 462651-05-4 CAPLUS

CN Piperazine, 1-[[[4,6-bis[[4-(dimethylamino)-2-methyl-6-quinolinyl]amino]-1,3,5-triazin-2-yl]amino]acetyl]-4-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 462651-06-5 CAPLUS

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis[4-(dimethylamino)-2-methyl-6-quinolinyl]-N''-[3-(2-methyl-1-piperidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 462651-08-7 CAPLUS

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis[4-(dimethylamino)-2-methyl-6-quinolinyl]-N''-[5-(1-piperidiny)pentyl]- (9CI) (CA INDEX NAME)




RN 462651-10-1 CAPLUS

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis[4-(dimethylamino)-2-methyl-6-quinolinyl]-N''-[2-(1H-imidazol-1-yl)ethyl]- (9CI) (CA INDEX NAME)



RN 462652-84-2 CAPLUS

CN 1-Propanol, 2-[[4,6-bis[[4-(dimethylamino)-2-methyl-6-quinolinyl]amino]-1,3,5-triazin-2-yl]amino]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 2 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:472151 CAPLUS

DOCUMENT NUMBER: 143:26644

TITLE: Preparation of triazine dimers for the treatment of autoimmune diseases

INVENTOR(S): Penney, Christopher; Zacharie, Boulos; Abbott, Shaun D.; Bienvenu, Jean-Francois; Cameron, Alan D.; Duceppe, Jean-Simon; Ezzitouni, Abdallah; Fortin, Daniel; Houde, Karine; Moreau, Nancie; Wilb, Nicole; Grouix, Brigitte; Gagnon, Lyne

PATENT ASSIGNEE(S): Prometic Biosciences Inc., Can.

SOURCE: PCT Int. Appl., 103 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005049607	A1	20050602	WO 2004-CA2003	20041122
WO 2005049607	B1	20050714		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004291186	A1	20050602	AU 2004-291186	20041122
CA 2554635	A1	20050602	CA 2004-2554635	20041122
EP 1687297	A1	20060809	EP 2004-818743	20041122

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS

PRIORITY APPLN. INFO.: US 2003-524021P P 20031124
WO 2004-CA2003 W 20041122

OTHER SOURCE(S): MARPAT 143:26644

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [A = (CH₂)_n; n = 0-2; B = 0, -CH(Ph)-, II, etc.; Y, Y' =

CH, N; C = (CH₂)_n, -CH(CH₃)-; X = NH, O, S; R₁, R₂, R₃, R₄ = H, alkenyl, hydroxyalkyl, etc.] and their pharmaceutically acceptable salts were prepared For example, aromatic nucleophilic substitution of N,N'-ethylenediamine di[4-chloro-6-(3-N-1-tert-butoxycarbonylamino)phenyl]amino-1,3,5-triazine], e.g., prepared from cyanuric chloride in 2 steps, with 2-(4-aminophenyl)ethylamine followed by treatment with HCl afforded compound III. In competitive protein A binding assays, the IC₅₀ value of compound III was 0.2 μM. Comps. I are claimed useful for the treatment of rheumatoid arthritis, inflammation, etc.

IT 852672-67-4P 852672-79-8P 852672-80-1P
852672-81-2P 852672-83-4P 852672-84-5P
852672-85-6P 852672-87-8P 852672-90-3P
852672-95-8P 852672-98-1P 852673-04-2P
852673-05-3P 852673-07-5P 852673-08-6P
852673-12-2P 852673-13-3P 852673-17-7P
852673-19-9P 852673-20-2P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of triazine dimers for treatment of autoimmune diseases)


RN 852672-67-4 CAPLUS

CN 1,3,5-Triazine-2,4,6-triamine, N,N'''-1,2-ethanediylbis[N'-[4-(2-aminoethyl)phenyl]-N''-phenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 852672-79-8 CAPLUS

CN Acetamide, N-[2-[[4-[[2-[4-[[2-(4-hydroxyphenyl)ethyl]amino]-6-(phenylamino)-1,3,5-triazin-2-yl]amino]phenyl]ethyl]amino]-6-(phenylamino)-1,3,5-triazin-2-yl]amino]ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A







RN 852672-80-1 CAPLUS

CN Phenol, 4-[2-[[4-[[4-[2-[[4-[(4-aminobutyl)amino]-6-(phenylamino)-1,3,5-triazin-2-yl]amino]ethyl]phenyl]amino]-6-(phenylamino)-1,3,5-triazin-2-yl]amino]ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 852672-81-2 CAPLUS

CN Ethanol, 2-[[4-[[2-[4-[[4-[[2-(4-aminophenyl)ethyl]amino]-6-(phenylamino)-1,3,5-triazin-2-yl]amino]phenyl]ethyl]amino]-6-(phenylamino)-1,3,5-triazin-2-yl]amino]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 852672-83-4 CAPLUS

CN Ethanol, 2-[[4-[(3-aminophenyl)amino]-6-[[2-[4-[[4-[(3-aminophenyl)amino]-6-[[2-(4-aminophenyl)ethyl]amino]-1,3,5-triazin-2-yl]amino]phenyl]ethyl]amino]-1,3,5-triazin-2-yl]amino]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 1-B





RN 852672-84-5 CAPLUS

CN 1,3,5-Triazine-2,4,6-triamine, N-[4-[2-[[4-[(2-aminoethyl)amino]-6-[(3-aminophenyl)amino]-1,3,5-triazin-2-yl]amino]ethyl]phenyl]-N'-(3-aminophenyl)-N''-[2-(4-aminophenyl)ethyl]- (9CI) (CA INDEX NAME)



RN 852672-85-6 CAPLUS
 CN Phenol, 4-[2-[[4-[[4-[2-[[4-[(2-hydroxyethyl)amino]-6-(phenylamino)-1,3,5-triazin-2-yl]amino]ethyl]phenyl]amino]-6-(phenylamino)-1,3,5-triazin-2-yl]amino]ethyl]- (9CI) (CA INDEX NAME)







RN 852672-87-8 CAPLUS

CN Phenol, 4-[2-[[4-[[4-[2-[[4-[(2-aminoethyl)amino]-6-[(2-methoxyphenyl)amino]-1,3,5-triazin-2-yl]amino]ethyl]phenyl]amino]-6-(phenylamino)-1,3,5-triazin-2-yl]amino]ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 852672-90-3 CAPLUS

CN Phenol, 4-[2-[[4-[[4-[2-[[4-[(3-aminopropyl)amino]-6-(phenylamino)-1,3,5-triazin-2-yl]amino]ethyl]phenyl]amino]-6-(phenylamino)-1,3,5-triazin-2-yl]amino]ethyl]- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 1-B



CN Phenol, 4-[2-[[4-[[4-[[[4-[[2-(1H-imidazol-4-yl)ethyl]amino]-6-(phenylamino)-1,3,5-triazin-2-yl]amino]methyl]phenyl]amino]-6-(phenylamino)-1,3,5-triazin-2-yl]amino]ethyl] - (9CI) (CA INDEX NAME)




CN Phenol, 4,4'-[1,4-phenylenebis[imino[6-(phenylamino)-1,3,5-triazine-4,2-diyl]imino-2,1-ethanediyl]]bis- (9CI) (CA INDEX NAME)

Oc1ccc(cc1)CCNc2nc(Nc3ccc(cc3)Nc4nc(Nc5ccccc5)n4)c(Nc6ccccc6)n2Oc1ccc(CCC1)cc1

CN Ethanol, 2-[[[4-[[[5-[[4-[[2-(4-aminophenyl)ethyl]amino]-6-(phenylamino)-1,3,5-triazin-2-yl]amino]-2-methylphenyl]methyl]amino]-6-(phenylamino)-1,3,5-triazin-2-yl]amino]- (9CI) (CA INDEX NAME)


Nc1ccc(cc1)CCNC2=NC(=NC(=N2)Nc3ccc(C)cc3)NC4=NC(=NC(=N4)Nc5ccc(C)cc5)Nc6ccc(C)cc6




RN 852673-05-3 CAPLUS

CN Ethanol, 2-[[4-[[[3-[[4-[[2-(4-aminophenyl)ethyl]amino]-6-(phenylamino)-1,3,5-triazin-2-yl]amino]phenyl]methyl]amino]-6-(phenylamino)-1,3,5-triazin-2-yl]amino]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 852673-07-5 CAPLUS



CN Phenol, 4-[2-[[4-[[2-[[[4-[[2-(4-hydroxyphenyl)ethyl]amino]-6-(phenylamino)-1,3,5-triazin-2-yl]amino]methyl]phenyl]amino]-6-(phenylamino)-1,3,5-triazin-2-yl]amino]ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A






RN 852673-08-6 CAPLUS
 CN Phenol, 4,4'-[1,3-phenylenebis[imino[6-(phenylamino)-1,3,5-triazine-4,2-diyl]imino-2,1-ethanediyl]]bis- (9CI) (CA INDEX NAME)




RN 852673-12-2 CAPLUS
 CN Ethanol, 2-[[4-[(3-aminophenyl)amino]-6-[[4-[[[4,6-bis[(3-aminophenyl)amino]-1,3,5-triazin-2-yl]amino]methyl]phenyl]amino]-1,3,5-triazin-2-yl]amino]- (9CI) (CA INDEX NAME)



—NH₂

RN 852673-13-3 CAPLUS
 CN Ethanol, 2-[[4-[(3-aminophenyl)amino]-6-[[3-[[[4,6-bis[(3-aminophenyl)amino]-1,3,5-triazin-2-yl]amino]methyl]phenyl]amino]-1,3,5-triazin-2-yl]amino]-(9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 1-B

—NH₂


RN 852673-17-7 CAPLUS
 CN Ethanol, 2,2'-[1,4-phenylenebis[imino[6-[(3-aminophenyl)amino]-1,3,5-triazine-4,2-diyl]imino]]bis- (9CI) (CA INDEX NAME)



RN 852673-19-9 CAPLUS
CN Ethanol, 2,2'-[1,3-phenylenebis[imino[6-[(3-aminophenyl)amino]-1,3,5-triazine-4,2-diyl]imino]]bis- (9CI) (CA INDEX NAME)



RN 852673-20-2 CAPLUS
CN 1,3-Propanediol, 2,2'-[1,3-phenylenebis[imino[6-[(3-aminophenyl)amino]-1,3,5-triazine-4,2-diyl]imino]]bis- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 3 OF 41. CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2006:1226082 CAPLUS

DOCUMENT NUMBER: 145:500066

TITLE: Triazine compounds and compositions thereof for the treatment of cancers

INVENTOR(S): Gagnon, Lyne; Zacharie, Boulos; Penney, Christopher

PATENT ASSIGNEE(S): Prometic Biosciences Inc., Can.

SOURCE: PCT Int. Appl., 46pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006122431	A1	20061123	WO 2006-CA832	20060519
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRIORITY APPLN. INFO.: US 2005-682374P P 20050519

AB Compds. useful in the treatment of metastatic melanoma and other

cancers containing a triazine ring scaffold are described. These compds. may be classified into two groups: (1) two disubstituted triazine rings are covalently linked by an organic linker to each other and (2) one trisubstituted triazine ring.

IT 852673-17-7 852673-19-9 915154-46-0

915154-47-1 915154-51-7 915154-53-9


915154-54-0 915154-56-2 915154-58-4

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(triazine compds. and compns. thereof for treatment of cancers)


RN 852673-17-7 CAPLUS

CN Ethanol, 2,2'-[1,4-phenylenebis[imino[6-[(3-aminophenyl)amino]-1,3,5-triazine-4,2-diyl]imino]]bis- (9CI) (CA INDEX NAME)



RN 852673-19-9 CAPLUS


CN Ethanol, 2,2'-[1,3-phenylenebis[imino[6-[(3-aminophenyl)amino]-1,3,5-triazine-4,2-diyl]imino]]bis- (9CI) (CA INDEX NAME)




RN 915154-46-0 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B




RN 915154-47-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A

H₂N—




PAGE 1-B




RN 915154-51-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B




RN 915154-53-9 CAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 915154-54-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



PAGE 1-A




PAGE 1-B



RN 915154-56-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 915154-58-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 4 OF 41 USPATFULL on STN
ACCESSION NUMBER: 2004:268339 USPATFULL
TITLE: Methods and compositions of novel triazine compounds
INVENTOR(S): Timmer, Richard T., Decatur, GA, UNITED STATES
Alexander, Christopher W., Norcross, GA, UNITED STATES

Pillariseti, Sivaram, Norcross, GA, UNITED STATES
 Saxena, Uday, Atlanta, GA, UNITED STATES
 Yeleswarapu, Koteswar Rao, Hyderabad, INDIA
 Pal, Manojit, Hyderabad, INDIA
 Reddy, Jangalgar Tirupathy, Hyderabad, INDIA
 Krishma Reddy, Velagala Venkata Rama Murali, Hyderabad, INDIA
 Sesila Sridevi, Bhatlapenumarthy, Hyderabad, INDIA
 Kumar, Potlapally Rajender, Hyderabad, INDIA
 Reddy, Gaddam Om, Hyderabad, INDIA


	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004209882	A1	20041021
APPLICATION INFO.:	US 2003-400169	A1	20030326 (10)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	WOMBLE CARLYLE SANDRIDGE & RICE, PLLC, P.O. BOX 7037, ATLANTA, GA, 30357-0037		
NUMBER OF CLAIMS:	19		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	86 Drawing Page(s)		
LINE COUNT:	12036		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB The present invention relates to methods and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses. In particular, the present invention is directed to compounds that inhibit or block glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells. The present invention relates to compounds that inhibit smooth muscle proliferation. In particular, the present invention is directed to compounds that inhibit smooth muscle cell proliferation by modulating HSPGs such as Perlecan. The present invention further relates to the use of compounds to treat vascular occlusive conditions characterized by smooth muscle proliferation such as restenosis and atherosclerosis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 676358-18-2P 676360-74-0P
 (preparation of novel triazine compds. for inhibiting smooth muscle cell proliferation)
 RN 676358-18-2 USPATFULL
 CN 1,3,5-Triazine-2,4,6-triamine, N-(3-chloro-4-ethoxyphenyl)-N'-[(1-ethyl-2-pyrrolidinyl)methyl]-N''-(2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 676360-74-0 USPATFULL
 CN 1,3,5-Triazine-2,4,6-triamine, N-[(1-ethyl-2-pyrrolidinyl)methyl]-N',N''-bis(3-fluoro-4-methoxyphenyl)- (9CI) (CA INDEX NAME)



L17 ANSWER 5 OF 41 USPATFULL on STN

ACCESSION NUMBER: 2004:268338 USPATFULL

TITLE: Methods and compositions of novel triazine compounds

INVENTOR(S): Timmer, Richard T., Decatur, GA, UNITED STATES
 Alexander, Christopher W., Norcross, GA, UNITED STATES
 Pillarisetti, Sivaram, Norcross, GA, UNITED STATES
 Saxena, Uday, Atlanta, GA, UNITED STATES
 Yeleswarapu, Koteswar Rao, Hyderabad, INDIA
 Pal, Manojit, Hyderabad, INDIA
 Reddy, Jangalgar Tirupathy, Hyderabad, INDIA
 Krishna Reddy, Velagala Venkata Rama Murali, Hyderabad, INDIA
 Sridevi, Bhatlapenumarthy Sesha, Hyderabad, INDIA
 Kumar, Potlapally Rajender, Hyderabad, INDIA
 Reddy, Gaddam Om, Hyderabad, INDIA

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004209881	A1	20041021
	US 7112587	B2	20060926
APPLICATION INFO.:	US 2003-400134	A1	20030326 (10)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	JOHN S. PRATT, ESQ, KILPATRICK STOCKTON, LLP, 1100 PEACHTREE STREET, ATLANTA, GA, 30309		
NUMBER OF CLAIMS:	19		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	86 Drawing Page(s)		
LINE COUNT:	9019		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to methods and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses. In particular, the present invention is directed to compounds that inhibit or block glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells. The present invention relates to compounds that inhibit smooth muscle proliferation. In particular, the present invention is directed to compounds that inhibit smooth muscle cell proliferation by modulating HSPGs such as Perlecan. The present invention further relates to the use of compounds to treat vascular occlusive conditions characterized by smooth muscle proliferation such as restenosis and atherosclerosis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 676360-74-0P

(preparation of novel triazine compds. for inhibiting smooth muscle cell proliferation)

RN 676360-74-0 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N-[(1-ethyl-2-pyrrolidinyl)methyl]-N',N''-

bis(3-fluoro-4-methoxyphenyl)- (9CI) (CA INDEX NAME)



L17 ANSWER 6 OF 41 USPATFULL on STN

ACCESSION NUMBER: 2004:268337 USPATFULL
TITLE: Methods and compositions of novel triazine compounds
INVENTOR(S): Timmer, Richard T., Decatur, GA, UNITED STATES
Alexander, Christopher W., Norcross, GA, UNITED STATES
Pillariseti, Sivaram, Norcross, GA, UNITED STATES
Saxena, Uday, Atlanta, GA, UNITED STATES
Yeleswarapu, Koteswar Rao, Begumpet, INDIA
Pal, Manojit, Miyapur, INDIA
Reddy, Jangalgar Tirupathy, Miyapur, INDIA
Krlshna Reddy, Velagala Venkata Rama Murali, Kukatpally, INDIA
Sridevi, Bhatlapenumarthy Sesha, Gandhinagar, INDIA
Kumar, Potlapally Rajender, Miyapur, INDIA
Reddy, Gaddam Om, Miyapur, INDIA

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004209880	A1	20041021
APPLICATION INFO.:	US 2003-397968	A1	20030326 (10)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	WOMBLE CARLYLE SANDRIDGE & RICE, PLLC, P.O. BOX 7037, ATLANTA, GA, 30357-0037		
NUMBER OF CLAIMS:	19		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	86 Drawing Page(s)		
LINE COUNT:	10190		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to methods and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses. In particular, the present invention is directed to compounds that inhibit or block glyated protein produced induction of the signaling-associated inflammatory response in endothelial cells. The present invention relates to compounds that inhibit smooth muscle proliferation. In particular, the present invention is directed to compounds that inhibit smooth muscle cell proliferation by modulating HSPGs such as Perlecan. The present invention further relates to the use of compounds to treat vascular occlusive conditions characterized by smooth muscle proliferation such as restenosis and atherosclerosis.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 676360-74-0P

(preparation of novel triazine compds. for inhibiting smooth muscle cell proliferation)

RN 676360-74-0 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N-[(1-ethyl-2-pyrrolidinyl)methyl]-N',N''-bis(3-fluoro-4-methoxyphenyl)- (9CI) (CA INDEX NAME)



L17 ANSWER 7 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2000:696130 CAPLUS

DOCUMENT NUMBER: 133:256223

TITLE: A chemometric approach to understanding the bioelimination of anionic, water-soluble dyes by a biomass - Part 3: direct dyes

AUTHOR(S): Churchley, J. H.; Greaves, A. J.; Mutchings, M. G.; Phillips, D. A. S.; Taylor, J. A.

CORPORATE SOURCE: Severn Trent Water Ltd, Coventry, CV3 6PR, UK

SOURCE: Journal of the Society of Dyers and Colourists (2000), 116(9), 279-284

CODEN: JSDCAA; ISSN: 0037-9859

PUBLISHER: Society of Dyers and Colourists

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Using rapid and robust laboratory method for assessing the bioelimination of water-soluble dyes, the level of bioelimination of a series of direct dyes was determined and a chemometric anal. was conducted on the bioelimination results to correlate bioelimination with chemical structure. Bioelimination was 0-95% and correlated, for the majority of the direct dyes studied, with their size/charge ratio. The bioelimination of direct dyes was enhanced by large size/charge ratios, the presence of aromatic amino functions and extended azo (naphthalene) chromophores.


IT 295807-12-4

RL: REM (Removal or disposal); PROC (Process)


(chemometric approach to understanding bioelimination of anionic water-soluble direct dyes by biomass)

RN 295807-12-4 CAPLUS

CN 2-Naphthalenesulfonic acid, 7,7'-[[6-[(2-hydroxyethyl)amino]-1,3,5-triazine-2,4-diyl]diimino]bis[4-hydroxy-3-[(4-methoxyphenyl)azo]-, disodium salt (9CI) (CA INDEX NAME)



● 2 Na



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 8 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1972:81124 CAPLUS

DOCUMENT NUMBER: 76:81124

TITLE: Antitumor activities of fluorescent whitening agents of the stilbene class

AUTHOR(S): Saito, Chiharu

CORPORATE SOURCE: Pharm. Div., Sumitomo Chem. Co., Ltd., Takarazuka, Japan

SOURCE: Oyo Yakuri (1970), 4(3), 521-4

CODEN: OYYAA2; ISSN: 0300-8533

DOCUMENT TYPE: Journal

LANGUAGE: Japanese


AB Tetrasodium 4,4'-bis-[[4-anilino-6-(p-sulfoanilino)-1,3,5-triazin-2-yl]amino]stilbene 2,2'-disulfonate (I) [34233-64-2], a stilbene [588-59-0] derivative used com. as a brightener, showed marked tumor inhibiting activity on solid forms of Ehrlich carcinoma, sarcoma 180, and carcinoma 63 in mice. Treatment before tumor transplant was superior to treatment after transplant. I had no effect on Ehrlich ascites carcinoma.

IT 17958-73-5


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(neoplasm inhibitor)

RN 17958-73-5 CAPLUS

CN Benzenesulfonic acid, 2,2'-(1,2-ethenediyl)bis[5-[[4-[(2-hydroxyethyl)amino]-6-(phenylamino)-1,3,5-triazin-2-yl]amino]-, disodium salt (9CI) (CA INDEX NAME)



● 2 Na



L17 ANSWER 9 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:69621 CAPLUS

DOCUMENT NUMBER: .134:256200

TITLE: A chemometric approach to understanding the bioelimination of anionic, water-soluble dyes by a biomass using empirical and semi-empirical molecular descriptors

AUTHOR(S): Greaves, A. J.; Churchley, J. H.; Hutchings, M. G.; Phillips, D. A. S.; Taylor, J. A.

CORPORATE SOURCE: Department of Colour Chemistry, University of Leeds, Leeds, LS2 9JT, UK

SOURCE: Water Research (2001), 35(5), 1225-1239

CODEN: WATRAG; ISSN: 0043-1354

PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Single correlation and multiple linear regression analyses were applied to understand the bioelimination of 103 anionic, water-soluble dyes by a biomass at a wastewater treatment works. The chemometric approach highlighted that anionic, water-soluble dyes with larger mol. size/ionic charge ratios and containing more primary aromatic amines and unsulfonated naphthalene nuclei and fewer aliphatic alc. groups had superior levels of bioelimination.


IT 50925-42-3

RL: REM (Removal or disposal); PROC (Process)


(chemometric approach to understanding bioelimination of anionic water-soluble dyes by biomass using empirical and semi-empirical mol. descriptors)

RN 50925-42-3 CAPLUS

CN 1,5-Naphthalenedisulfonic acid, 3,3'-[[6-[(2-hydroxyethyl)amino]-1,3,5-triazine-2,4-diyl]bis[imino(2-methyl-4,1-phenylene)azo]]bis-, tetrasodium salt (9CI) (CA INDEX NAME)



●4 Na



REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 10 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1961:27935 CAPLUS

DOCUMENT NUMBER: 55:27935

ORIGINAL REFERENCE NO.: 55:5521e-i, 5522a-i, 5523a-i

TITLE: Search for chemotherapeutic amidines. XVI.
Amidinoanilino-1,3,5-triazines and related compounds

AUTHOR(S): Ashley, J. N.; Berg, S. S.; MacDonald, R. D.

CORPORATE SOURCE: May & Baker, Dagenham, UK

SOURCE: Journal of the Chemical Society (1960) 4525-32
CODEN: JCSOA9; ISSN: 0368-1769

DOCUMENT TYPE: Journal

LANGUAGE: Unavailable

GI For diagram(s), see printed CA Issue.


AB cf. CA 52, 14559e. A series of amidinoanilino-1,3,5-triazines was prepared. Only 2,4-bis(p-amidinoanilino)-6-amino-1,3,5-triazine (I) had significant activity against Trypanosoma congolense. Attempts to improve this activity by various modifications to the structure gave less active products. 2-Amino-4,6-dichloro-1,3,5-triazine (II) was first prepared (0.5 molar scale) with Et₂O as the solvent for the cyanuric chloride; NH₃ was admitted (cooling bath at -20 to -25°) so that the internal temperature did not rise above -5°. II (66-79%) crystallized from C₆H₆ in white prisms, m. 234-5° (decomposition). The following method was preferred for preparation of larger amts. of II. Cyanuric chloride (553.5 g.) in 6 l. dry CHCl₃ treated 48 min. with NH₃ at a rate of 3 l./min. (below -12°) gave 638 g. II containing NH₄Cl; purification gave 367 g. pure II. 4,6-Dichloro-2-methylamino-1,3,5-triazine (82%), m. 160-1°, and 84% 4,6-dichloro-2-ethylamino-1,3,5-triazine, m. 106-7°, were prepared by a known method. 4,6-Dichloro-2-diethylamino-1,3,5-triazine (96%) m. 79-80°; 4,6-dichloro-2-methoxy-1,3,5-triazine (61%) m. 90-1°. II (165 g.) in 220 ml. anisole added in one portion to 472

g. p-aminobenzonitrile in 2400 ml. anisole at 100-110°, the bath temperature raised to 180-5°, refluxed 1.5 hrs., the mixture cooled, filtered, and the solid stirred 1 hr. at 20-5° with 10 l. 2N NaOH gave 325 g. 2-amino-4,6-bis(p-cyanoanilino)-1,3,5-triazine (III), yellow prisms, m. 339-41° (PhNO₂, C₅H₅N, or HCONMe₂). The following 1,3,5-triazines were prepared by the same method as for III: 70% 4,6-bis(p-cyanoanilino)-2-methylamino-, yellow, m. 281-2° (PhNO₂); 67% 4,6-bis(p-cyanoanilino)-2-ethylamino-, prisms, m. 249-51° (PhNO₂); 60% 4,6-bis(p-cyanoanilino)-2-diethylamino-, prisms, m. 205-7° (anisole); 60% 2-amino-4,6-bis(p-nitroanilino)-, green prisms, m. above 300° (PhNO₂); 64% 2-diethylamino-4,6-bis(p-nitroanilino)-, yellow needles, m. 316-17° (PhNO₂); 87% 4,6-bis(p-cyanoanilino)-2-methoxy-, white needles, m. above 300° (AcOH); and 58% 2-amino-4,6-bis(m-cyanoanilino)-1,3,5-triazine as the monoacetate, m. 240-2° (AcOH). p-Aminobenzonitrile (70.8 g.) in 250 ml. CHCl₃ added dropwise during 1 hr. to 55.35 g. cyanuric chloride in 500 ml. CHCl₃ at 15-20°, and the solid washed with 2N HCl gave 65 g. 2,4-dichloro-6-(p-cyanoanilino)-1,3,5-triazine (IV). white rhombs, m. above 300° (Me₂CO, EtCOMe, or dioxane). Condensation carried out in Me₂CO or EtCOMe at 30-5°, 45-50°, or 55-60° gave IV; no 2-chloro-4,6-bis(p-cyanoanilino)-1,3,5-triazine was obtained. II (16.5 g.) added to 23.6 g. p-hydroxybenzonitrile in 8 g. NaOH and 125 ml. H₂O at 8-10°, the temperature allowed to rise during 2 hrs. to 25°, the mixture heated rapidly to 90-5°, kept 4 hrs. at this temperature, and filtered gave 23.5 g. 2-amino-4,6-bis(p-cyanophenoxy)-1,3,5-triazine, white plates, m. 288-9° (EtOCH₂CH₂OH). The following were prepared similarly: 72% 4,6-bis(p-cyanophenoxy)-2-diethylamino-1,3,5-triazine, white needles, m. 144-5° (alc.), and 57.5% 2-amino-4,6-bis(p-dimethylaminoanilino)-1,3,5-triazine, m. 283-6° (PhNO₂) (the di-HCl salt was deliquescent). The bis-(methosulfate), m. 274-6° (decomposition), was prepared from the base and Me₂SO₄ at 100° in PhNO₂. 4,6-Bis(p-cyanoanilino)-2-methoxy-1,3,5-triazine (3.4 g.) and 1 g. PhCH₂NH₂ in 100 ml. PhNO₂ heated 4-5 hrs. at 190° gave 1.3 g. 4,6-bis(p-cyanoanilino)-2-hydroxy-1,3,5-triazine as a crude product (insol. in alcs., hydrocarbons, AcOH, dioxane, anisole, PhCl, PhNO₂, and cresylic acid). 2-Amino-4,6-bis(p-nitroanilino)-1,3,5-triazine (18.3 g.) suspended in 183 ml. refluxing AcOH treated in one portion with 183 g. SnCl₂ in 183 ml. concentrated HCl, stirred 2 hrs. at 100°, cooled, the chloride filtered off and washed, and the red base filtered and treated with 2N HCl gave 9 g. 2-amino-4,6-bis(p-aminoanilino)-1,3,5-triazine-2HCl, white needles, m. above 300° (2N HCl). 4,6-Bis(p-aminoanilino)-2-diethylamino-1,3,5-triazine, obtained in 61% yield as pink needles, m. 196-7° (C₆H₆); di-HCl salt m. above 280°. p-Aminobenzonitrile (23.6 g.) in 150 ml. Me₂CO containing 0.05 g. KI added to 13.3 g. 2,4-dichloro-6-(p-cyanoanilino)-1,3,5-triazine in 600 ml. refluxing Me₂CO, the mixture refluxed 16 hrs., and the suspension filtered gave 14.1 g. 2,4,6-tris(p-cyanoanilino)-1,3,5-triazine, yellow, m. above 300° (PhNO₂). 4,6-Diaminoquinaldine (8.7 g.) in 200 ml. AcOH stirred 3 hrs. at 40-50° with 13.3 g. 2,4-dichloro-6-(p-cyanoanilino)-1,3,5-triazine (V) in 200 ml. AcOH and the solid ground up with 2N NaOH gave 8.4 g. 4-(4-aminoquinaldin-6-ylamino)-2-chloro-6-(p-cyanoanilino)-1,3,5-triazine, yellow needles, m. above 300° (aqueous alc.). 2-Diethylaminoethylamine (11.6 g.) in 100 ml. Me₂CO added dropwise to a suspension of 13.3 g. V in 200 ml. Me₂CO, kept 3 hrs., evaporated, and the residual gum dissolved in 2N HCl gave (after basification) 10 g. 2-chloro-6-(p-cyanoanilino)-4-(2-diethylaminoethylamino)-1,3,5-triazine (VI), m. 143-5° (alc.). VI (16.1 g.) and 9.5 g. p-aminobenzonitrile in 120 ml. anisole refluxed 4 hrs. and the mixture filtered and ground with 2N NaOH gave 8.1 g. 4-(4-aminoquinaldin-6-ylamino)-2,6-bis(p-cyanoanilino)-1,3,5-triazine, brown prisms, m. above 300°. 2,6-Bis(p-cyanoanilino)-4-(2-diethylaminoethylamino)-1,3,5-triazine was prepared similarly (40% yield) from the corresponding 2-chloro compound as white prisms, m. 155-9° (alc.). V (26.6 g.) and 80 g. PhOH heated at 182-9°, NH₃ bubbled through for 6 hrs., the mass


ground with 500 ml. H₂O, and the product crystallized gave 18.3 g. 2,4-diamino-6-(p-cyanoanilino)-1,3,5-triazine, m. 282-3° (PhNO₂). Na dicyanamide (44.5 g.) in 250 ml. H₂O refluxed 6 hrs. with 129.8 g. p-aminobenzonitrile in 110 ml. concentrated HCl and 880 ml. H₂O and the precipitate collected, washed (2N NaOH), and crystallized gave 52.4 g. N1,N5-bis(p-cyanophenyl)biguanide (VII), m. 203-4° (slight decomposition). VII (23 g.) in 150 ml. 90% HCO₂H refluxed 3 hrs., cooled to 30°, and the product isolated gave 10.5 g. 2,4-bis(p-cyanoanilino)-1,3,5-triazine, prismatic needles, m. above 300° (PhNO₂). VII (20 g.), 60 ml. Me₂CO, and 0.9 ml. piperidine refluxed 2.5 hrs. gave 18.5 g. 2,4-bis(p-cyanoanilino)-1,6-dihydro-6,6-dimethyl-1,3,5-triazine, m. 269-71° (decomposition) (MeOH). 2,4-Bis(p-cyanoanilino)-6-ethyl-1,6-dihydro-6-methyl-1,3,5-triazine, similarly prepared in 85% yield from EtMeCO as white needles, m. above 360°. 2-Diethylamino-4,6-bis(p-guanidinoanilino)-1,3,5-triazine, similarly prepared in 84% yield as white prisms, m. 174-5° (decomposition). III (500 g.) suspended in 1.5 l. dry alc. was ground 4 days in a ball-mill, the suspension saturated 12 hrs. at -15 to -20° with dry HCl, and the solid collected, washed, and dried; the yields of diimidoate (VIII) from 2 runs were 1400 g. and 1250 g. VIII stirred with dry alc. and added at 20-5° to liquid NH₃ in alc., the mixture stirred 6 hrs. at 50-5° and cooled, the solid filtered off and added (at 90°) to 20 l. 0.5N HCl, the mixture refluxed, filtered, treated with C, refiltered, cooled, and treated with HCl gave 804 g. and 606 g. crude 4,6-bis(p-amidinoanilino)-2-amino-1,3,5-triazine-3HCl.2H₂O (IX) from two runs. IX (50 g.) in hot MeOH cooled to 25°, treated with C, filtered, and treated with 300 ml. concentrated HCl gave 20-5 g. IX, m. above 360°. The amorphous diamidine base (80% yield), m. 195-8° (decomposition), was obtained by grinding the salt, VIII, with MeOH-2N NaOH; it did not crystallize; the diphosphate m. above 290°. The acid-insol. material obtained at the amination stage was essentially the corresponding 4,4'-dicarboxamide. The corresponding di-HCl salt, decomposing 255° (10.6 g.) ground with 2N NaOH and ice with 0.2 ml. Lissapol N gave 7 g. of the diimidoate. Treatment with aqueous alc. and NH₄Cl yielded 12% 2-amino-4,6-bis[p-(ethoxyiminomethyl)anilino]-1,3,5-triazine (together with the dicarboxamide). When ammonium isethionate was used in this conversion, only the dicarboxamide was obtained. A mixture of III (3.5 g.) and 3.5 g. ammonium benzenesulfonate heated 2.5 hrs. at 300° in a stream of NH₃ and cooled, the melt powdered and dissolved in 15 ml. hot H₂O, and the mixture filtered and cooled gave 2.3 g. melamine benzenesulfonate, m. above 300°. Treatment of a hot aqueous solution with NaOH gave melamine. Concentration of the aqueous liquors gave 0.2 g. p-aminobenzamide, m. 180-3°. Extraction of the initial aqueous mother liquor gave 0.1 g. p-aminobenzonitrile, m. 86-8°. The following p-[H₂N(HN:)C]C₆H₄XC:N.C{XC₆H₄[C(:NH)NH₂]p}:N. CR:N were prepared from the resp. nitriles by the Pinner method (X, R, alc. and solvent for imidoate preparation, time in days for imidoate preparation, amidine salt, crystallization solvent, % yield, and m.p. of product given): NH, NEt₂, alc., 10, 2HCl, MeOH, 42, above 300°; O, NH₂, alc.-CHCl₃, 5, 2HCl, MeOH-Me₂CO, 33, 160° (decomposition); O, NEt₂, alc.-CHCl₃, 5, 2HCl, MeOH-Me₂CO, 45, 255-7° (decomposition); NH, NHMe, alc., 14, 2HCl, aqueous NaCl, 53, 319-20° (decomposition); NH, NH₂Et, alc., 21, 2HCl, aqueous NaCl, 55, 275-6° (decomposition); NH, NH(CH₂)₂NEt₂, alc.-CHCl₃, 6, 3HCl, MeOH-Me₂CO, 42, 245-7° (decomposition); NH, 4-aminoquinaldin-6-ylamino, alc.-PhNO₂, 21, 3HCl, MeOH, 26.5, above 300°; NH, OMe, alc., 21, 2HCl, MeOH-Me₂CO, 41, above 300°; NH, p-amidinoanilino, HO(CH₂)₂OEt, 30, 4MeSO₃H, MeOH, 23.3, 212-14° (decomposition); NH, H, alc., 21, 2MeSO₃H, MeOH, 60, 306-8° (decomposition). N1,N5-Bis(p-amidinophenyl)biguanide was prepared by the general method (using 2-ethoxyethanol as the alc.); the imidoate preparation was kept 1 month; the diamidine-3HCl (13.2%) separated as white crystals, m. 355-6° (decomposition). 6-(p-Amidinoanilino)-2,4-diamino-1,3,5-triazine was prepared

61% yield as the HCl salt after 4 weeks, m. 306-8° (decomposition). The imidoate preparation was kept 3 days only and a 62% yield of 2,4-bis(p-amidinoanilino)-1,6-dihydro-6,6-dimethyl-1,3,5-triazine-3HCl separated as white prisms, m. above 300° (MeOH-Me2CO). 2,4-Bis(p-amidinoanilino)-6-ethyl-1,6-dihydro-6-methyl-1,3,5-triazine-3HCl was similarly prepared (70% yield), prisms, m. above 300° (Me2CO-MeOH). The following N-alkylamidines were obtained from the diimidoate-3HCl and the requisite amine in alc.: 56% 2-amino-4,6-bis[p-(N-methylamidino)]-(from MeOH-Et2O) and 2-amino-4,6-bis[p-(N,N-dimethylamidino)anilino]-1,3,5-triazine-2HCl (from MeOH-Et2O). 3-Dimethylaminopropylamine (20.4 g.) added to 16.5 g. II in 50 ml. H2O, the mixture heated slowly to the b.p., a solution of 8 g. NaOH in 40 ml. H2O added during 1 hr., and the mixture refluxed 2 hrs. and extracted with CHCl3 gave a liquid, b.p. 200°, which solidified to a glass (25% yield). This base (5.8 g.) in 50 ml. EtOH treated with 5.7 g. tartaric acid in 25 ml. alc. gave the bis(H tartrate) of 2-amino-4,6-bis(3-dimethylaminopropylamino)-1,3,5-triazine, m. 78-80°. The base (7.2 g.) in 50 ml. Me2CO treated with 3.5 ml. MeI gave the MeI salt. This product dissolved in H2O and heated 5 min. with 1 mole diammonium 4,4'-diaminostilbene-2,2'-disulfonate gave the bisquaternary 4,4'-diaminostilbene-2,2'-disulfonate, pinkish powder, m. 283-5° (decomposition). 4,6-Bis(m-amidinoanilino)-2-amino-1,3,5-triazine was prepared by the standard method (using alc. as the solvent). The preparation kept 3 weeks afforded the di-HCl salt, m. above 300° (MeOH).


IT 109568-47-0P, Benzonitrile, 4,4'-[(6-ethylamino-s-triazine-2,4-diyl)diimino]di- 110058-99-6P, Benzonitrile, 4,4'-[(6-methylamino-s-triazine-2,4-diyl)diimino]di- 110061-41-1P, Benzanidine, 4,4'-[(6-methylamino-s-triazine-2,4-diyl)diimino]di-, dihydrochloride 111416-03-6P, Benzanidine, 4,4'-[(6-ethylamino-s-triazine-2,4-diyl)diimino]di-, dihydrochloride 115122-82-2P, Benzonitrile, 4,4'-[[6-[(2-diethylaminoethyl)amino]-s-triazine-2,4-diyl]diimino]di- 118927-30-3P, Benzanidine, 4,4'-[[6-[(2-diethylaminoethyl)amino]-s-triazine-2,4-diyl]diimino]di-, trihydrochloride
 RL: PREP (Preparation)
 (preparation of)
 RN 109568-47-0 CAPLUS
 CN Benzonitrile, 4,4'-[(6-ethylamino-s-triazine-2,4-diyl)diimino]di- (6CI)
 (CA INDEX NAME)



RN 110058-99-6 CAPLUS
 CN Benzonitrile, 4,4'-[(6-methylamino-s-triazine-2,4-diyl)diimino]di- (6CI)
 (CA INDEX NAME)




RN 110061-41-1 CAPLUS
 CN Benzanidine, 4,4'-[(6-methylamino-s-triazine-2,4-diyl)diimino]di-, dihydrochloride (6CI) (CA INDEX NAME)




● 2 HCl

RN 111416-03-6 CAPLUS
 CN Benzamidine, 4,4'-[(6-ethylamino-s-triazine-2,4-diyl)diimino]di-, dihydrochloride (6CI) (CA INDEX NAME)




● 2 HCl

RN 115122-82-2 CAPLUS
 CN Benzonitrile, 4,4'-[[6-[(2-diethylaminoethyl)amino]-s-triazine-2,4-diyl]diimino]di- (6CI) (CA INDEX NAME)



RN 118927-30-3 CAPLUS
 CN Benzamidine, 4,4'-[[6-[(2-diethylaminoethyl)amino]-s-triazine-2,4-diyl]diimino]di-, trihydrochloride (6CI) (CA INDEX NAME)



● 3 HCl

L17 ANSWER 11 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1969:27953 CAPLUS

DOCUMENT NUMBER: 70:27953

TITLE: Substituted melamines as chemosterilants of houseflies

AUTHOR(S): LaBrecque, Germain C.; Fye, Richard L.; DeMilo, Albert B.; Borkovec, Alexej B.

CORPORATE SOURCE: Entomol. Res. Div., Agr. Res. Serv., Gainesville, FL, USA

SOURCE: Journal of Economic Entomology (1968), 61(6), 1621-32
CODEN: JEENAI; ISSN: 0022-0493

DOCUMENT TYPE: Journal

LANGUAGE: English


AB One hundred ten substituted melamines were tested as chemosterilants against *Musca domestica*. Melamines that were sufficiently basic to form stable salts were tested as hydrochlorides. Fifty-five effectively inhibited hatch or pupation. The most effective inhibitors of hatch were tri- to hexasubstituted methylmelamines. Melamines without Me groups or methylmelamines containing large alkyl, aryl, or other bulky groups were ineffective against males. As a rule, compds. that affected hatch when both sexes were treated were also effective when only males were treated. Melamines that had 2 free amino groups and small cyclic substituents on the 3rd exocyclic N were generally without effect on hatch but they inhibited pupation of larvae produced by treated females. The inhibitors of pupation were ineffective in sterilizing males. All compds. were evaluated in 2 diets: sugar and fly food. The effects of the 2 foods and of the 2 forms of the compds. were often large, but only relatively uniform series of results were considered in structure-activity correlations.

IT 19860-91-4

RL: BIOL (Biological study)
(as insect sterilants)

RN 19860-91-4 CAPLUS

CN 1,3,5-Triazine-2,4,6-triamine, N-butyl-N'-(4-methylphenyl)-N''-phenyl-
(9CI) (CA INDEX NAME)



L17 ANSWER 12 OF 41 USPATFULL on STN

ACCESSION NUMBER: 2005:82123 USPATFULL

TITLE: Chemical derivatives and their application as antitelomerase agents

INVENTOR(S): Mailliet, Patrick, Fontenay Sous Bois, FRANCE
Laoui, Abdekazize, Bridgewater, NJ, UNITED STATES
Riou, Jean-Francois, Reims, FRANCE
Doerflinger, Gilles, Les Ulis, FRANCE
Mergny, Jean-Louis, Villejuif, FRANCE
Hamy, Francois, Illzach, FRANCE
Caulfield, Thomas, Paris, FRANCE

PATENT ASSIGNEE(S): Aventis Pharma S.A., Antony, FRANCE (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005070571	A1	20050331

APPLICATION INFO.: US 2004-993637 A1 20041119 (10)
 RELATED APPLN. INFO.: Division of Ser. No. US 2002-103883, filed on 25 Mar
 2002, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	FR 2001-3916	20010323
	FR 2001-10370	20010802
	US 2001-332009P	20011123 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	ROSS J. OEHLER, AVENTIS PHARMACEUTICALS INC., ROUTE 202-206, MAIL CODE: D303A, BRIDGEWATER, NJ, 08807	
NUMBER OF CLAIMS:	19	
EXEMPLARY CLAIM:	1	
LINE COUNT:	2205	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to cancer therapy and to novel anticancer agents having a mechanism of action which is quite specific. It also relates to novel chemical compounds as well as their therapeutic application in humans.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 462649-12-3P, 2-[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-[[4-dimethylamino-2-methylquinolin-6-yl]amino]-6-[[3-(dimethylamino)propyl]amino]triazine 462649-16-7P,
 2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[2-chlorophenyl]amino]-6-[[2-(dimethylamino)ethyl]amino]triazine 462649-17-8P,
 2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[2-chlorophenyl]amino]-6-[[3-(dimethylamino)propyl]amino]triazine 462649-20-3P,
 2-[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-[[3-(dimethylamino)propyl]amino]triazine 462649-23-6P,
 2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-[[3-(dimethylamino)propyl]amino]triazine 462649-36-1P,
 2-[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-[[4-dimethylamino-2-methylquinolin-6-yl]amino]-6-[[2-methoxyethyl]amino]triazine 462649-37-2P,
 2-[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-[[4-dimethylamino-2-methylquinolin-6-yl]amino]-6-[[phenethyl]amino]triazine 462649-38-3P,
 2-[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-[[4-dimethylamino-2-methylquinolin-6-yl]amino]-6-[[pyridin-4-yl]methyl]amino]triazine 462649-39-4P,
 2-[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-[[4-dimethylamino-2-methylquinolin-6-yl]amino]-6-[[[N-(3-methylphenyl)-N-ethylamino]methyl]amino]triazine 462649-41-8P,
 2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-[[2-(dimethylamino)ethyl]amino]triazine 462649-42-9P,
 , 2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-((benzyl)amino)triazine 462649-44-1P,
 2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-((2-(acetylaminomethyl)amino)triazine 462649-45-2P,
 2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-((2-(diethylamino)ethyl)amino)triazine 462649-46-3P,
 , 2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-[[2-[N-(2-(dimethylamino)ethyl)-N-(benzyl)amino]ethyl]amino]triazine 462649-47-4P,
 2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-((2-((methoxycarbonyl)amino)ethyl)amino)triazine 462649-48-5P,
 2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-[[2-(diisopropylamino)ethyl]amino]triazine 462649-54-3P,
 2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-[[1-ethylpyrrolidin-2-yl]methyl]amino]triazine 462649-55-4P,
 2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-[[2-(pyrrolidinyl)ethyl]amino]triazine 462649-56-5P,


2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-[[pyridin-4-yl]methyl]amino]triazine 462649-57-6P,
2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-[[1-methylpiperidin-4-yl]methyl]amino]triazine 462649-58-7P, 2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-[[pyridin-2-yl]methyl]amino]triazine 462649-60-1P, 2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-[[3-methoxybenzyl]amino]triazine 462649-61-2P 462649-72-5P
, 2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-[[pyridin-3-yl]methyl]amino]triazine 462649-73-6P,
2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-[[4-chlorobenzyl]amino]triazine 462649-80-5P,
2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-[[4-benzylpiperazinyl]methyl]amino]triazine 462649-86-1P, 2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-[[2-morpholinyl]ethyl]amino]triazine 462649-87-2P, 2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-[[isoquinolin-5-yl]methyl]amino]triazine 462649-89-4P, 2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-[[4-methoxybenzyl]amino]triazine 462649-90-7P, 2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-[[2-methoxyethyl]amino]triazine 462649-91-8P, 2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-[[[4-dimethylaminophenyl]methyl]amino]triazine 462649-96-3P,
2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-[[2-piperidinyl]ethyl]amino]triazine 462649-97-4P,
2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-[[2-isopropylamino]ethyl]amino]triazine 462650-53-9P
, 2-[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-[[4-dimethylamino-2-methylquinolin-6-yl]amino]-6-[[[4-benzylpiperazinyl]methyl]amino]triazine 462650-55-1P 462650-62-0P, 2-[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-[[4-dimethylamino-2-methylquinolin-6-yl]amino]-6-[[2-(acetylamino)ethyl]amino]triazine 462650-68-6P,
2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-[[2-methoxy-2-methylethyl]amino]triazine 462650-69-7P
, 2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-[[2-hydroxymethyl-2-ethylethyl]amino]triazine 462650-70-0P, 2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-[[2-hydroxyethyl]amino]triazine 462650-77-7P, 2-[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-[[4-dimethylamino-2-methylquinolin-6-yl]amino]-6-[[2-methoxy-2-methylethyl]amino]triazine 462650-78-8P, 2-[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-[[4-dimethylamino-2-methylquinolin-6-yl]amino]-6-[[2-hydroxymethyl-2-ethylethyl]amino]triazine 462650-79-9P, 2-[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-[[4-dimethylamino-2-methylquinolin-6-yl]amino]-6-[[2-hydroxyethyl]amino]triazine 462650-82-4P, 2-[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-[[4-dimethylamino-2-methylquinolin-6-yl]amino]-6-[[1,3-dihydroxypropan-2-yl]amino]triazine 462650-83-5P 462650-84-6P 462650-85-7P,
2-[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-[[4-dimethylamino-2-methylquinolin-6-yl]amino]-6-[[1,2-dihydroxyethyl]amino]triazine 462650-88-0P, 2-[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-[[4-dimethylamino-2-methylquinolin-6-yl]amino]-6-[[2-morpholinoethyl]amino]triazine 462650-89-1P,
2-[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-[[4-dimethylamino-2-methylquinolin-6-yl]amino]-6-[[2-piperidinylethyl]amino]triazine 462651-00-9P, 2-[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-[[4-dimethylamino-2-methylquinolin-6-yl]amino]-6-[[4-methoxybenzyl]amino]triazine 462651-01-0P, 2-[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-[[4-dimethylamino-2-methylquinolin-6-yl]amino]-6-[[2-(isopropylamino)ethyl]amino]triazine 462651-05-4P

, 2-[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-[[4-dimethylamino-2-methylquinolin-6-yl]amino]-6-[[[4-isopropylpiperazinyl]carbonyl]methyl]amino]triazine 462651-06-5P, 2-[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-[[4-dimethylamino-2-methylquinolin-6-yl]amino]-6-[[3-[2-methylpiperidinyl]propyl]amino]triazine 462651-08-7P, 2-[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-[[4-dimethylamino-2-methylquinolin-6-yl]amino]-6-[[5-(piperidinyl)pentyl]amino]triazine 462651-10-1P, 2-[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-[[4-dimethylamino-2-methylquinolin-6-yl]amino]-6-[[2-(imidazolyl)ethyl]amino]triazine 462652-84-2P

(preparation of trisubstituted 2,4,6-triamino[1,3,5]triazines as anti-telomerase agents)


RN 462649-12-3 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis[4-(dimethylamino)-2-methyl-6-quinolinyl]-N''-[3-(dimethylamino)propyl]- (9CI) (CA INDEX NAME)




RN 462649-16-7 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N-(4-amino-2-methyl-6-quinolinyl)-N'-(2-chlorophenyl)-N''-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 462649-17-8 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N-(4-amino-2-methyl-6-quinolinyl)-N'-(2-chlorophenyl)-N''-[3-(dimethylamino)propyl]- (9CI) (CA INDEX NAME)




RN 462649-20-3 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N-(4-amino-2-methyl-6-quinolinyl)-N'-(4-(dimethylamino)-2-methyl-6-quinolinyl)-N''-[3-(dimethylamino)propyl]- (9CI) (CA INDEX NAME)




RN 462649-23-6 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinolinyl)-N''-[3-(dimethylamino)propyl]- (9CI) (CA INDEX NAME)




RN 462649-36-1 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis[4-(dimethylamino)-2-methyl-6-quinolinyl]-N''-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 462649-37-2 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis[4-(dimethylamino)-2-methyl-6-quinolinyl]-N''-(2-phenylethyl)- (9CI) (CA INDEX NAME)




RN 462649-38-3 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis[4-(dimethylamino)-2-methyl-6-quinolinyl]-N''-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 462649-39-4 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis[4-(dimethylamino)-2-methyl-6-quinolinyl]-N''-[4-(pyridin-2-ylmethyl)amino]methyl- (9CI) (CA INDEX NAME)




RN 462649-41-8 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis[4-(dimethylamino)-2-methyl-6-quinolinyl]-N''-[2-(4-methylphenyl)ethyl]methyl- (9CI) (CA INDEX NAME)




RN 462649-42-9 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis[4-(dimethylamino)-2-methyl-6-quinolinyl]-N''-[2-(4-amino-2-methyl-6-quinolinyl)ethyl]methyl- (9CI) (CA INDEX NAME)




RN 462649-44-1 USPATFULL

CN Acetamide, N-[2-[[4,6-bis[(4-amino-2-methyl-6-quinolinyl)amino]-1,3,5-triazin-2-yl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 462649-45-2 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinolinyl)-N''-[2-(diethylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 462649-46-3 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinolinyl)-N''-[2-[[2-(dimethylamino)ethyl](phenylmethyl)amino]ethyl]- (9CI) (CA INDEX NAME)




RN 462649-47-4 USPATFULL

CN Carbamic acid, [2-[[4,6-bis[(4-amino-2-methyl-6-quinolinyl)amino]-1,3,5-triazin-2-yl]amino]ethyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 462649-48-5 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinolinyl)-N''-[2-[bis(1-methylethyl)amino]ethyl]- (9CI) (CA INDEX NAME)




RN 462649-54-3 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinolinyl)-N''-[(1-ethyl-2-pyrrolidinyl)methyl]- (9CI) (CA INDEX NAME)




RN 462649-55-4 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinolinyl)-N''-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 462649-56-5 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinolinyl)-N''-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 462649-57-6 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinolinyl)-N''-[(1-methyl-4-piperidinyl)methyl]- (9CI) (CA INDEX NAME)




RN 462649-58-7 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinolinyl)-N''-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 462649-60-1 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinolinyl)-N''-[(3-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 462649-61-2 USPATFULL


CN Ethanaminium, 2-[[4,6-bis[(4-amino-2-methyl-6-quinolinyl)amino]-1,3,5-triazin-2-yl]amino]-N,N,N-trimethyl-, chloride (9CI) (CA INDEX NAME)



● Cl^-


RN 462649-72-5 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinolinyl)-N''-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 462649-73-6 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinolinyl)-N''-[(4-chlorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 462649-80-5 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinolinyl)-N''-[4-(phenylmethyl)-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)




RN 462649-86-1 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinolinyl)-N''-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 462649-87-2 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinolinyl)-N''-(5-isoquinolinylmethyl)- (9CI) (CA INDEX NAME)




RN 462649-89-4 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinolinyl)-N''-[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 462649-90-7 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinolinyl)-N''-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 462649-91-8 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinolinyl)-N''-[[4-(dimethylamino)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 462649-96-3 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinolinyl)-N''-[2-(1-piperidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 462649-97-4 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinolinyl)-N''-[2-[(1-methylethyl)amino]ethyl]- (9CI) (CA INDEX NAME)



RN 462650-53-9 USPATFULL


CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis[4-(dimethylamino)-2-methyl-6-quinolinyl]-N''-[4-(phenylmethyl)-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)




```

RN      462650-62-0  USPATFULL
CN      Acetamide, N-[2-[[4,6-bis[[4-(dimethylamino)-2-methyl-6-quinolinyl]amino]-
        1,3,5-triazin-2-yl]amino]ethyl]- (9CI)  (CA INDEX NAME)

```




RN 462650-68-6 USPATFULL
CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinolinyl)-N''-(2-methoxypropyl)- (9CI) (CA INDEX NAME)




RN 462650-69-7 USPATFULL

CN 1-Butanol, 2-[[[4,6-bis[[4-amino-2-methyl-6-quinolinyl]amino]-1,3,5-triazin-2-yl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 462650-70-0 USPATFULL

CN Ethanol, 2-[[[4,6-bis[[4-amino-2-methyl-6-quinolinyl]amino]-1,3,5-triazin-2-yl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 462650-77-7 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis[4-(dimethylamino)-2-methyl-6-quinolinyl]-N''-(2-methoxypropyl)- (9CI) (CA INDEX NAME)




RN 462650-78-8 USPATFULL

CN 1-Butanol, 2-[[[4,6-bis[[4-(dimethylamino)-2-methyl-6-quinolinyl]amino]-1,3,5-triazin-2-yl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 462650-79-9 USPATFULL

CN Ethanol, 2-[[4,6-bis[[4-(dimethylamino)-2-methyl-6-quinolinyl]amino]-1,3,5-triazin-2-yl]amino] - (9CI) (CA INDEX NAME)




RN 462650-82-4 USPATFULL

CN 1,3-Propanediol, 2-[[4,6-bis[[4-(dimethylamino)-2-methyl-6-quinolinyl]amino]-1,3,5-triazin-2-yl]amino] - (9CI) (CA INDEX NAME)



RN 462650-83-5 USPATFULL


CN 1,3-Propanediol, 2-[[4,6-bis[[4-amino-2-methyl-6-quinolinyl]amino]-1,3,5-triazin-2-yl]amino] - (9CI) (CA INDEX NAME)



RN 462650-84-6 USPATFULL


CN 1,2-Ethanediol, 1-[[[4,6-bis[[4-amino-2-methyl-6-quinolinyl]amino]-1,3,5-triazin-2-yl]amino]phenylmethyl]-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 462650-85-7 USPATFULL

CN 1,2-Ethanediol, 1-[[[4,6-bis[[4-(dimethylamino)-2-methyl-6-quinolinyl]amino]-1,3,5-triazin-2-yl]amino]- (9CI) (CA INDEX NAME)




RN 462650-88-0 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis[4-(dimethylamino)-2-methyl-6-quinolinyl]-N''-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 462650-89-1 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis[4-(dimethylamino)-2-methyl-6-quinolinyl]-N''-[2-(1-piperidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 462651-00-9 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis[4-(dimethylamino)-2-methyl-6-quinolinyl]-N''-(4-methoxyphenyl)methyl- (9CI) (CA INDEX NAME)




RN 462651-01-0 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis[4-(dimethylamino)-2-methyl-6-quinolinyl]-N''-[2-[(1-methylethyl)amino]ethyl]- (9CI) (CA INDEX NAME)




RN 462651-05-4 USPATFULL

CN Piperazine, 1-[[[4,6-bis[[4-(dimethylamino)-2-methyl-6-quinolinyl]amino]-1,3,5-triazin-2-yl]amino]acetyl]-4-(1-methylethyl)- (9CI) (CA INDEX NAME).




RN 462651-06-5 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis[4-(dimethylamino)-2-methyl-6-quinolinyl]-N''-[3-(2-methyl-1-piperidiny)propyl]- (9CI) (CA INDEX NAME)




RN 462651-08-7 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis[4-(dimethylamino)-2-methyl-6-quinolinyl]-N''-[5-(1-piperidiny)pentyl]- (9CI) (CA INDEX NAME)




RN 462651-10-1 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis[4-(dimethylamino)-2-methyl-6-quinolinyl]-N''-[2-(1H-imidazol-1-yl)ethyl]- (9CI) (CA INDEX NAME)



RN 462652-84-2 USPATFULL

CN 1-Propanol, 2-[[[4,6-bis[[4-(dimethylamino)-2-methyl-6-quinolinyl]amino]-1,3,5-triazin-2-yl]amino]-(9CI) (CA INDEX NAME)



L17 ANSWER 13 OF 41 USPATFULL on STN

ACCESSION NUMBER: 2003:127716 USPATFULL

TITLE: Chemical derivatives and their application as antitelomerase agent

INVENTOR(S): Mailliet, Patrick, Fontenay Sous Bois, FRANCE
Laoui, Abdelazize, Bridgewater, NJ, UNITED STATES
Riou, Jean-Francois, Reims, FRANCE
Doerflinger, Gilles, Les Ulis, FRANCE
Mergny, Jean-Louis, Villejuif, FRANCE
Hamy, Francois, Illzach, FRANCE
Caulfield, Thomas, Paris, FRANCE

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003087931	A1	20030508
	US 6887873	B2	20050503
APPLICATION INFO.:	US 2002-103883	A1	20020325 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	FR 2001-3916	20010323
	FR 2001-10370	20010802
	US 2001-332009P	20011123 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: Finnegan, Henderson, Farabow,, Garrett & Dunner, L.L.P., 1300 I Street, N.W., Washington, DC, 20005-3315

NUMBER OF CLAIMS: 37

EXEMPLARY CLAIM: 1

LINE COUNT: 2835

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to cancer therapy and to novel

anticancer agents having a mechanism of action which is quite specific. It also relates to novel chemical compounds as well as their therapeutic application in humans.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 462649-12-3P, 2-[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-[[4-dimethylamino-2-methylquinolin-6-yl]amino]-6-[[3-(dimethylamino)propyl]amino]triazine 462649-16-7P, 2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[2-chlorophenyl]amino]-6-[[2-(dimethylamino)ethyl]amino]triazine 462649-17-8P, 2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[2-chlorophenyl]amino]-6-[[3-(dimethylamino)propyl]amino]triazine 462649-20-3P, 2-[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-[[3-(dimethylamino)propyl]amino]triazine 462649-23-6P, 2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-[[3-(dimethylamino)propyl]amino]triazine 462649-36-1P, 2-[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-[[4-dimethylamino-2-methylquinolin-6-yl]amino]-6-[[2-methoxyethyl]amino]triazine 462649-37-2P, 2-[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-[[4-dimethylamino-2-methylquinolin-6-yl]amino]-6-[[phenethyl]amino]triazine 462649-38-3P, 2-[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-[[4-dimethylamino-2-methylquinolin-6-yl]amino]-6-[[pyridin-4-yl]methyl]amino]triazine 462649-39-4P, 2-[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-[[4-dimethylamino-2-methylquinolin-6-yl]amino]-6-[[N-(3-methylphenyl)-N-ethylamino]methyl]amino]triazine 462649-41-8P, 2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-[[2-(dimethylamino)ethyl]amino]triazine 462649-42-9P, 2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-((benzyl)amino)triazine 462649-44-1P, 2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-((2-(acetyl amino)ethyl)amino)triazine 462649-45-2P, 2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-((2-(diethylamino)ethyl)amino)triazine 462649-46-3P, 2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-[[2-[N-(2-(dimethylamino)ethyl)-N-(benzyl)amino]ethyl]amino]triazine 462649-47-4P, 2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-((2-((methoxycarbonyl)amino)ethyl)amino)triazine 462649-48-5P, 2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-[[2-(diisopropylamino)ethyl]amino]triazine 462649-54-3P, 2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-[[[1-ethylpyrrolidin-2-yl]methyl]amino]triazine 462649-55-4P, 2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-[[2-(pyrrolidinyl)ethyl]amino]triazine 462649-56-5P, 2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-[[[pyridin-4-yl]methyl]amino]triazine 462649-57-6P, 2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-[[[1-methylpiperidin-4-yl]methyl]amino]triazine 462649-58-7P, 2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-[[[pyridin-2-yl]methyl]amino]triazine 462649-60-1P, 2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-[[3-methoxybenzyl]amino]triazine 462649-61-2P 462649-72-5P, 2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-[[[pyridin-3-yl]methyl]amino]triazine 462649-73-6P, 2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-[[4-chlorobenzyl]amino]triazine 462649-80-5P, 2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-[[[4-benzylpiperazinyl]methyl]amino]triazine 462649-86-1P, 2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-[[2-[morpholinyl]ethyl]amino]triazine 462649-87-2P, 2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-

amino-2-methylquinolin-6-yl]amino]-6-[[[isoquinolin-5-yl)methyl]amino]triazine 462649-89-4P, 2-[[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[[4-amino-2-methylquinolin-6-yl]amino]-6-[[[4-methoxybenzyl]amino]triazine 462649-90-7P, 2-[[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[[4-amino-2-methylquinolin-6-yl]amino]-6-[[[2-methoxyethyl]amino]triazine 462649-91-8P, 2-[[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[[4-amino-2-methylquinolin-6-yl]amino]-6-[[[4-dimethylaminophenyl)methyl]amino]triazine 462649-96-3P, 2-[[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[[4-amino-2-methylquinolin-6-yl]amino]-6-[[[2-(piperidinyl)ethyl]amino]triazine 462649-97-4P, 2-[[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[[4-amino-2-methylquinolin-6-yl]amino]-6-[[[2-(isopropylamino)ethyl]amino]triazine 462650-53-9P, 2-[[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-[[[4-dimethylamino-2-methylquinolin-6-yl]amino]-6-[[[4-benzylpiperazinyl)methyl]amino]triazine 462650-55-1P 462650-62-0P, 2-[[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-[[[4-dimethylamino-2-methylquinolin-6-yl]amino]-6-[[[2-(acetylamin)ethyl]amino]triazine 462650-68-6P, 2-[[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[[4-amino-2-methylquinolin-6-yl]amino]-6-[[[2-methoxy-2-methylethyl]amino]triazine 462650-69-7P, 2-[[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[[4-amino-2-methylquinolin-6-yl]amino]-6-[[[2-hydroxymethyl-2-ethylethyl]amino]triazine 462650-70-0P, 2-[[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[[4-amino-2-methylquinolin-6-yl]amino]-6-[[[2-hydroxyethyl]amino]triazine 462650-77-7P, 2-[[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-[[[4-dimethylamino-2-methylquinolin-6-yl]amino]-6-[[[2-methoxy-2-methylethyl]amino]triazine 462650-78-8P, 2-[[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-[[[4-dimethylamino-2-methylquinolin-6-yl]amino]-6-[[[2-hydroxymethyl-2-ethylethyl]amino]triazine 462650-79-9P, 2-[[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-[[[4-dimethylamino-2-methylquinolin-6-yl]amino]-6-[[[2-hydroxyethyl]amino]triazine 462650-82-4P, 2-[[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-[[[4-dimethylamino-2-methylquinolin-6-yl]amino]-6-[[[1,3-dihydroxypropan-2-yl]amino]triazine 462650-83-5P 462650-84-6P 462650-85-7P, 2-[[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-[[[4-dimethylamino-2-methylquinolin-6-yl]amino]-6-[[[1,2-dihydroxyethyl]amino]triazine 462650-88-0P, 2-[[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-[[[4-dimethylamino-2-methylquinolin-6-yl]amino]-6-[[[2-morpholinoethyl]amino]triazine 462650-89-1P, 2-[[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-[[[4-dimethylamino-2-methylquinolin-6-yl]amino]-6-[[[2-piperidinylethyl]amino]triazine 462651-00-9P, 2-[[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-[[[4-dimethylamino-2-methylquinolin-6-yl]amino]-6-[[[4-methoxybenzyl]amino]triazine 462651-01-0P, 2-[[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-[[[4-dimethylamino-2-methylquinolin-6-yl]amino]-6-[[[2-(isopropylamino)ethyl]amino]triazine 462651-05-4P, 2-[[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-[[[4-dimethylamino-2-methylquinolin-6-yl]amino]-6-[[[4-isopropylpiperazinyl]carbonyl)methyl]amino]triazine 462651-06-5P, 2-[[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-[[[4-dimethylamino-2-methylquinolin-6-yl]amino]-6-[[[3-[2-methylpiperidinyl]propyl]amino]triazine 462651-08-7P, 2-[[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-[[[4-dimethylamino-2-methylquinolin-6-yl]amino]-6-[[[5-(piperidinyl)pentyl]amino]triazine 462651-10-1P, 2-[[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-[[[4-dimethylamino-2-methylquinolin-6-yl]amino]-6-[[[2-(imidazolyl)ethyl]amino]triazine 462652-84-2P

(preparation of trisubstituted 2,4,6-triamino[1,3,5]triazines as anti-telomerase agents)


RN 462649-12-3 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis[4-(dimethylamino)-2-methyl-6-quinolinyl]-N''-[3-(dimethylamino)propyl]- (9CI) (CA INDEX NAME)




RN 462649-16-7 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N-(4-amino-2-methyl-6-quinolinyl)-N'-(2-chlorophenyl)-N''-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 462649-17-8 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N-(4-amino-2-methyl-6-quinolinyl)-N'-(2-chlorophenyl)-N''-[3-(dimethylamino)propyl]- (9CI) (CA INDEX NAME)




RN 462649-20-3 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N-(4-amino-2-methyl-6-quinolinyl)-N'-(4-(dimethylamino)-2-methyl-6-quinolinyl)-N''-[3-(dimethylamino)propyl]- (9CI) (CA INDEX NAME)




RN 462649-23-6 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinolinyl)-N''-[3-(dimethylamino)propyl]- (9CI) (CA INDEX NAME)




RN 462649-36-1 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis[4-(dimethylamino)-2-methyl-6-quinolinyl]-N''-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 462649-37-2 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis[4-(dimethylamino)-2-methyl-6-quinolinyl]-N''-(2-phenylethyl)- (9CI) (CA INDEX NAME)




RN 462649-38-3 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis[4-(dimethylamino)-2-methyl-6-quinolinyl]-N''-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 462649-39-4 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis[4-(dimethylamino)-2-methyl-6-quinolinyl]-N''-[[ethyl(3-methylphenyl)amino]methyl]- (9CI) (CA INDEX NAME)




RN 462649-41-8 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinolinyl)-N''-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 462649-42-9 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinolinyl)-N''-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 462649-44-1 USPATFULL

CN Acetamide, N-[2-[[[4,6-bis[(4-amino-2-methyl-6-quinolinyl)amino]-1,3,5-triazin-2-yl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 462649-45-2 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinolinyl)-N''-[2-(diethylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 462649-46-3 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinolinyl)-N''-[2-[[2-(dimethylamino)ethyl](phenylmethyl)amino]ethyl]- (9CI) (CA INDEX NAME)




RN 462649-47-4 USPATFULL

CN Carbamic acid, [2-[[[4,6-bis[(4-amino-2-methyl-6-quinolinyl)amino]-1,3,5-triazin-2-yl]amino]ethyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 462649-48-5 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinolinyl)-N''-[2-[bis(1-methylethyl)amino]ethyl]- (9CI) (CA INDEX NAME)




RN 462649-54-3 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinolinyl)-N''-[1-ethyl-2-pyrrolidinyl)methyl]- (9CI) (CA INDEX NAME)




RN 462649-55-4 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinolinyl)-N''-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 462649-56-5 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinolinyl)-N''-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 462649-57-6 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinolinyl)-N''-[(1-methyl-4-piperidinyl)methyl]- (9CI) (CA INDEX NAME)




RN 462649-58-7 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinolinyl)-N''-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 462649-60-1 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinolinyl)-N''-[(3-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 462649-61-2 USPATFULL


CN Ethanaminium, 2-[[[4,6-bis[(4-amino-2-methyl-6-quinolinyl)amino]-1,3,5-triazin-2-yl]amino]-N,N,N-trimethyl-, chloride (9CI) (CA INDEX NAME)



● Cl⁻


RN 462649-72-5 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinolinyl)-N''-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 462649-73-6 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinolinyl)-N''-[(4-chlorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 462649-80-5 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinolinyl)-N''-[[4-(phenylmethyl)-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)




RN 462649-86-1 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinolinyl)-N''-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 462649-87-2 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinolinyl)-N''-(5-isoquinolinylmethyl)- (9CI) (CA INDEX NAME)




RN 462649-89-4 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinolinyl)-N''-[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 462649-90-7 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinolinyl)-N''-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 462649-91-8 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinolinyl)-N''-[[4-(dimethylamino)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 462649-96-3 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinolinyl)-N''-[2-(1-piperidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 462649-97-4 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinolinyl)-N''-[2-[(1-methylethyl)amino]ethyl]- (9CI) (CA INDEX NAME)




RN 462650-53-9 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis[4-(dimethylamino)-2-methyl-6-quinolinyl]-N''-[4-(phenylmethyl)-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)



RN 462650-55-1 USPATFULL


CN Ethanaminium, 2-[[4,6-bis[[4-(dimethylamino)-2-methyl-6-quinolinyl]amino]-1,3,5-triazin-2-yl]amino]-N,N,N-trimethyl-, chloride (9CI) (CA INDEX NAME)



● Cl⁻


RN 462650-62-0 USPATFULL

CN Acetamide, N-[2-[[[4,6-bis[[4-(dimethylamino)-2-methyl-6-quinolinyl]amino]-1,3,5-triazin-2-yl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 462650-68-6 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinolinyl)-N''-(2-methoxypropyl)- (9CI) (CA INDEX NAME)




RN 462650-69-7 USPATFULL

CN 1-Butanol, 2-[[[4,6-bis[[4-amino-2-methyl-6-quinolinyl]amino]-1,3,5-triazin-2-yl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 462650-70-0 USPATFULL

CN Ethanol, 2-[[[4,6-bis[[4-amino-2-methyl-6-quinolinyl]amino]-1,3,5-triazin-2-yl]amino]- (9CI) (CA INDEX NAME)




RN 462650-77-7 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis[4-(dimethylamino)-2-methyl-6-quinolinyl]-N''-(2-methoxypropyl)- (9CI) (CA INDEX NAME)




RN 462650-78-8 USPATFULL

CN 1-Butanol, 2-[[[4,6-bis[[4-(dimethylamino)-2-methyl-6-quinolinyl]amino]-1,3,5-triazin-2-yl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 462650-79-9 USPATFULL

CN Ethanol, 2-[[[4,6-bis[[4-(dimethylamino)-2-methyl-6-quinolinyl]amino]-1,3,5-triazin-2-yl]amino]- (9CI) (CA INDEX NAME)




RN 462650-82-4 USPATFULL

CN 1,3-Propanediol, 2-[[[4,6-bis[[4-(dimethylamino)-2-methyl-6-quinolinyl]amino]-1,3,5-triazin-2-yl]amino]- (9CI) (CA INDEX NAME)



RN 462650-83-5 USPATFULL


CN 1,3-Propanediol, 2-[[[4,6-bis[(4-amino-2-methyl-6-quinolinyl)amino]-1,3,5-triazin-2-yl]amino]- (9CI) (CA INDEX NAME)



RN 462650-84-6 USPATFULL


CN 1,2-Ethanediol, 1-[[[4,6-bis[(4-amino-2-methyl-6-quinolinyl)amino]-1,3,5-triazin-2-yl]amino]phenylmethyl]-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 462650-85-7 USPATFULL

CN 1,2-Ethanediol, 1-[[[4,6-bis[[4-(dimethylamino)-2-methyl-6-quinolinyl]amino]-1,3,5-triazin-2-yl]amino]- (9CI) (CA INDEX NAME)




RN 462650-88-0 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis[4-(dimethylamino)-2-methyl-6-quinolinyl]-N''-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 462650-89-1 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis[4-(dimethylamino)-2-methyl-6-quinolinyl]-N''-[2-(1-piperidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 462651-00-9 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis[4-(dimethylamino)-2-methyl-6-quinolinyl]-N''-[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 462651-01-0 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis[4-(dimethylamino)-2-methyl-6-quinolinyl]-N''-[2-[(1-methylethyl)amino]ethyl]- (9CI) (CA INDEX NAME)




RN 462651-05-4 USPATFULL

CN Piperazine, 1-[[[4,6-bis[[4-(dimethylamino)-2-methyl-6-quinolinyl]amino]-1,3,5-triazin-2-yl]amino]acetyl]-4-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 462651-06-5 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis[4-(dimethylamino)-2-methyl-6-quinolinyl]-N''-[3-(2-methyl-1-piperidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 462651-08-7 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis[4-(dimethylamino)-2-methyl-6-quinolinyl]-N''-[5-(1-piperidinyl)pentyl]- (9CI) (CA INDEX NAME)




RN 462651-10-1 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis[4-(dimethylamino)-2-methyl-6-quinolinyl]-N''-[2-(1H-imidazol-1-yl)ethyl]- (9CI) (CA INDEX NAME)



RN 462652-84-2 USPATFULL

CN 1-Propanol, 2-[[4,6-bis[[4-(dimethylamino)-2-methyl-6-quinolinyl]amino]-1,3,5-triazin-2-yl]amino]- (9CI) (CA INDEX NAME)



L17 ANSWER 14 OF 41 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2004:964820 CAPLUS
 DOCUMENT NUMBER: 141:395584
 TITLE: Preparation of novel triazine compounds for inhibiting smooth muscle cell proliferation
 INVENTOR(S): Timmer, Richard T.; Alexander, Christopher W.; Pillarisetti, Sivaram; Saxena, Uday; Yeleswarapu, Koteswar Rao; Pal, Manojit; Reddy, Jangalgar Tirupathy; Reddy, Velagala Venkita Rama Murali Krishna; Sridevi, Bhatlapenumarphy Shesha; Kumar, Potlapally Rajender; Reddy, Gaddam Om
 PATENT ASSIGNEE(S): Reddy Us Therapeutics, Inc., USA
 SOURCE: U.S. Pat. Appl. Publ., 433 pp., Cont.-in-part of U.S. Ser. No. 390,485.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 6
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004224950	A1	20041111	US 2003-400140	20030326
US 7132423	B2	20061107		
US 2004077648	A1	20040422	US 2003-390485	20030317
JP 2006188533	A	20060720	JP 2006-79816	20060322
US 2006258641	A1	20061116	US 2006-441326	20060525
PRIORITY APPLN. INFO.:			US 2001-324147P	P 20010921
			US 2002-253388	B1 20020923
			US 2003-390485	A2 20030317
			JP 2004-538153	A3 20030326
			US 2003-400140	A1 20030326

OTHER SOURCE(S): MARPAT 141:395584
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The present invention relates to methods and compns. comprising compds. I or II [R1 = H, alkyl, cycloalkyl, etc.; G = NR1, O; J = CH, N; n = 0-3; X1 = o-R1, m-R1, m-OR1, m-OCF3, etc.; X2 = o-R1, p-R1, p-OR1, p-OCF3, etc.; X3 = o-R1, m-R1, p-R1, o-OR1, p-OR1; or X2 and X3 together is a fused benzene, pyridine, dioxane, tetrahydropyran ring; AY, DY = OR1, F, Cl, Br, I, tetrahydroquinolin-1-yl, etc.; or A, B = O, NR1; and Y = R1, (CHR1)qR1, (CHR1)qCF3, etc.; q = 0-3] that treat pathophysiol. conditions arising from inflammatory responses. Over 100 synthetic examples described synthesis of compds. I and II and their intermediates. E.g., a multi-step synthesis of the triazine III, starting from cyanuric chloride, is given. In particular, the present invention is directed to compds. that inhibit

or block glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells. The present invention relates to compds. that inhibit smooth muscle cell (SMC) proliferation. Many of the compds. I and II inhibited SMC proliferation by greater than 70%. Also, the most effective compds. I and II showed an 80% decrease in IL-6 secretion in test for AGE-induced inflammatory response determination. In particular, the present invention is directed to compds. that inhibit smooth muscle cell proliferation by modulating HSPGs such as Perlecan. The present invention further relates to the use of compds. to treat vascular occlusive conditions characterized by smooth muscle proliferation such as restenosis and atherosclerosis.


IT 676358-18-2P 676360-74-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of novel triazine compds. for inhibiting smooth muscle cell proliferation)


RN 676358-18-2 CAPLUS

CN 1,3,5-Triazine-2,4,6-triamine, N-(3-chloro-4-ethoxyphenyl)-N'-[(1-ethyl-2-pyrrolidinyl)methyl]-N''-(2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 676360-74-0 CAPLUS

CN 1,3,5-Triazine-2,4,6-triamine, N-[(1-ethyl-2-pyrrolidinyl)methyl]-N',N''-bis(3-fluoro-4-methoxyphenyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 15 OF 41 USPATFULL on STN

ACCESSION NUMBER: 2003:296926 USPATFULL

TITLE: Chemical derivatives and their application as antitelomerase agent

INVENTOR(S): Mailliet, Patrick, Fontenay Sous Bois, FRANCE
Riou, Jean-Fran.cedilla.ois, Paris, FRANCE

Mergny, Jean-Louis, Villejuif, FRANCE
 Laoui, Abdelazize, Nogent sur Marne, FRANCE
 Lavelle, Fran.cedilla.ois, Paris, FRANCE
 Petitgenet, Odile, Paris, FRANCE
 PATENT ASSIGNEE(S): Aventis Pharma S.A., Atony, FRANCE (non-U.S.
 corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6645964	B1	20031111
APPLICATION INFO.:	US 2000-722361		20001128 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	FR 1999-15031	19991129
	FR 2000-10561	20000811
	US 2000-218059P	20000713 (60)
	US 2000-176632P	20000119 (60)


DOCUMENT TYPE: Utility
 FILE SEGMENT: GRANTED
 PRIMARY EXAMINER: Raymond, Richard L.
 LEGAL REPRESENTATIVE: Finnegan, Henderson, Farabow, Garrett & Dunner LLP
 NUMBER OF CLAIMS: 19
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
 LINE COUNT: 1372

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to cancer therapy and to novel
 anticancer agent having a mechanism of action which is quite specific.
 It also relates to novel chemical compounds as well as their therapeutic
 application in humans.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 343875-95-6P 343876-01-7P
 (preparation of triazinediamine derivs. as telomerase inhibitors and
 antitumor agents)
 RN 343875-95-6 USPATFULL
 CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinoliny1)-N''-
 methyl-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl

RN 343876-01-7 USPATFULL
 CN 1,3,5-Triazine-2,4,6-triamine, N-methyl-N',N''-bis[2-methyl-4-
 (methylamino)-6-quinoliny1]-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl

L17 ANSWER 16 OF 41 USPATFULL on STN

ACCESSION NUMBER: 2004:70738 USPATFULL

TITLE: Chemical derivatives and their application as antitelomerase agent

INVENTOR(S): Mailliet, Patrick, Fontenay Sous Bois, FRANCE
 Riou, Jean-Francois, Paris, FRANCE
 Mergny, Jean-Louis, Villejuif, FRANCE
 Laoui, Abdelazize, Nogent Sur Marne, FRANCE
 Lavelle, Francois, Paris, FRANCE
 Petitgenet, Odile, Paris, FRANCE

PATENT ASSIGNEE(S): Aventis Pharms S.A. (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004053966	A1	20040318
APPLICATION INFO.:	US 2003-658394	A1	20030910 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 2000-722361, filed on 28 Nov 2000, GRANTED, Pat. No. US 6645964		

	NUMBER	DATE
PRIORITY INFORMATION:	FR 1999-15031	19991129
	FR 2002-10561	20020811
	US 2000-176632P	20000119 (60)
	US 2000-218059P	20000713 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, LLP,
 1300 I STREET, NW, WASHINGTON, DC, 20005

NUMBER OF CLAIMS: 21

EXEMPLARY CLAIM: 1

LINE COUNT: 1422

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to cancer therapy and to novel anticancer agent having a mechanism of action which is quite specific. It also relates to novel chemical compounds as well as their therapeutic application in humans.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 343875-95-6P 343876-01-7P

(preparation of triazinediamine derivs. as telomerase inhibitors and antitumor agents)

RN 343875-95-6 USPATFULL


CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis(4-amino-2-methyl-6-quinolinyl)-N''-methyl-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl

RN 343876-01-7 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N-methyl-N',N''-bis[2-methyl-4-(methylamino)-6-quinolinyl]-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl

L17 ANSWER 17 OF 41 USPATFULL on STN

ACCESSION NUMBER: 2002:303594 USPATFULL

TITLE: Asymmetric stilbene compounds

INVENTOR(S): Metzger, Georges, Moernach, FRANCE

Reinehr, Dieter, Kandern, GERMANY, FEDERAL REPUBLIC OF

Eckhardt, Claude, Riedisheim, FRANCE

Cuesta, Fabienne, Roppentzwiller, FRANCE

PATENT ASSIGNEE(S): Ciba Specialty Chemicals Corporation, Tarrytown, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6482241	B1	20021119
APPLICATION INFO.:	US 2000-657737		20000908 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1998-209940, filed on 11 Dec 1998, now patented, Pat. No. US 6143889		

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1997-26365	19971213
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Gupta, Yogendra N.	
ASSISTANT EXAMINER:	Hamlin, Derrick G.	
LEGAL REPRESENTATIVE:	Mansfield, Kevin T.	
NUMBER OF CLAIMS:	24	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)	
LINE COUNT:	778	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides, as a first aspect, an asymmetric compound having the formula: ##STR1##

in which M is hydrogen, an alkali metal atom, ammonium or a cation formed from an amine; Xa and Xb are the same or different and each is NH.sub.2; NH(C.sub.1-C.sub.4alkyl); NH(C.sub.2-C.sub.4alkoxyalkyl); N(C.sub.1-C.sub.4alkyl).sub.2; N(CH.sub.2CH.sub.2OH).sub.2; a group NH--Z--NR.sub.1R.sub.2 in which Z is C.sub.2-C.sub.14alkylene or optionally substituted arylene, and R.sub.1 and R.sub.2 are the same or different and each is C.sub.1-C.sub.12alkyl or R.sub.1 and R.sub.2, together with the nitrogen atom to which they are each attached, form a morpholino, piperidino or piperazino ring; an aminoacid residue; C.sub.1-C.sub.4alkoxy; hydroxy-substituted-C.sub.2-C.sub.4alkoxy; ##STR2##

and Ya and Yb are the same or different and each is a substituted amino group having both UVA and UVB-absorbing properties having the formula: ##STR3##

in which R.sub.3 is CN; SO.sub.2R.sub.5 in which R.sub.5 is, C.sub.1-C.sub.12alkyl, C.sub.1-C.sub.12alkoxy, NH.sub.2, NH(C.sub.1-C.sub.4alkyl), N(C.sub.1-C.sub.4alkyl).sub.2, N(CH.sub.2CH.sub.2OH).sub.2, C.sub.1-C.sub.4alkoxy or hydroxy-substituted-C.sub.2-C.sub.4alkoxy; COR.sub.5 in which R.sub.5 has its previous significance; COOM in which M has its previous significance or NHCOR.sub.5 in which R.sub.5 has its previous significance and in which R.sub.4 has the same significance as R.sub.3 or is H, OH, C.sub.1-C.sub.4alkyl or C.sub.1-C.sub.4alkoxy and one of Xa and Xb can be identical to one of Ya and Yb, provided that one of Xa and Xb is different from the other and/or one of Ya and Yb is different from the other.

The present invention also relates to a method of improving the sun protection factor (SPF) of textile fibre material, especially cotton, polyamide and wool, comprising treating them with the new compounds.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 31900-04-6P 200395-08-0P 203250-74-2P
226721-06-8P 226721-09-1P 226721-14-8P
226721-17-1P 226721-26-2P 226721-33-1P

(UV absorber; asym. triazinylaminostilbene compds. useful as sun protection agents applied to textiles)

RN 31900-04-6 USPATFULL

CN Benzenesulfonic acid, 2,2'-(1,2-ethenediyl)bis[5-[[4-(methylamino)-6-(phenylamino)-1,3,5-triazin-2-yl]amino]-, disodium salt (9CI) (CA INDEX NAME)




● 2 Na

RN 200395-08-0 USPATFULL


CN Benzenesulfonic acid, 2,2'-(1,2-ethenediyl)bis[5-[[4-[(4-acetylphenyl)amino]-6-[(2-methoxyethyl)amino]-1,3,5-triazin-2-yl]amino]-, disodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



● 2 Na


PAGE 1-B



RN 203250-74-2 USPATFULL


CN Benzenesulfonic acid, 2,2'-(1,2-ethenediyl)bis[5-[[4-(methylamino)-6-[[4-[(methylamino)carbonyl]phenyl]amino]-1,3,5-triazin-2-yl]amino]-, disodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



● 2 Na


PAGE 1-B



RN 226721-06-8 USPATFULL


CN Benzoic acid, 4-[[[4-[[2-[4-[[[4-[[4-(aminocarbonyl)phenyl]amino]-6-(methylamino)-1,3,5-triazin-2-yl]amino]-2-sulfophenyl]ethenyl]-3-sulfophenyl]amino]-6-(methylamino)-1,3,5-triazin-2-yl]amino]-, trisodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



●3 Na


PAGE 1-B



RN 226721-09-1 USPATFULL


CN Benzenesulfonic acid, 5-[[4-[[4-(aminosulfonyl)phenyl]amino]-6-(methylamino)-1,3,5-triazin-2-yl]amino]-2-[2-[4-[[4-(methylamino)-6-[[4-[(methylamino)carbonyl]phenyl]amino]-1,3,5-triazin-2-yl]amino]-2-sulfophenyl]ethenyl]-, disodium salt (9CI) (CA INDEX NAME)

PAGE 1-A




●2 Na

PAGE 1-B




RN 226721-14-8 USPATFULL

CN Benzenesulfonic acid, 2,2'-(1,2-ethenediyl)bis[5-[[4-[[4-(aminosulfonyl)phenyl]amino]-6-(methylamino)-1,3,5-triazin-2-yl]amino]-, disodium salt (9CI) (CA INDEX NAME)




●2 Na




RN 226721-17-1 USPATFULL

CN Benzenesulfonic acid, 5-[[4-(methylamino)-6-[[4-
 [(methylamino)carbonyl]phenyl]amino]-1,3,5-triazin-2-yl]amino]-2-[2-[4-
 [[4-(methylamino)-6-(phenylamino)-1,3,5-triazin-2-yl]amino]-2-
 sulfophenyl]ethenyl]-, disodium salt (9CI) (CA INDEX NAME)




●2 Na



RN 226721-26-2 USPATFULL


CN Benzenesulfonic acid, 2,2'-(1,2-ethenediyl)bis[5-[[4-[[4-
 (aminocarbonyl)phenyl]amino]-6-[(2-methoxyethyl)amino]-1,3,5-triazin-2-
 yl]amino]-, disodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



● 2 Na


PAGE 1-B



RN 226721-33-1 USPATFULL


CN Benzenesulfonic acid, 5-[[4-[(4-acetylphenyl)amino]-6-[(2-methoxyethyl)amino]-1,3,5-triazin-2-yl]amino]-2-[2-[4-[[4-(aminocarbonyl)phenyl]amino]-6-[(2-methoxyethyl)amino]-1,3,5-triazin-2-yl]amino]-2-sulfophenyl]ethenyl]-, disodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



● 2 Na

PAGE 1-B



L17 ANSWER 18 OF 41 USPATFULL on STN

ACCESSION NUMBER: 2002:1233 USPATFULL

TITLE: Triazine antiviral compounds

INVENTOR(S): Arenas, Jaime E., Lexington, MA, United States
Cload, Sharon T., Cambridge, MA, United States

Fleming, Elizabeth S., Belmont, MA, United States
 Xiang, Yi Bin, Acton, MA, United States
 PATENT ASSIGNEE(S): Scriptgen Pharmaceuticals, Inc., Waltham, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6335339	B1	20020101
APPLICATION INFO.:	US 1999-229703		19990113 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-113656P	19980113 (60)
	US 1998-113656P	19980113 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Travers, Russell	
LEGAL REPRESENTATIVE:	Darby & Darby	
NUMBER OF CLAIMS:	14	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	265 Drawing Figure(s); 93 Drawing Page(s)	
LINE COUNT:	1606	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides pharmaceutical formulations comprising 1,3,5-triazine derivatives. The compounds and formulations of the present invention exhibit a range of activities, including antiviral and antibiotic activities, and the formulations may be used, alone or in combination, as a method of treating a patient in need of antiviral and/or antibiotic therapy. The triazine derivatives of the present invention bind to and inhibit functional nucleic acids, and hence, have broad applicability in the treatment of conditions associated with DNA and RNA viruses.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 232937-01-8P 232937-02-9P 232937-06-3P
 232937-55-2P 232937-59-6P

(preparation of N-(diaminotriazinyl)arylaldehyde hydrazones and analogs as antiviral agents)


RN 232937-01-8 USPATFULL

CN Phenol, 4-chloro-2-[[4-[(3,4-dimethylphenyl)amino]-6-(methylamino)-1,3,5-triazin-2-yl]amino]- (9CI) (CA INDEX NAME)




RN 232937-02-9 USPATFULL

CN Phenol, 4-chloro-2-[[4-[(3,4-dimethylphenyl)amino]-6-[(phenylmethyl)amino]-1,3,5-triazin-2-yl]amino]- (9CI) (CA INDEX NAME)




RN 232937-06-3 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N-(3,4-dimethylphenyl)-N'-(4-nitrophenyl)-N''-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 232937-55-2 USPATFULL

CN Benzamide, 4-[[4-[(3,4-dimethylphenyl)amino]-6-[(phenylmethyl)amino]-1,3,5-triazin-2-yl]amino]- (9CI) (CA INDEX NAME)



RN 232937-59-6 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N-[(2,5-difluorophenyl)methyl]-N'-(3,4-dimethylphenyl)-N''-(4-nitrophenyl)- (9CI) (CA INDEX NAME)



L17 ANSWER 19 OF 41 USPATFULL on STN

ACCESSION NUMBER: 2000:150307 USPATFULL

TITLE: Asymmetric stilbene compounds

INVENTOR(S): Metzger, Georges, Moernach, France
 Reinehr, Dieter, Kandern, Germany, Federal Republic of
 Eckhardt, Claude, Riedisheim, France
 Cuesta, Fabienne, Roppentzwiller, France
 PATENT ASSIGNEE(S): Ciba Specialty Chemicals Corporation, Tarrytown, NY,
 United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6143889		20001107
APPLICATION INFO.:	US 1998-209940		19981211 (9)


	NUMBER	DATE
PRIORITY INFORMATION:	GB 1997-26365	19971213
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Liott, Caroline D.	
LEGAL REPRESENTATIVE:	Mansfield, Kevin T.	
NUMBER OF CLAIMS:	13	
EXEMPLARY CLAIM:	1	
LINE COUNT:	751	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Asymmetric compounds having the formula: in which M is hydrogen, an alkali metal atom, ammonium or a cation formed from an amine: Xa and Xb are the same or different and each is NH(C.sub.1 -C.sub.4 alkyl); NH(C.sub.2 -.sub.4 alkoxyalkyl); N(C.sub.1 -C.sub.4 alkyl).sub.2 ; N(CH.sub.2 CH.sub.2 OH).sub.2 ; a group NH--Z--NR.sub.1 R.sub.2 in which Z is C.sub.2 -C.sub.14 alkylene or optionally substituted arylene, and R.sub.1 and R.sub.2 are the same or different and each is C.sub.1 -C.sub.12 alkyl or R.sub.1 and R.sub.2, together with the nitrogen atom to which they are each attached, form a morpholino, piperidino or piperazino ring; an aminoacid residue; C.sub.1 -C.sub.4 alkoxy; hydroxy-substituted-C.sub.2 -C.sub.4 alkoxy; ##STR1## and Ya and Yb are the same or different and each is a substituted amino group having both UVA and UVB-absorbing properties having the formula: ##STR2## in which R.sub.3 is CN; SO.sub.2 R.sub.5 in which R.sub.5 is C.sub.1 -C.sub.12 alkyl, C.sub.1 -C.sub.12 alkoxy, NH.sub.2, NH(C.sub.1 -C.sub.4 alkyl), N(C.sub.1 -C.sub.4 alkyl).sub.2, N(CH.sub.2 CH.sub.2 OH).sub.2, C.sub.1 -C.sub.4 alkoxy or hydroxy-substituted-C.sub.2 -C.sub.4 alkoxy; COR.sub.5. In which R.sub.5 has its previous significance; COOM or NHCOR.sub.5 and in which R.sub.4 has the same meaning as R.sub.3 or H, OH, C.sub.1 -C.sub.4 alkyl or C.sub.1 -C.sub.4 alkoxy and one of Xa and Xb can be identical to one of Ya and Yb, provided that one of Xa and Xb is different from the other and/or one of Ya and Yb is different from the other, and their use improve the sun protection factor (SPF) of textile fiber material.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 31900-04-6P 200395-08-0P 203250-74-2P
 226721-06-8P 226721-09-1P 226721-14-8P
 226721-17-1P 226721-26-2P 226721-33-1P
 (UV absorber; asym. triazinylaminostilbene compds. useful as sun protection agents applied to textiles)
 RN 31900-04-6 USPATFULL
 CN Benzenesulfonic acid, 2,2'-(1,2-ethenediyl)bis[5-[[4-(methylamino)-6-(phenylamino)-1,3,5-triazin-2-yl]amino]-, disodium salt (9CI) (CA INDEX NAME)



●2 Na

RN 200395-08-0 USPATFULL


CN Benzenesulfonic acid, 2,2'-(1,2-ethenediyl)bis[5-[[4-[(4-acetylphenyl)amino]-6-[(2-methoxyethyl)amino]-1,3,5-triazin-2-yl]amino]-, disodium salt (9CI) (CA INDEX NAME)



PAGE 1-A


●2 Na

PAGE 1-B




RN 203250-74-2 USPATFULL

CN Benzenesulfonic acid, 2,2'-(1,2-ethenediyl)bis[5-[[4-(methylamino)-6-[[4-[(methylamino)carbonyl]phenyl]amino]-1,3,5-triazin-2-yl]amino]-, disodium salt (9CI) (CA INDEX NAME)




PAGE 1-A

●2 Na




RN 226721-06-8 USPATFULL

CN Benzoic acid, 4-[[4-[[4-[2-[4-[[4-[(aminocarbonyl)phenyl]amino]-6-(methylamino)-1,3,5-triazin-2-yl]amino]-2-sulfophenyl]ethenyl]-3-sulfophenyl]amino]-6-(methylamino)-1,3,5-triazin-2-yl]amino]-, trisodium salt (9CI) (CA INDEX NAME)




●3 Na




RN 226721-09-1 USPATFULL

CN Benzenesulfonic acid, 5-[[4-[[4-(aminosulfonyl)phenyl]amino]-6-(methylamino)-1,3,5-triazin-2-yl]amino]-2-[2-[4-[[4-(methylamino)-6-[[4-[(methylamino)carbonyl]phenyl]amino]-1,3,5-triazin-2-yl]amino]-2-sulfophenyl]ethenyl]-, disodium salt (9CI) (CA INDEX NAME)



●2 Na


PAGE 1-B



RN 226721-14-8 USPATFULL


CN Benzenesulfonic acid, 2,2'-(1,2-ethenediyl)bis[5-[[4-[[4-(aminosulfonyl)phenyl]amino]-6-(methylamino)-1,3,5-triazin-2-yl]amino]-2-sulfophenyl]ethenyl]-, disodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



●2 Na


PAGE 1-B




RN 226721-17-1 USPATFULL

CN Benzenesulfonic acid, 5-[[4-(methylamino)-6-[[4-[(methylamino)carbonyl]phenyl]amino]-1,3,5-triazin-2-yl]amino]-2-[2-[4-[[4-(methylamino)-6-(phenylamino)-1,3,5-triazin-2-yl]amino]-2-sulfophenyl]ethenyl]-, disodium salt (9CI) (CA INDEX NAME)

PAGE 1-A




●2 Na




RN 226721-26-2 USPATFULL

CN Benzenesulfonic acid, 2,2'-(1,2-ethenediyl)bis[5-[[4-[[4-(aminocarbonyl)phenyl]amino]-6-[(2-methoxyethyl)amino]-1,3,5-triazin-2-yl]amino]-, disodium salt (9CI) (CA INDEX NAME)




●2 Na




RN 226721-33-1 USPATFULL

CN Benzenesulfonic acid, 5-[[4-[(4-acetylphenyl)amino]-6-[(2-methoxyethyl)amino]-1,3,5-triazin-2-yl]amino]-2-[2-[4-[[4-[(aminocarbonyl)phenyl]amino]-6-[(2-methoxyethyl)amino]-1,3,5-triazin-2-yl]amino]-2-sulfophenyl]ethenyl]-, disodium salt (9CI) (CA INDEX NAME)



●2 Na



L17 ANSWER 20 OF 41 USPATFULL on STN

ACCESSION NUMBER: 96:96755 USPATFULL

TITLE: Dendritic amplifier molecules having multiple terminal active groups stemming from a benzyl core group

INVENTOR(S): Keana, John F. W., Eugene, OR, United States

Martin, Vladimir, Eugene, OR, United States

Ralston, William H., St. Charles, MO, United States

PATENT ASSIGNEE(S): State of Oregon Acting by and Through the State Board of Higher Education on Behalf of the University of Oregon, Eugene, OR, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5567411		19961022
APPLICATION INFO.:	US 1994-316787		19940929 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1993-133652, filed on 6 Oct 1993, now patented, Pat. No. US 5412148 which is a division of Ser. No. US 1992-887542, filed on 22 May 1992, now patented, Pat. No. US 5252317 which is a division of Ser. No. US 1989-403595, filed on 5 Sep 1989, now patented, Pat. No. US 5135737 which is a continuation-in-part of Ser. No. US 1986-928943, filed on 10 Nov 1986, now patented, Pat. No. US 4863717		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Higel, Floyd D.		
LEGAL REPRESENTATIVE:	Klarquist Sparkman Campbell Leigh & Whinston, LLP		
NUMBER OF CLAIMS:	30		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	6 Drawing Figure(s); 4 Drawing Page(s)		
LINE COUNT:	2948		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Dendritic derivatives of 3,5-bis(aminomethyl)benzene and aminomethyl benzene core groups are disclosed. In each derivative, termed an "amplifier" because the dendritic structure on each molecule terminates with multiple termini to each of which an "active group" can be attached, the desired effect of the active group per mole is amplified compared to conventional compounds having only one active group per molecule. Amplifier molecules can include a targeting group permitting the molecules to preferentially attach to a particular anatomical or physiological situs. Active groups are any of various pharmacologically or therapeutically active moieties, including moieties useful for magnetic-resonance contrast enhancement. The dendritic structures comprise linkers and branch groups covalently bonded to each other in any of various structural combinations. The amplifiers can be prepared as a solution or mixture with a physiologically compatible carrier for administration to a warm-blooded animal subject. Also disclosed are methods for using the compounds in diagnosis and therapy, such as obtaining a magnetic resonance image of a subject.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 184177-05-7P

(preparation of dendritic amplifier mols. having multiple terminal active groups stemming from a benzyl core group as MRI contrast agents)


RN 184177-05-7 USPATFULL

CN Benzoic acid, 3,5-bis[[[4,6-bis[(4-methylphenyl)amino]-1,3,5-triazin-2-yl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



L17 ANSWER 21 OF 41 USPATFULL on STN

ACCESSION NUMBER: 2003:33159 USPATFULL

TITLE: Combinations of sunscreens

INVENTOR(S): Malpede, Alverio, Bergamo, ITALY

Zanchi, Giorgio, Bergamo, ITALY

PATENT ASSIGNEE(S): 3V Sigma S.p.A., Milan, ITALY (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6514485	B1	20030204
APPLICATION INFO.:	US 1999-475018		19991230 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	IT 1999-BG1	19990111
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Dees, Jose' G.	

ASSISTANT EXAMINER: George, Konata M.
LEGAL REPRESENTATIVE: Birch, Stewart, Kolasch & Birch, LLP
NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 781

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Combinations of sunscreens comprising at least one specific anti uv-B filter with triazinoaniline structure and at least one specific anti UV-A filter selected from filters with benzoxazol substituted triazinoaniline structure and a long chain alkyl ester of a benzoxazolyl-aminophenyl-cyanoacrylic acid. Cosmetic and dermatological compositions containing them, optionally in combination with vitamins and/or other anti UV-A and anti UV-B filters.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 205493-09-0

(sunscreens containing UV-A and UV-B filters)

RN 205493-09-0 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis[4-[5-(1,1-dimethylethyl)-2-benzoxazolyl]phenyl]-N''-(1,1,3,3-tetramethylbutyl)- (9CI) (CA INDEX NAME)




IT 288254-14-8P 288254-15-9P 288254-16-0P

(sunscreens containing UV-A and UV-B filters)

RN 288254-14-8 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N-(1,1-dimethylethyl)-N',N''-bis[4-[5-(1,1-dimethylpropyl)-2-benzoxazolyl]phenyl]- (9CI) (CA INDEX NAME)




PAGE 1-A

PAGE 1-B


RN 288254-15-9 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis[4-[5-(1,1-dimethylethyl)-2-benzoxazolyl]phenyl]-N''-(2-ethylhexyl)- (9CI) (CA INDEX NAME)



RN 288254-16-0 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis[4-[5-(1,1-dimethylpropyl)-2-benzoxazolyl]phenyl]-N''-(2-ethylhexyl)- (9CI) (CA INDEX NAME)



PAGE 1-A

PAGE 1-B

— Et

L17 ANSWER 22 OF 41 USPATFULL on STN

ACCESSION NUMBER: 1999:96330 USPATFULL

TITLE: Triazine derivatives and their use

INVENTOR(S): Eckhardt, Claude, Riedisheim, France

Reinehr, Dieter, Kandern, Germany, Federal Republic of

Metzger, Georges, Moernach, France

Sauter, Hanspeter, Schopfheim, Germany, Federal Republic of

PATENT ASSIGNEE(S): Ciba Specialty Chemicals Corporation, Tarrytown, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5939379		19990817
APPLICATION INFO.:	US 1997-867110		19970602 (8)

NUMBER	DATE
--------	------

PRIORITY INFORMATION: GB 1996-17322 19960817
 DOCUMENT TYPE: Utility
 FILE SEGMENT: Granted
 PRIMARY EXAMINER: Lieberman, Paul
 ASSISTANT EXAMINER: Petruncio, John M.
 LEGAL REPRESENTATIVE: Mansfield, Kevin T.
 NUMBER OF CLAIMS: 13
 EXEMPLARY CLAIM: 1,10
 LINE COUNT: 653
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to new compounds which are useful as ultraviolet absorbing agents (UVAs) and as fluorescent whitening agents (FWAs), and to a method of improving the sun protection factor (SPF) of textile fibre material, especially cotton, polyamide and wool, treated with the new compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 203250-74-2P 203250-76-4P

(preparation of triazine derivs. as fluorescent whitening agents and UV absorbers for increasing the sun protection factor of textile material)

RN 203250-74-2 USPATFULL


CN Benzenesulfonic acid, 2,2'-(1,2-ethenediyl)bis[5-[[4-(methylamino)-6-[[4-[(methylamino)carbonyl]phenyl]amino]-1,3,5-triazin-2-yl]amino]-, disodium salt (9CI) (CA INDEX NAME)

PAGE 1-A




●2 Na

PAGE 1-B




RN 203250-76-4 USPATFULL

CN Benzoic acid, 4,4'-[1,2-ethenediylbis[(3-sulfo-4,1-phenylene)imino[6-(methylamino)-1,3,5-triazine-4,2-diyl]imino]]bis[2-hydroxy-, tetrasodium salt (9CI) (CA INDEX NAME)



● 4 Na



L17 ANSWER 23 OF 41 USPATFULL on STN

ACCESSION NUMBER: 2006:40138 USPATFULL

TITLE: Cosmetic and dermatological light protection formulations

INVENTOR(S): Hoop, Kerstin, Pinneberg, GERMANY, FEDERAL REPUBLIC OF
 Lerg, Heike, Hamburg, GERMANY, FEDERAL REPUBLIC OF
 Mueller, Anja Sabine, Rumpel, GERMANY, FEDERAL REPUBLIC OF
 Nissen, Bente, Hamburg, GERMANY, FEDERAL REPUBLIC OF
 Steinforth, Melanie, Hamburg, GERMANY, FEDERAL REPUBLIC OF
 Sugar, Martin, Hamburg, GERMANY, FEDERAL REPUBLIC OF

PATENT ASSIGNEE(S): Beiersdorf AG (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006034785	A1	20060216
APPLICATION INFO.:	US 2005-39376	A1	20050119 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	DE 2004-102004	20040119
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	ALSTON & BIRD LLP, BANK OF AMERICA PLAZA, 101 SOUTH TRYON STREET, SUITE 4000, CHARLOTTE, NC, 28280-4000, US	
NUMBER OF CLAIMS:	20	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1000	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Light protective cosmetic or dermatological preparation, characterized in that it comprises (a) PEG-30 dipolyhydroxystearate, (b) 2-ethylhexyl 2-cyano-3,3-diphenylacrylate, (c) at least one dibenzoylmethane derivative and (d) at least 2% by weight of titanium dioxide particles (based on the total weight of the preparation), the preparation being free from water-soluble UV-A filter substances.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 288254-16-0, Uvasorb K2A

(cosmetic and dermatol. sunscreen formulations free of water-soluble UV-A filters)

RN 288254-16-0 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis[4-[5-(1,1-dimethylpropyl)-2-benzoxazolyl]phenyl]-N''-(2-ethylhexyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

— Et

L17 ANSWER 24 OF 41 USPATFULL on STN

ACCESSION NUMBER: 2006:9579 USPATFULL

TITLE: Cosmetic and dermatological photoprotective formulations

INVENTOR(S): Doring, Thomas, Dormagen, GERMANY, FEDERAL REPUBLIC OF
Sugar, Martin, Hamburg, GERMANY, FEDERAL REPUBLIC OF
Wolber, Rainer, Hamburg, GERMANY, FEDERAL REPUBLIC OF
Wendel, Volker, Frankfurt/Main, GERMANY, FEDERAL
REPUBLIC OF
Blatt, Thomas, Wedel, GERMANY, FEDERAL REPUBLIC OF
Mundt, Claudia, Bremen, GERMANY, FEDERAL REPUBLIC OF
Schulz, Jens, Schenefeld, GERMANY, FEDERAL REPUBLIC OF
Batzner, Jan, Hamburg, GERMANY, FEDERAL REPUBLIC OF
Dippe, Rixa, Hamburg, GERMANY, FEDERAL REPUBLIC OF

PATENT ASSIGNEE(S): Beiersdorf AG (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006008426	A1	20060112
APPLICATION INFO.:	US 2005-87395	A1	20050323 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	DE 2004-10200	20040323
	DE	20040427
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	ALSTON & BIRD LLP, BANK OF AMERICA PLAZA, 101 SOUTH TRYON STREET, SUITE 4000, CHARLOTTE, NC, 28280-4000, US	
NUMBER OF CLAIMS:	36	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1891	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Cosmetic or dermatological preparations which have a UVA balance of more than 15, and use thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 288254-16-0

(cosmetic and dermatol. compns. containing water-soluble sunscreens)

RN 288254-16-0 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis[4-[5-(1,1-dimethylpropyl)-2-benzoxazolyl]phenyl]-N''-(2-ethylhexyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

— Et

L17 ANSWER 25 OF 41 USPATFULL on STN

ACCESSION NUMBER: 2005:318024 USPATFULL

TITLE: Emulsion concentrate containing water-soluble and oil-soluble polymers

INVENTOR(S): Pfeifer, Svenja, Hamburg, GERMANY, FEDERAL REPUBLIC OF
Mundt, Claudia, Bremen, GERMANY, FEDERAL REPUBLIC OF
Daniels, Rolf, Salzgitter, GERMANY, FEDERAL REPUBLIC OF

PATENT ASSIGNEE(S): Beiersdorf AG (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005276763	A1	20051215
APPLICATION INFO.:	US 2005-132821	A1	20050519 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	DE 2004-1020040	20040519
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	ALSTON & BIRD LLP, BANK OF AMERICA PLAZA, 101 SOUTH TRYON STREET, SUITE 4000, CHARLOTTE, NC, 28280-4000, US	
NUMBER OF CLAIMS:	23	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1715	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is the preparation and use of an emulsion concentrate obtainable by drying an oil-in-water emulsion comprising a

lipid phase, one or more oil-soluble polymers; an aqueous phase, one or more water-soluble polymers, one or more UV photoprotective filters and optionally further cosmetic or dermatological active ingredients, auxiliaries and additives, to produce a water content of from 0.1 to 20% by weight, based on the total weight of the dried preparation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 288254-16-0, UVA-sorb K2A

(cosmetic emulsion concentrate containing water-soluble and oil-soluble polymers)

RN 288254-16-0 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis[4-[5-(1,1-dimethylpropyl)-2-benzoxazolyl]phenyl]-N''-(2-ethylhexyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

— Et

L17 ANSWER 26 OF 41 USPATFULL on STN

ACCESSION NUMBER: 2005:280500 USPATFULL

TITLE: Cosmetic concentrate

INVENTOR(S): Stiller, Sabine, Hamburg, GERMANY, FEDERAL REPUBLIC OF
Schulz, Jens, Schenefeld, GERMANY, FEDERAL REPUBLIC OF

PATENT ASSIGNEE(S): BEIERSDORF AG, Hamburg, GERMANY, FEDERAL REPUBLIC OF
(non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005244443	A1	20051103
APPLICATION INFO.:	US 2005-133295	A1	20050520 (11)
RELATED APPLN. INFO.:	Continuation of Ser. No. WO 2003-EP50845, filed on 18 Nov 2003, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	DE 2002-10254334	20021121
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	GREENBLUM & BERNSTEIN, P.L.C., 1950 ROLAND CLARKE PLACE, RESTON, VA, 20191, US	
NUMBER OF CLAIMS:	37	
EXEMPLARY CLAIM:	1	

LINE COUNT: 1704

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A process for preparing an O/W emulsion concentrate. The process comprises subjecting an O/W emulsion comprising 20% to 95% by weight of one or more lipids, 0.5% to 80% by weight of microfine amphiphilic metal oxide particles, amphiphilic polymer particles, and/or modified polysaccharide particles and water to spray-drying and/or freeze-drying.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 288254-16-0, UVAsorb K2A

(concentrated cosmetics and method for preparation)

RN 288254-16-0 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis[4-[5-(1,1-dimethylpropyl)-2-benzoxazolyl]phenyl]-N''-(2-ethylhexyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

— Et

L17 ANSWER 27 OF 41 USPATFULL on STN

ACCESSION NUMBER: 2005:164657 USPATFULL

TITLE: Cosmetic or dermatological light protection formulation with a benzoxazole derivative

INVENTOR(S): Goppel, Anja, Hamburg, GERMANY, FEDERAL REPUBLIC OF
Schulz, Jens, Schenefeld, GERMANY, FEDERAL REPUBLIC OF
Lerg, Heike, Hamburg, GERMANY, FEDERAL REPUBLIC OF

PATENT ASSIGNEE(S): Beiersdorf AG (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005142080	A1	20050630
APPLICATION INFO.:	US 2004-871819	A1	20040618 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. WO 2002-EP14298, filed on 16 Dec 2002, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	DE 2001-10162841	20011220
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	ALSTON & BIRD LLP, BANK OF AMERICA PLAZA, 101 SOUTH TRYON STREET, SUITE 4000, CHARLOTTE, NC, 28280-4000, US	

NUMBER OF CLAIMS: 38
EXEMPLARY CLAIM: 1
LINE COUNT: 1932
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention is a light protection-active cosmetic or dermatological preparation comprising (a) at least one benzoxazole derivative, and (b) at least one oil component having a surface tension (σ) of less than 37 mN/m (at 25° C). The invention is also a method of treating or preventing cosmetic or dermatological changes in the skin, a method of tanning or accelerating tanning of the skin, and a method of protecting the skin against light-induced aging, each comprising applying the cosmetic or dermatological preparation to the skin. The invention is also a method of increasing the solubility of benzoxazole in a preparation comprising adding at least one oil component. The invention also includes a wipe impregnated with the preparation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 288254-16-0

(cosmetic and dermatol. light protection formulations having a content of benzoxazol derivs.)

RN 288254-16-0 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis[4-[5-(1,1-dimethylpropyl)-2-benzoxazolyl]phenyl]-N''-(2-ethylhexyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

— Et

L17 ANSWER 28 OF 41 USPATFULL on STN

ACCESSION NUMBER: 2005:56098 USPATFULL

TITLE: Cosmetic or dermatological light-protective formulation comprising a water-soluble UV filter substance and a benzoxazole derivative

INVENTOR(S): Goppel, Anja; Hamburg, GERMANY, FEDERAL REPUBLIC OF
Schulz, Jens, Schenefeld, GERMANY, FEDERAL REPUBLIC OF
Klette, Eckhard, Bad Odesloe, GERMANY, FEDERAL REPUBLIC OF

PATENT ASSIGNEE(S): Beiersdorf AG (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005048009	A1	20050303

APPLICATION INFO.: US 7060257 B2 20060613
 US 2004-871840 A1 20040618 (10)
 RELATED APPLN. INFO.: Continuation of Ser. No. WO 2002-EP14296, filed on 16
 Dec 2002, UNKNOWN

	NUMBER	DATE
PRIORITY INFORMATION:	DE 2001-10162840	20011220
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	ALSTON & BIRD LLP, BANK OF AMERICA PLAZA, 101 SOUTH TRYON STREET, SUITE 4000, CHARLOTTE, NC, 28280-4000	
NUMBER OF CLAIMS:	66	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1842	


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention is a light-protective cosmetic or dermatological preparation comprising (a) at least one water-soluble UV-filter substance and (b) at least one benzoxazole derivative. The invention is also a cosmetic or dermatological preparation comprising at least one water-soluble UV-filter substance and at least one benzoxazole derivative of a specified chemical structure. The invention is also a method of treating or preventing cosmetic or dermatological changes in the skin, a method of tanning or accelerating tanning of the skin, and a method of protecting the skin against light-induced aging, each comprising applying the cosmetic or dermatological preparation to the skin. The invention also includes a wipe impregnated with the preparation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 288254-16-0, Uvasorb K2A
 (cosmetic and dermatol. light-protective formulations comprising water-soluble UV-filter substances and benzoxazole derivs.)
 RN 288254-16-0 USPATFULL
 CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis[4-[5-(1,1-dimethylpropyl)-2-benzoxazolyl]phenyl]-N''-(2-ethylhexyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

— Et

ACCESSION NUMBER: 2005:36883 USPATFULL
 TITLE: Cosmetic or dermatological light-protective formulation comprising a hydroxybenzophenone and a benzoxazole derivative
 INVENTOR(S): Goppel, Anja, Hamburg, GERMANY, FEDERAL REPUBLIC OF
 Schulz, Jens, Schenefeld, GERMANY, FEDERAL REPUBLIC OF
 Eitrich, Anja, Hamburg, GERMANY, FEDERAL REPUBLIC OF
 PATENT ASSIGNEE(S): Beiersdorf AG (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005031556	A1	20050210
APPLICATION INFO.:	US 2004-871861	A1	20040618 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. WO 2002-EP14391, filed on 17 Dec 2002, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	DE 2001-10162843	20011220
	DE 2002-10249367	20021023
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	ALSTON & BIRD LLP, BANK OF AMERICA PLAZA, 101 SOUTH TRYON STREET, SUITE 4000, CHARLOTTE, NC, 28280-4000	
NUMBER OF CLAIMS:	50	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1827	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention is a light-protective cosmetic or dermatological preparation, comprising (a) at least hydroxybenzophenone and (b) at least one benzoxazole derivative. The invention is also a cosmetic or dermatological preparation comprising at least one hydroxybenzophenone of a specified chemical structure and at least one benzoxazole derivative. The invention is also a method of treating or preventing cosmetic or dermatological changes in the skin, a method of tanning or accelerating tanning of the skin, and a method of protecting the skin against light-induced aging, each comprising applying the preparation to the skin. The invention also includes a wipe impregnated with the preparation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 288254-16-0

(cosmetic and dermatol. light-protective formulations comprising hydroxybenzophenones and benzoxazole derivs.)

RN 288254-16-0 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis[4-[5-(1,1-dimethylpropyl)-2-benzoxazolyl]phenyl]-N''-(2-ethylhexyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



— Et

L17 ANSWER 30 OF 41 USPATFULL on STN

ACCESSION NUMBER: 2005:30296 USPATFULL

TITLE: Cosmetic or dermatological light-protective formulation comprising a benzotriazole and a benzoxazole derivative

INVENTOR(S): Goppel, Anja, Hamburg, GERMANY, FEDERAL REPUBLIC OF
Schulz, Jens, Schenefeld, GERMANY, FEDERAL REPUBLIC OF
Groteluschen, Birgit, Wildeshausen, GERMANY, FEDERAL
REPUBLIC OF

PATENT ASSIGNEE(S): Beiersdorf AG (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005025726	A1	20050203
	US 7029660	B2	20060418
APPLICATION INFO.:	US 2004-871839	A1	20040618 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. WO 2002-EP14392, filed on 17 Dec 2002, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	DE 2001-10162842	20011220
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	ALSTON & BIRD LLP, BANK OF AMERICA PLAZA, 101 SOUTH TRYON STREET, SUITE 4000, CHARLOTTE, NC, 28280-4000	
NUMBER OF CLAIMS:	54	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1897	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention is a light-protective cosmetic or dermatological preparation, comprising (a) at least benzotriazole and (b) at least one benzoxazole derivative. The invention is also a cosmetic or dermatological preparation comprising at least one benzotriazole from a select group and at least one benzoxazole derivative of a specified chemical structure. The invention is also a method of treating or preventing cosmetic or dermatological changes in the skin, a method of tanning or accelerating tanning of the skin, and a method of protecting the skin against light-induced aging, each comprising applying the preparation to the skin. The invention also includes a wipe impregnated with the preparation.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 288254-16-0

(cosmetic and dermatol. light-protective formulations comprising benzotriazoles and benzoxazole derivs.)

RN 288254-16-0 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis[4-[5-(1,1-dimethylpropyl)-2-benzoxazolyl]phenyl]-N''-(2-ethylhexyl)- (9CI) (CA INDEX NAME)



— Et

L17 ANSWER 31 OF 41 USPATFULL on STN

ACCESSION NUMBER: 2005:16381 USPATFULL

TITLE: Cosmetic or dermatological light-protective formulation comprising a bisresorcinyltriazine derivative and a benzoxazole derivative

INVENTOR(S): Goppel, Anja, Hamburg, GERMANY, FEDERAL REPUBLIC OF
Schulz, Jens, Schenefeld, GERMANY, FEDERAL REPUBLIC OF
Hoop, Kerstin, Pinneberg, GERMANY, FEDERAL REPUBLIC OF

PATENT ASSIGNEE(S): Beiersdorf AG (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005013782	A1	20050120
APPLICATION INFO.:	US 2004-871818	A1	20040618 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. WO 2002-EP14297, filed on 16 Dec 2002, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	DE 2001-10162844	20011220
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	ALSTON & BIRD LLP, BANK OF AMERICA PLAZA, 101 SOUTH TRYON STREET, SUITE 4000, CHARLOTTE, NC, 28280-4000	
NUMBER OF CLAIMS:	64	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1838	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention is a cosmetic or dermatological preparation effective as light-protective, comprising (a) at least one bis-resorcinyltriazine derivative and (b) at least one benzoxazole derivative. The invention is also a cosmetic or dermatological preparation comprising at least one bis-resorcinyltriazine derivative and at least one benzoxazole derivative of a specified chemical structure. The invention is also a method of treating or preventing cosmetic or dermatological changes in the skin, a method of tanning or accelerating tanning of the skin, and a method of protecting the skin against light-induced aging, each comprising applying the preparation to the skin. The invention also includes a wipe impregnated with the preparation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 288254-16-0

(cosmetic and dermatol. light-protective formulations comprising
derivs. of bis-resorcinyll triazine derivs. and benzoxazole)

RN 288254-16-0 USPATFULL

CN 1,3,5-Triazine-2,4,6-triamine, N,N'-bis[4-[5-(1,1-dimethylpropyl)-2-
benzoxazolyl]phenyl]-N'-(2-ethylhexyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

— Et

L17 ANSWER.32 OF 41 USPATFULL on STN

ACCESSION NUMBER: 2000:120834 USPATFULL

TITLE: Protective method

INVENTOR(S): Reinehr, Dieter, Kandern, Germany, Federal Republic of
Fankhauser, Peter, Ettingen, Switzerland
Eckhardt, Claude, Riedisheim, France

PATENT ASSIGNEE(S): Ciba Specialty Chemicals Corporation, Tarrytown, NY,
United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6117189		20000912
APPLICATION INFO.:	US 1995-438591		19950510 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1994-9465	19940512
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Diamond, Alan	
LEGAL REPRESENTATIVE:	Mansfield, Kevin T.	
NUMBER OF CLAIMS:	20	
EXEMPLARY CLAIM:	1	
LINE COUNT:	493	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a method for the improvement of the sun protection factor (SPF) of textile fiber material, comprising applying to the textile fiber material a detergent comprising at least one fluorescent whitening agent, which absorbs radiation in the wavelength

range 280-400 nm, preferably by washing the textile fiber material with a detergent containing said fluorescent whitening agent.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 31900-04-6

(fluorescent whitener, detergent component; textile finishing for sun protection)

RN 31900-04-6 USPATFULL

CN Benzenesulfonic acid, 2,2'-(1,2-ethenediyl)bis[5-[[4-(methylamino)-6-(phenylamino)-1,3,5-triazin-2-yl]amino]-, disodium salt (9CI) (CA INDEX NAME)



● 2 Na

L17 ANSWER 33 OF 41 USPATFULL on STN

ACCESSION NUMBER: 2000:80216 USPATFULL

TITLE: Stilbene compounds and their use

INVENTOR(S): Reinehr, Dieter, Kandern, Germany, Federal Republic of
Metzger, Georges, Moernach, France
Sauter, Hanspeter, Schopfheim, Germany, Federal Republic of

PATENT ASSIGNEE(S): Ciba Specialty Chemicals Corporation, Tarrytown, NY,
United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6080208		20000627
APPLICATION INFO.:	US 1998-218246		19981222 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1997-862036, filed on 22 May 1997, now patented, Pat. No. US 5892031		

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1996-10832	19960523
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Gupta, Yogendra	
ASSISTANT EXAMINER:	Mruk, Brian P.	
LEGAL REPRESENTATIVE:	Mansfield, Kevin T.	
NUMBER OF CLAIMS:	28	
EXEMPLARY CLAIM:	1	
LINE COUNT:	717	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides new stilbene compounds which are useful as fluorescent whitening agents (FWAs), imparting high whiteness levels to textile fibre material treated with them, and which also impart a high sun protection factor (SPF) to textile fibre material treated with them. The present invention also concerns a method of imparting a high whiteness level and a high sun protection factor to textile fibre material, especially cotton, polyamide and wool, comprising treating the textile material with the new compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 199791-75-8P

(manufacture and use of stilbene compds. as fluorescent whitening agents and UV absorbers)

RN 199791-75-8 USPATFULL


CN Benzenesulfonic acid, 2,2'-(1,2-ethenediyl)bis[5-[[4-[[4-(acetylamino)phenyl]amino]-6-(methylamino)-1,3,5-triazin-2-yl]amino]-, disodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



● 2 Na

PAGE 1-B



L17 ANSWER 34 OF 41 USPATFULL on STN

ACCESSION NUMBER: 1999:102785 USPATFULL

TITLE: Compounds

INVENTOR(S): Eckhardt, Claude, Riedisheim, France
Metzger, Georges, Moernach, France
Reinehr, Dieter, Kandern, Germany, Federal Republic of
Sauter, Hanspeter, Schopfheim, Germany, Federal Republic of
Dubini, Mario, Niederdorf, Switzerland

PATENT ASSIGNEE(S): Ciba Specialty Chemicals Corporation, Tarrytown, NY,
United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5945396		19990831
APPLICATION INFO.:	US 1997-996895		19971223 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1996-26851	19961224
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Green, Anthony	
LEGAL REPRESENTATIVE:	Mansfield, Kevin T.	
NUMBER OF CLAIMS:	24	
EXEMPLARY CLAIM:	9	
LINE COUNT:	623	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a compound having the formula: ##STR1##

in which each R.sub.d is the same or different and each is --NH--Z--N(R.sub.a)(R.sub.b) or --N--[Z--N(R.sub.a)(R.sub.b)].sub.2 in which Z is C.sub.2 -C.sub.14 alkylene or optionally substituted arylene, R.sub.a and R.sub.b are the same or different and each is C.sub.1 -C.sub.12 alkyl, or R.sub.a and R.sub.b, together with the nitrogen atom to which they are each attached, form a morpholino, piperidino or piperazino ring; each R.sub.c is the same or different and is NH.sub.2, NH(C.sub.1 -C.sub.4 alkyl), N(C.sub.1 -C.sub.4 alkyl).sub.2, N(CH.sub.2 OH).sub.2, O--C.sub.1 -C.sub.4 alkyl, ##STR2## alkali metal atom, ammonium or a cation formed from an amine; or a quaternized form thereof. The present invention also relates to a composition for the treatment of textiles, in particular to a composition containing the new ultra-violet absorbing agents; and to a method for the improvement of both the sun protection factor (UPF) and the whiteness of textile fiber material, comprising treating the material with the composition according to the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 210101-86-3P

(preparation of triazinylaminostilbenes as ultra-violet absorbing agents for textile fibers)

RN 210101-86-3 USPATFULL


CN Benzoic acid, 4,4'-[1,2-ethenediylbis[(3-sulfo-4,1-phenylene)imino[6-[[2-(dimethylamino)ethyl]amino]-1,3,5-triazine-4,2-diyl]imino]]bis-, tetrasodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



●4 Na

PAGE 1-B



L17 ANSWER 35 OF 41 USPATFULL on STN

ACCESSION NUMBER: 1999:43769 USPATFULL

TITLE: Stilbene compounds and their use

INVENTOR(S): Reinehr, Dieter, Kandern, Germany, Federal Republic of
Metzger, Georges, Moernach, France
Sauter, Hanspeter, Schopfheim, Germany, Federal Republic of

PATENT ASSIGNEE(S): Ciba Specialty Chemicals Corporation, Tarrytown, NY,
United States (U.S. corporation)

NUMBER KIND DATE

PATENT INFORMATION: US 5892031 19990406
APPLICATION INFO.: US 1997-862036 19970522 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1996-10832	19960523
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Ford, John M.	
LEGAL REPRESENTATIVE:	Mansfield, Kevin T.	
NUMBER OF CLAIMS:	11	
EXEMPLARY CLAIM:	1	
LINE COUNT:	624	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides new stilbene compounds which are useful as fluorescent whitening agents (FWAs), imparting high whiteness levels to textile fibre material treated with them, and which also impart a high sun protection factor (SPF) to textile fibre material treated with them. The present invention also concerns a method of imparting a high whiteness level and a high sun protection factor to textile fibre material, especially cotton, polyamide and wool, comprising treating the textile material with the new compounds.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 199791-75-8P
(manufacture and use of stilbene compds. as fluorescent whitening agents and UV absorbers)

RN 199791-75-8 USPATFULL


CN Benzenesulfonic acid, 2,2'-(1,2-ethenediyl)bis[5-[[4-[[4-(acetylamino)phenyl]amino]-6-(methylamino)-1,3,5-triazin-2-yl]amino]-, disodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



●2 Na

PAGE 1-B



L17 ANSWER 36 OF 41 USPATFULL on STN

ACCESSION NUMBER: 1998:104437 USPATFULL

TITLE: Textile treatment

INVENTOR(S): Kaufmann, Werner, Rheinfelden, Switzerland
Reinehr, Dieter, Kandern, Germany, Federal Republic of
Hilfiker, Rolf, Basel, Switzerland

PATENT ASSIGNEE(S): Ciba Specialty Chemicals Corporation, Tarrytown, NY,
United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5800862		19980901
APPLICATION INFO.:	US 1995-438590		19950510 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1994-9466	19940512
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Bell, Janyce	
LEGAL REPRESENTATIVE:	Mansfield, Kevin T.	
NUMBER OF CLAIMS:	54	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1059	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a improving the sun protection factor (SPF) of textile fibre material comprising treating the textile fibre material with a composition comprising at least one flourescent whitening agent which absorbs radiation in the wavelength range 280-400 nm.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 31900-04-6

(fluorescent whitener, detergent component; textile finishing for sun protection)

RN 31900-04-6 USPATFULL

CN Benzenesulfonic acid, 2,2'-(1,2-ethenediyl)bis[5-[[4-(methylamino)-6-(phenylamino)-1,3,5-triazin-2-yl]amino]-, disodium salt (9CI) (CA INDEX NAME)



● 2 Na

L17 ANSWER 37 OF 41 USPATFULL on STN

ACCESSION NUMBER: 1998:82878 USPATFULL

TITLE: Dyestuff mixtures of fiber-reactive azo dyestuffs and their use for dyeing fiber material containing hydroxyl and/or carboxamide groups

INVENTOR(S): Schumacher, Christian, Kelkheim, Germany, Federal Republic of
Russ, Werner Hubert, Florsheim, Germany, Federal Republic of

PATENT ASSIGNEE(S): Pystar Textilfarben GmbH & Co. KG, Deutschland, Germany, Federal Republic of (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5780602		19980714
APPLICATION INFO.:	US 1997-924746		19970905 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1996-19635999	19960905
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Powers, Fiona T.	
LEGAL REPRESENTATIVE:	Connolly & Hutz	
NUMBER OF CLAIMS:	21	
EXEMPLARY CLAIM:	1	
LINE COUNT:	957	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Mixtures of fiber-reactive azo dyestuffs with which black dyeings, including prints, are obtained on fiber materials containing hydroxy and/or carboxamide groups, such as cellulosic fiber materials, wool and synthetic polyamide fibers, are described. These dyestuffs mixtures comprise one or more dyestuffs of the following formulae (1) and (2): ##STR1## in which the substituents have the meaning given in the specification.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 183205-49-4

(mixts. of fiber-reactive azo dyes and their use for dyeing hydroxy and/or carboxamide group-containing fibers)

RN 183205-49-4 USPATFULL

CN Benzenesulfonic acid, 2-amino-4-[[4-(cyanoamino)-6-[(3-sulfophenyl)amino]-1,3,5-triazin-2-yl]amino]-5-[[4-[[2-(sulfooxy)ethyl]sulfonyl]phenyl]azo]-, trisodium salt (9CI) (CA INDEX NAME)



● 3 Na

L17 ANSWER 38 OF 41 USPATFULL on STN

ACCESSION NUMBER: 1998:82064 USPATFULL

TITLE: Dye mixtures of fiber-reactive azo dyes and their use for dyeing hydroxy-and/or carboxamido-containing fiber material

INVENTOR(S): Von Der Eltz, Andreas, Frankfurt am Main, Germany, Federal Republic of
Russ, Werner Hubert, Florsheim, Germany, Federal Republic of
Grobel, Bengt-Thomas, Niederems, Germany, Federal Republic of

PATENT ASSIGNEE(S): Hoechst Aktiengesellschaft, Germany, Federal Republic of (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5779739		19980714
APPLICATION INFO.:	US 1996-627937		19960328 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1995-19511688	19950330
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Einsmann, Margaret	
LEGAL REPRESENTATIVE:	Connolly and Hutz	
NUMBER OF CLAIMS:	18	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	1 Drawing Figure(s); 1 Drawing Page(s)	
LINE COUNT:	975	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Dye mixtures of fiber-reactive azo dyes and their use for dyeing hydroxy- and/or carboxamido-containing fiber material

Red-dyeing fiber-reactive phenylazoaminonaphthol dyes, yellow-dyeing fiber-reactive phenylazoaminobenzene dyes, blue-dyeing fiber-reactive copper formazan dyes and navy-dyeing fiber-reactive disazo dyes of the formulae (1) to (5) as claimed and defined in claim 1 are described which are suitable for dyeing hydroxy- and/or carboxamido-containing fiber material, such as cellulose fiber materials, wool and synthetic polyamide fibers individually or together or some of them together or as a mixture in trichromatic dyeing methods. During the dyeing process a definite hue within the color triangle can be obtained and kept constant by adding the individual dye solutions of the individual dyes and/or mixtures of some of the dyes in a controlled manner by means of the ATR measurement technique.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 183205-49-4

(mixts. of reactive azo dyes for trichrome dyeing of fibers containing hydroxy and/or carbonamide functional groups)

RN 183205-49-4 USPATFULL

CN Benzenesulfonic acid, 2-amino-4-[[4-(cyanoamino)-6-[(3-sulfophenyl)amino]-1,3,5-triazin-2-yl]amino]-5-[[4-[[2-(sulfooxy)ethyl]sulfonyl]phenyl]azo]-, trisodium salt (9CI) (CA INDEX NAME)



● 3 Na


	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5690698		19971125
APPLICATION INFO.:	US 1996-611630		19960306 (8)

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

(dyes containing; black dye mixts. of reactive azo dyes for dyeing of hydroxy- and/or carbonamide group-containing fibers)

CN Benzenesulfonic acid, 2-amino-4-[[4-(cyanoamino)-6-[(3-sulfophenyl)amino]-1,3,5-triazin-2-yl]amino]-5-[[4-[[2-(sulfooxy)ethyl]sulfonyl]phenyl]azo]- (9CI) (CA INDEX NAME)



L17 ANSWER 40 OF 41 USPATFULL on STN

ACCESSION NUMBER: 97:107045 USPATFULL

TITLE: Textile treatment

INVENTOR(S): Reinehr, Dieter, Kandern, Germany, Federal Republic of
Eckhardt, Claude, Riedisheim, France

PATENT ASSIGNEE(S): Ciba Specialty Chemicals Corporation, Tarrytown, NY,
United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5688758		19971118
APPLICATION INFO.:	US 1996-662091		19960612 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1995-471043, filed on 6 Jun 1995, now abandoned		

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1994-13270	19940701
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Green, Anthony	
LEGAL REPRESENTATIVE:	Mansfield, Kevin T.	
NUMBER OF CLAIMS:	27	
EXEMPLARY CLAIM:	1	
LINE COUNT:	790	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB There is provided a stable, concentrated fabric rinse composition comprising 0.3 to 10, preferably 0.3 to 3% by weight of a fluorescent whitening agent which is compatible with a fabric care ingredient, preferably a cationic, amphoteric or anionic fluorescent whitening agent, based on the total weight of the composition, and optionally a fabric care ingredient, preferably a fabric softener, a stain release or stain repellent ingredient or a water-proofing agent, the remainder being substantially water. The fabric rinse composition is preferably a fabric softener composition comprising 5 to 25, preferably 10 to 20% by weight of a cationic fabric softening agent and 0.3 to 10, preferably 0.3 to 3% by weight of a cationic, amphoteric or anionic fluorescent whitening agent, each based on the total weight of the composition, the remainder being substantially water. The present invention also provides method for the treatment of a textile article, comprising applying, to the previously washed article, the said fabric rinse composition, preferably the rinse cycle fabric softener composition, whereby the sun protection factor, and other properties such as the tear strength and lightfastness of articles so treated can be significantly increased.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 31900-04-6

(fluorescent whitener, detergent component; textile finishing for sun protection)

RN 31900-04-6 USPATFULL

CN Benzenesulfonic acid, 2,2'-(1,2-ethenediyl)bis[5-[[4-(methylamino)-6-(phenylamino)-1,3,5-triazin-2-yl]amino]-, disodium salt (9CI) (CA INDEX NAME)



● 2 Na

L17 ANSWER 41 OF 41 USPATFULL on STN
 ACCESSION NUMBER: 83:41227 USPATFULL
 TITLE: Method for immunochemical measurement of trace components
 INVENTOR(S): Masuda, Nobuhito, Minami-ashigara, Japan
 Nagatomo, Shigeru, Minami-ashigara, Japan
 Mihara, Yuji, Minami-ashigara, Japan
 PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Kanagawa, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4404289		19830913
APPLICATION INFO.:	US 1981-298719		19810902 (6)

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1980-120597	19800902
	JP 1980-120598	19800902
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Marantz, Sidney	
LEGAL REPRESENTATIVE:	Sughrue, Mion, Zinn, Macpeak, and Seas	
NUMBER OF CLAIMS:	8	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1619	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB In an immunochemical measurement method of an antigen or antibody which comprises competitively reacting an antigen or antibody labelled with spectral sensitizer and an antigen or antibody to be measured, bringing either the reaction product of immune reaction or the unreacted component into contact with silver halide, exposing the same to light having a wavelength which the spectral sensitizer absorbs, developing the exposed silver, and, measuring optical density of the thus formed silver image and/or colored dye, the contact with silver halide is performed in the presence of a specific hydrazine compound. Thus, detection sensitivity is markedly improved.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 28837-51-6


(stabilizer, in immunoassay with photochem. detection)

RN 28837-51-6 USPATFULL

CN Benzenesulfonic acid, 2,2'-(1,2-ethenediyl)bis[5-[[4-(2-naphthalenylamino)-6-[(phenylmethyl)amino]-1,3,5-triazin-2-yl]amino]-, disodium salt (9CI)
 (CA INDEX NAME)



●2 Na



> file caplus medline l19

'L19' IS NOT A VALID FILE NAME

Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files that are available. If you have requested multiple files, you can specify a corrected file name or you can enter "IGNORE" to continue accessing the remaining file names entered.

ENTER A FILE NAME OR (IGNORE):end

=> file caplus medline

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	166.94	1350.47

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-24.75

FILE 'CAPLUS' ENTERED AT 16:38:35 ON 20 DEC 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 16:38:35 ON 20 DEC 2006

=> s l19

L20 208 L19

=> s l20 and (cancer or tumour or tumor or carcinoma or neoplas? or chemo? or cancer?)

L21 0 L20 AND (CANCER OR TUMOUR OR TUMOR OR CARCINOMA OR NEOPLAS? OR CHEMO? OR CANCER?)

=> s l20 and (edg or lpa or lysophosphatidic acid)

L22 0 L20 AND (EDG OR LPA OR LYSOPHOSPHATIDIC ACID)

=> s l20 and (ov202 or htc or caov or mda-mb or ht-1080 or huvec or a431 or hamster or ovary or ovarian or hepatoma or breast)

L23 0 L20 AND (OV202 OR HTC OR CAO V OR MDA-MB OR HT-1080 OR HUVEC OR A431 OR HAMSTER OR OVARY OR OVARIAN OR HEPATOMA OR BREAST)

=> file caplus uspatful

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	59.95	1410.42

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-24.75

FILE 'CAPLUS' ENTERED AT 16:41:03 ON 20 DEC 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 16:41:03 ON 20 DEC 2006

CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

=> s l19

L24 377 L19

=> s l24 and (ov202 or htc or caov or mda-mb or ht-1080 or huvec or a431 or hamster or ovary or ovarian or hepatoma or breast)

L25 0 L24 AND (OV202 OR HTC OR CAO V OR MDA-MB OR HT-1080 OR HUVEC OR A431 OR HAMSTER OR OVARY OR OVARIAN OR HEPATOMA OR BREAST)